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1  Introduction 
This chapter was adapted from: Jie Luo, Ernst Wagner and Yanfang Wang. Artificial peptides 
for antitumoral siRNA delivery. J. Mater. Chem. B, 2020, 8, 2020-2031. 
1.1 Nucleic acid formulation as therapeutic agents 
The therapy of macromolecules like proteins or nucleic acids (consisting of plasmid 
DNA, small interfering RNA siRNA, microRNA) is the promising way for infectious 
disease or cancer. As the therapeutic way, these macromolecules should be stable 
against degradation in the bloodstream and cleared by kidneys. 
Viral vectors have been widely investigated many years for intracellular nucleic acid 
delivery. However, the big obstacles of this kind of vector are immunogenicity and gene 
recombination with host. Therefore, non-viral vector appeals many researchers.  
In August 2018, FDA approved the first siRNA drug, Patisiran, a lipid nanoparticle (LNP) 
containing transthyretin (TTR) siRNA for treatment of hereditary transthyretin-mediated 
amyloidosis (ATTR). Extracellular and intracellular delivery has been critical for the 
success of siRNA cargo. A further refinement of delivery carriers will have a 
tremendous impact for efficacy of future nanomedicines. Three different directions can 
be considered: (i) chemical modifications of siRNA oligonucleotide backbone; (ii) 
covalent conjugation of siRNA with transport vehicles, such as with cholesterol for 
delivery to several organs, or with tri-(N-acetyl-galactosamine)-PEG for targeting the 
hepatocyte-specific asialoglycoprotein receptor; or (iii) supramolecular assembly into 
lipid-, peptide-, polymer- or inorganic-organic hybrid- based siRNA nanoparticles. 
siRNA LNPs have been developed for liver-specific applications and already reached 
drug status (see Patisiran, above). Givosiran, a completely chemically modified and tri-
(N-acetyl-galactosamine)-PEG conjugated siRNA targeting aminolevulinic acid 
synthase, was recently approved in November 2019 as second siRNA medicine 
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(GIVLAARI), as subcutaneously administered drug for the treatment of acute hepatic 
porphyria. Clinical studies are less advanced for cancer. Nevertheless, first tumor-
targeted siRNA polyplexes formed with cyclodextrin-oligocations and coated with 
transferrin-coated have already been tested in cancer patients and showed gene 
silencing of M2 subunit of ribonucleotide reductase (RRM2) in tumor tissue.  
1.2  Evolution of artificial peptides as siRNA nanocarriers 
Poly(amidoamines) already received a lot of attention in drug and gene delivery due to 
their favorable properties such as solubility, biocompatibility, low hemolysis and 
reduced cytotoxicity compared to other delivery carriers.[1] Hartmann and Börner 
applied SPS for generation of sequence-defined oligo(amidoamines) based on building 
blocks such as spermine and succinic acid.[2-5]  Such oligomers were firstly applied 
in plasmid DNA (pDNA) polyplex formulations, which presented an interesting starting 
point of the artificial peptide based strategy developed in our own laboratory. Synthetic 
peptides have been previously successfully applied as siRNA carriers or targeting 
ligands of siRNA formulations.[6-19] Lu and collaborators designed artificial lipo-
peptide carriers for siRNA delivery,[20-23] by combining one artificial building block 
triethylene tetramine with natural amino acids histidine, cysteine and conjugated oleic 
acid. Some of these carriers, such as EHCO (an ethylenediamine head group, a 
histidine-cysteine amino acid based linker and two oleic acid tails) and ECO (an 
ethylenediamine head group, a cysteine amino acid based linker and two oleic acid 
tails) were successfully applied in RGD-PEG siRNA formulations for tumor-targeted 
therapy in mice. Mixson and colleagues had designed linear and branched peptide 
libraries containing histidines (as endosomal buffering domain) and lysines (as nucleic 
acid binding domain) for pDNA and siRNA delivery.[11-16]  Langel and colleagues 
had developed a series of cell-penetrating peptides termed PepFects, which optionally 
also contained a fatty acid domain, for nucleic acid delivery.[17-19] 
Introduction 
3 
In our laboratory, in order to utilize the well-known proton sponge activity of 
polyethylenimine (PEI), which is a gold standard in successful pDNA transfection,[24-
26] the chemical amino ethylene motif was combined with the established methodology
of SPS of peptides. Schaffert et al [27] developed a versatile approach for incorporation 
of fluorenyl-methoxycarbonyl (Fmoc)- and t-butyl oxycarbonyl (Boc)-protected 
oligoamino acids, which allowed the synthesis of orthogonally protected cationic 
building blocks for Fmoc-SPS. Combined with lysines as the branching sites, cysteines 
as crosslinking terminals and fatty acids as hydrophobic domains, the designed 
artificial amino acids (tetraethylenepentamine artificial peptide Stp, Gtp, 
triethylenetetramine artificial peptide Gtt) were applied to establish more than 300 
linear, 3-arm, 4-arm, T-, i-, or U-shape sequence-defined oligomers for siRNA or pDNA 
delivery (Fig. 1).[28] Identification (ID) number, sequence, molecular characterization 
and biofunction of representative artificial peptides are displayed in Table 1. First proof-
of-concept studies proved the encouraging potential of such oligoaminoamides (OAA) 
in siRNA delivery. Results indicated that cysteine-containing 3-arm Stp-based oligomer 
displayed significantly higher gene silencing efficiency than the corresponding 
oligomer with alanines instead of cysteines. The i-shape oligomers with two cysteines 
and a hydrophobic domain indicated the important contribution of cysteines and 
hydrophobic fatty acids to stable siRNA complex formation, thereby significantly 
enhancing the internalization of formed nanoparticles into cells and the subsequent 
gene silencing efficiency. Meanwhile, the stabilization contributed by cysteines was 
able to be compensated by hydrophobic stabilization contributed by fatty acids. The U-
shape oligomers with diacyl groups were able to transfect in the absence of cysteines. 
The study not only highlighted the important role of cysteine and hydrophobic fatty 
acids in the design of oligomers, but also offer a convenient strategy to incorporate 
targeting ligands and shielding agents.[29, 30] The beneficial role of cysteine for siRNA 
delivery was further confirmed by Salcher et al in the evaluation of transfection 
efficiency by 4-arm oligomers.[31]  
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Based on SPS, precise sequence-defined artificial oligomers with different cationic 
building backbones (tetraethylenepentamine artificial peptide Stp, Gtp and Ptp, 
triethylenetetramine artificial peptide Gtt) and topologies (three-armed; T-shape, i-
shape and U-shape) were further optimized for nucleic acid delivery.[32] Although 
these cationic backbones have the same 1,2-diaminoethane proton-sponge motif, 
siRNA binding and reporter gene silencing experiments showed that Stp-containing 
oligomers have the greatest potential among these artificial amino acids. The 
screening of fatty acids incorporated in oligomers as hydrophobic domains revealed 
the most effective gene silencing with oligomers containing unsaturated fatty acids 
compared to oligomers with saturated fatty acids. In addition, it was proven that the 
topology of the investigated lipo-oligomers played a minor role in siRNA transfection 
efficiency as compared to the effect contributed by the incorporation of different 
building blocks, terminal cysteines and lipid moieties. By formulating with antitumoral 
EG5 siRNA, two promising oligomers, T-shape 49 with the sequence of C-Stp2-K[K-
(OleA)2]-Stp2-C and i-shape 229 with the sequence of C-Stp3-C-K-LinA2, exhibited 
efficient gene silencing and resulted mitotic monoastral spindles formation and cell 
cycle arrest both in vitro and in vivo. EG5 polyplexes upon intratumoral injection 
showed a significant inhibition of tumor growth in subcutaneous Neuro2A-eGFPLuc-
bearing mice.  
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Fig.1 Schematic overview of A) artificial oligo-amino acids (Stp, Gtp, Gtt, Ptp and Sph) used 
as cationic building block, and B) Stp-based oligomers with different topologies: linear, 2-arm 
with targeting ligand, 3-arm, 4-arm, i-, T- and U- shape. K, lysine; Stp, succinoyl-tetraethylene-
pentamine. 
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Table 1: Summary of representative artificial peptides in siRNA delivery. 
Oligomer ID Sequence (N→C) Topology* Biofunction Ref. 
49 C-Stp2-K[K-(OleA)2]-Stp2-C T-shape Efficient gene silencing, with siEG5 
both in vitro and in vivo.  
32 
229 C-Stp3-C-K-LinA2 i-shape 
386 C-Stp3-K(Stp3-C)2 3-arm Cysteine-containing oligomer 
exhibited significant stronger siRNA 
binding and higher gene knockdown 
as compared to the corresponding 
alanines-containing oligomer.  
28 
279 A-K[K(LinA)2]-Stp3-
K[K(LinA)2]-A 
U-shape Hydrophobic stabilization by four fatty 
acids may compensate the lack of 
disulfide crosslinking. 
28 
356 C-Stp4-K(PEG24-FolA)- 
Stp4-C 
2-arm Gene silencing activity depends on 
use of endosomolytic INF7-
conjugated siRNA.  
33 
640 K(Stp4-C)2-K(PEG24-E4-
MTX) 
2-arm γ-glutamic acid inserted into 
oligomers enhanced the antitumoral 
effect of nanoplexes as compared 
with 356.  
38 
454 C-Y3-Stp2-K[K(OleA)2]-
Stp2-Y3-C 
T-shape Y3-containing oligomer exhibited 
more stability, higher gene silencing 
efficiency and longer circulation time 
than Y3-free oligomer 49. 
47 
1027 C-Y3-(H-Stp)2-H-
K[K(CholA)2]- 
H-(Stp-H)2-Y3-C 
T-shape Histidine-containing oligomers 
showed enhanced gene silencing 
effect than corresponding histidine-
free oligomers among cysteine-
containing oligomers. 
50 
990(CholA) 
992(SteA) 
1082(MyrA) 
Y3-Stp2-K[G-ssbb-K(Fatty 
acid)2]-Stp2-Y3 
T-shape ssbb-containing oligomers for GSH-
triggered siRNA release exhibited 
higher transfection efficiency with 
lower cytotoxicity. 
39 
Series 
X1-MyrA-X2 
Y3-Stp2-X1-K[X2-
K(MyrA)2]- X1-Stp2-Y3 
(X1 and X2=L-Arg (R, RR) 
or D-Arg (r, rr) 
T-shape L-Arg dipeptides-containing 
oligomers for endolysosomal 
protease cathepsin B-triggered 
siRNA release displayed reduced 
cytotoxicity.   
42 
1106 K(N3)-Y3-Stp2-K[G-
K(CholA)2]-Stp2-Y3 
T-shape Azido groups were introduced to 
provide the option for subsequent 
copper-free click modification of 
shielding and targeting ligands. 
55 
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K, lysine; Stp, succinoyl-tetraethylene-pentamin; OleA: oleic acid; PEG, polyethylene glycol; 
CRC, cysteine-arginine-cysteine; ssbb, disulfide building block = succinoyl-cystamine; GSH, 
glutathione; MyrA, myristic acid; SteA, stearic acid; CholA, 5β-cholanic acid; Y3, tyrosine 
tripeptide. *Topologies of representative artificial peptides are displayed in Fig.1. 
1.3  Targeted siRNA nanoplexes 
Targeted delivery to tissues different from liver remains a major barrier in the process 
of siRNA therapeutics. Therefore, we present a series of targeted multifunctional 
artificial oligomers based on SPS chemistry.  
Dohmen and co-workers developed [33, 34] an oligoaminoamide core, terminated by 
cysteines for crosslinking, containing a monodisperse PEG chain at a defined central 
position and a folic acid (FolA) as cell targeting ligand. An endosomolytic influenza 
peptide, Inf7,[35, 36] was attached to the 5’-ends of siRNA sense strand to increase 
the endosomal escape ability. The multifunctional polyplexes with endosomolytic 
siRNA-Inf7 conjugates indicated a ligand- and Inf7- dependent reporter gene silencing. 
Stained slices of tumor harvested after 24 h i.t. treatment with of siEG5-Inf7 / oligomer 
356 with the sequence FolA-PEG24-K(Stp4-C)2 displayed the expected formation of 
mitotic asters. Although the siRNA-Inf7 356 polyplexes due to their small particle size 
exhibited a short systemic circulation time, the strong shielding effect of PEG chain 
prevented the unspecific affinity to other tissues. Based on oligomer 356 with FolA as 
targeting ligand, methotrexate (MTX) was coupled to the oligo(ethanamino)amide as 
dual-functional ligand to induce folate-receptor (FR) targeted cellular internalization as 
well as cytotoxic activity directed to dihydrofolate reductase (DHFR).[37] The MTX-
containing oligomers exhibited good cellular uptake and a cytotoxicity in FR-
overexpressing KB cells that was enhanced by synthetic oligo-glutamylation (En) of the 
ligand. Lee et al [38] evaluated these oligomers for dual antitumoral siRNA therapy 
(Fig. 2A and B).  
                                                                                     Introduction 
8 
 
 
Fig. 2 Bifunctional siRNA nanoplexes.  A) Schematic overview of the siRNA nanoplexes with 
MTX ligands and endosomolytic Inf7-siRNA conjugate.[38]  B) Oligomers with MTX 
polyglutamates. MTX was coupled to dPEG24 via the γ-glutamic acid (oligomers 638-641) or 
α-carboxy group (oligomer 642), and then linked to a 2-arm cationic backbone. E, glutamic 
acid. Tumor sizes C) and survival curves D) of KB tumor treated by the indicated different 
formulations, HBG buffer, 640, 640 containing siCtrl-Inf7 or siEG5-Inf7, or 356/siEG5-Inf7 
polyplexes.Reproduced from Lee et al.[38] with permissions of Elsevier.   
MTX-conjugated siEG5-Inf7 polyplexes exhibited efficient gene silencing in vitro as 
well as, upon intratumoral injection in KB tumors in mice, significantly extended 
retention of siRNA in tumors in vivo. Meanwhile, due to the dual antitumoral 
mechanism, siEG5-Inf7 polyplexes formed with oligomer 640 with the sequence of 
MTX-E4-PEG24-K(Stp4-C)2 mediated superior tumor suppression as compared to the 
FolA-conjugated 356 groups (Fig. 2C and D). 
1.4  Evolution of siRNA lipopolyplexes  
1.4.1 Biodegradable T-shape lipo-oligomers 
                                                                                     Introduction 
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For siRNA delivery, our studies indicated that extracellular stability of polyplexes is an 
essential requirement, yet the cytosolic release of siRNA in the intracellular space is 
also required. By introduction of a disulfide between the fatty acid domain and the 
cationic siRNA binding domain (Stp or Sph), Klein et al [39] used Fmoc-protected 
succinoyl-cystamine as disulfide building block (ssbb) and developed a library of bio-
degradable oligomers via SPS. The new bio-degradable lipo-oligomers containing 
ssbb block exhibited acidic pH-triggered endosomal escape analogously to the 
standard lipo-oligomers. The cytosolic glutathione (GSH) levels however was expected 
to trigger favorable cytosolic siRNA release of siRNA polyplexes. In addition, cleavage 
of the disulfide bond was expected to convert a detergent-like lipo-oligomer into a 
neutral lipid and a nontoxic small hydrophilic oligomer. Compared with the 
corresponding siRNA polyplexes formed with ssbb-free oligomers, the bio-cleavable 
oligomers demonstrated higher transfection efficiency with lower cytotoxicity.[39]  
For lipid nanoparticles, only 1-2% of siRNA is estimated to be released from 
endosomes into the cytosol,[40, 41] which apparently is sufficient to realize subsequent 
RNAi. It however also means that a large number of carriers are accumulating in the 
lysosomal compartment and may damage these organelles and cell functions. By 
precisely introducing short enzymatically cleavable L-arginine peptides (RR) between 
lipophilic di-myristic acid (MyrA) and the cationic Stp units via SPS, Reinhard et al.[42] 
developed a library of T-shaped oligomers for endolysosomal protease cathepsin B-
triggered siRNA release. Compared with analogous non-degradable oligomers, 
enzymatic bio-degradable lipopolyplexes containing L-arginine displayed reduced lytic 
activity after cleavage, thereby exhibited lower cytotoxicity without affecting the 
transfection efficiency. 
1.4.2 Targeted combination complexes TCP and TLP 
Based on previous studies, FR-targeted combinatorial polyplexes (TCP) were 
developed by co-formulating siRNA with two different oligomers to provide efficient 
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alternatives for multifunctional delivery system.[43, 44] To activate the cysteine thiol 
groups, 5,5′-dithio-bis(2-nitrobenzoic acid) (DTNB) was reacted with one thiol-
containing oligomer, resulting in a TNB modified oligomer which would undergo rapid 
conjugation with another thiol-containing oligomer by formation of disulfide bonds. 
Based on previous work, oligomers with 2, 3 or 4-arm Stp/Sph without or with PEG-
FolA-conjugation were selected [28, 45, 46] or designed. The TCPs displayed 
significant gene silencing efficiency in FR-positive cells. Intravenous administration 
showed that TCP formed with a TNB-bearing PEGylated 4-arm Sph oligomer 873 of 
the sequence of K-(PEG24-FolA)-K-[K-(Sph4-C-TNB)2]2 with a 3-arm Stp oligomer 386 
of the sequence of C-Stp3-K-(Stp3-C)2 exhibited siRNA delivery into a subcutaneous 
L1210 leukemia site and a 46% reduction of EG5 mRNA.  
Afterwards, Lee et al [47] further developed FR-targeted lipopolyplexes (TLPs) by first 
formulating siRNA with an optionally tyrosine-containing oligomer and then co-
formulating targeted PEGylated oligomer 356 with the sequence of FolA-PEG24-
K(Stp4-C)2 by cysteine disulfide cross-linking for shielding and targeting modification. 
Fluorescence resonance energy transfer (FRET) showed that intracellular siRNA 
stability of TLP1 formed by tyrosine-containing oligomer 454 was superior compared 
with other TLPs formed by tyrosine-free oligomers. TLP1 showed folate ligand-
dependent siRNA accumulation in subcutaneous L1210 leukemia with a 65% EG5 
gene silencing. The results demonstrated that the incorporation of tyrosines was 
favorable to protect siRNA from cytosolic degradation, hence caused explicit changes 
to the RNAi effect. 
1.4.3 Surface shielded and targeted siRNA lipopolyplexes 
PEG shielding and targeting domains can be directly introduced into nanocarriers by 
SPS. This process however provides limitation to the nanoparticle design, formation of 
only very small nanoplexes in case of lipid-free formulations, or rather difficile 
combination formulations. An alternative approach presents the formation of stable 
                                                                                     Introduction 
11 
 
lipopolyplex core nanoparticles, followed by post-modification with a PEG-ligand shell. 
This covalent modification of siRNA core nanoparticles was performed in two different 
variations; either by coupling of cysteine thiols on the polyplex surface with maleimide- 
or OPSS- containing PEG-ligands (Fig. 3A);[48-51]  or via copper-free click reaction 
of lipopolyplexes generated with azido-containing oligomers with dibenzocyclooctyne 
amine (DBCO) PEG-ligands (Fig.3B). [52-57] The oligomers as well as the shielding 
and targeting ligands can be synthesized by SPS, which enables precise variation of 
functional units, such as PEG length, or the amount of attachment sites.  
Müller et al [48] used oligomers 454 with the sequence of C-Y3-Stp2-K[K-(OleA)2]-Stp2-
Y3-C and 595 with the sequence of CRC-Y3-Stp2-K[K-(OleA)2]-Stp2-Y3-CRC to prepare 
core siRNA polyplexes. Then the core polyplexes were modified by coupling with 
maleimide-PEG reagents with or without targeting ligand folic acid (FolA) to provide 
FR targeting and PEG shielding, respectively (Fig. 3A). The coupling efficiency of 
maleimide-PEG with oligomers was monitored via an Ellman’s assay. Modification with 
the standard FolA-PEG resulted in nanoparticle aggregation, most likely due to the low 
solubility of FolA. To resolve this problem, tetra-γ-glutamylated folate gE4-FolA was 
designed as ligand. The four negative glutamate charges improve solubility of FolA 
and provide the resulting nanoparticles with a negative zeta potential, which prevents 
nanoparticle aggregation by electrostatic repulsion interactions. The beneficial effect 
of such oligo-glutamylation in FR-targeted delivery was previously confirmed.[38, 58] 
PEGylated gE4-FolA polyplexes showed FR-mediated uptake and effective gene 
transfection efficacy in cervical carcinoma KB cells. Biodistribution of gE4-FolA 
formulations showed extended persistence in L1210 tumor bearing mice, however only 
a moderate in vivo delivery into the subcutaneous leukemia site.  
The epidermal growth factor receptor (EGFR) targeting peptide ligand GE11 was also 
introduced onto the surface of 454 siRNA (or microRNA) polyplexes by coupling 
maleimide-PEG-GE11 with the free cysteines.[49] The resulting GE11 454 siRNA (or 
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microRNA) lipopolyplexes showed enhanced cellular uptake in many EGFR-positive 
cell lines, and also functional delivery of microRNA-200c. Zhang et al [51] developed 
transferrin receptor (TfR) delivery on the basis of 454 siRNA polyplexes. Such 
designed Tf&Inf7 454 siRNA polyplexes displayed effective receptor specific 
internalization and enhanced gene silencing in TfR positive tumor cell lines. In vivo 
distribution further demonstrated the enhanced tumor persistence of siRNA for Tf&Inf7 
polyplexes in murine Neuro2A tumor bearing mice, as compared to the corresponding 
albumin or non-modified groups. 
By introducing azido lysine at the N terminus, Klein et al developed oligomer 1106 with 
the sequence K(N3)-Y3-Stp2-K[G-K(CholA)2]-Stp2-Y3 for click functionalization of 
polyplexes with DBCO reagents (Fig. 3B).[55] A library of defined PEG shielding and 
FolA targeting reagents were precisely synthesized by SPS. This library included 
different PEG lengths and monovalent (DBCO-PEG or DBCO-PEG-FolA) or bivalent 
DBCO with biodegradable linkers (DBCO2-ss2-PEG or DBCO2-ss2-PEG-FolA) for click 
modification, or double-click modification, respectively. Because of the instability of 
DBCO under standard 95% trifluoroacetic acid (TFA) deprotection, in the 5% TFA has 
to be applied in the final cleavage step of SPS. 1106 siRNA polyplexes incorporated 
with bivalent DBCO reagents was superior at size distribution, cellular internalization 
as well as gene silencing effect in vitro. Intravenous injection of the resulting 
1106/siEG5/DBCO2-ss2-PEG24-FolA lipo-polyplexes displayed extended tumor 
retention in L1210 tumor-bearing mice, with a knockdown of ~60% of target mRNA 
(Fig. 3C and Fig. 3D). The click reaction between DBCO and azide is highly specific 
and biorthogonal to other functional domains and without by-products. [59-61] 
Compared to the disulfide bonding modification, click modification will not affect the 
main purpose of cysteines and keep the stability of core polyplexes by internal disulfide 
crosslinking.  
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Fig. 3. Lipopolyplexes containing shielding and targeting domains. A) Cysteine-containing 
oligomers 454 or 595 were mixed with siRNA, and then the polyplexes were post-PEGylation 
with Mal-PEG24-FolA (FolA) or Mal-PEG24-gE4-FolA (gE4-FolA) by reaction with free cysteines 
on the surface of polyplexes.[48] FolA: folate acid. Reproduced from Müller et al.[48] with 
permission of American Chemical Society. B) siRNA polyplexes made with azido-bearing lipo-
oligomer 1106. Shielding or targeting reagents with monovalent or bivalent terminal DBCO 
were attached to the lipopolyplexes via click or double-click reaction with the exposed 
azides.[55] C) In vivo gene silencing efficiency of 1106/siRNA/DBCO2-ss2-PEG24-FolA 
lipopolyplexes. EG5 mRNA expression level in L1210 tumor mice was measured by qPCR.[55]  
D) Tumor sizes and survival curves of mice treated by HBG, PT, 1106/siRNA/DBCO2-ss2-
PEG24-FolA lipopolyplexes with siCtrl or siEG5, without or in combination with pretubulysin 
(PT). The arrows indicate the days of treatment.[55]  B) to D) reproduced from Klein et al. [55] 
with permission of Elsevier.  
Introduction 
14 
Conventionally, siRNA polyplexes were prepared by rapid manual pipetting up and 
down. Loy et al developed a microfluidic platform by designing two successive Y 
junctions for controlled and sequential formulation of functionalized polyplexes.[62] 
The core siRNA polyplexes were first assembled through single-meander channel 
(SMC). Then the polyplexes were click-modified with DBCO-PEG-FolA of different 
PEG lengths by a double-meander channel (DMC). The results demonstrated a clear 
influence of the PEG linker on gene silencing efficacy, which was consistent with 
previous findings. [55] 
1.5 Aim of thesis 
siRNA therapeutics has shown great potential, yet the downregulation of targeted gene 
expression may only partially inhibit tumor progression. Therefore, combined siRNA 
together with chemotherapeutic drugs or miRNA into one delivery system has to be 
developed to increase the therapeutic efficiency. Compared with monotherapy of 
cancer treatment, combination therapy enables different therapeutic entities 
simultaneously arrive the respective target site, results increased therapeutic efficiency 
due to the synergistic effect as well as lower side effects due to reduced dosage of 
chemotherapeutic drugs.[56, 63, 64] With regard to future optimization of this class of 
siRNA cancer therapeutics, emphasis has to be directed to (i) siRNA functionalized by 
chemical modification to combine with some antitumoral peptides/drug, and (ii) 
optimization of cationic oligo-formulation to fast attach to the tumor endothelial cells 
and achieve siRNA function in vivo.  
The first aim of the thesis was to present a monodisperse carrier synthesized by solid 
phase supported chemistry. The sequence-defined assembly contains two oleic acids 
attached to a cationizable oligoaminoamide backbone in T-shape configuration, and a 
terminal azide functionality for coupling to the atherosclerotic plaque-specific peptide-
1 (AP-1) as cell targeting ligand for interleukin-4 receptor (IL-4R) which is 
overexpressed in a variety of solid cancers. For combined cytosolic delivery with siRNA, 
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different apoptotic peptides (KLK, BAK and BAD) were covalently conjugated via 
bioreversible disulfide linkage to the 5’end of the siRNA sense strand. The optimized 
targeted carrier was complexed with dual antitumoral siEG5-KLK conjugates. The 
functionality of each subdomain was individually confirmed. The lipo-oligomer 
conferred stable assembly of siRNA conjugates and was click-shielded with 
dibenzocyclootyne-PEG-AP-1 (DBCO-PEG-AP-1). Structure-activity relationships of 
these oligomers were investigated, and the further mechanism of apoptotic peptide 
and siRNA in vitro function were also evaluated and discussed. 
The second aim of the thesis was that a cationizable sequence-defined lipo-
oligoaminoamide (lipo-OAA) modified with an N-terminal azide and HA modified with 
DBCO groups were used as clickable modules, respectively. By variation of the ratio 
of DBCO-HA to OAA azide of the siRNA nanoparticle, colloidal stable cationic and 
anionic HA-based siRNA polyplexes were established. Evaluation of these 
nanoparticles should explore any relations of surface charge with in vivo tumor 
accumulation, tumor penetration and subsequent gene silencing efficacy in vivo. The 
effect of the different coatings on the cellular uptake, endocytic pathways, endosomal 
escape in vitro, and tumor accumulation, tumor penetration, and gene silencing of 
siRNA carriers in vivo should also be evaluated.  
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2. Materials and Methods
2.1  Materials 
Materials: 2-Chlorotrityl Chloride resin, protected Fmoc-α-amino acids, N, N-
dimethylformamide (DMF), N,N-diisopropylethylamine (DIPEA), N-methyl-2-
pyrrolidone (NMP) and trifluoroacetic acid (TFA) were obtained from Iris Biotech 
(Marktredewitz, Germany). 1-hydroxybenzotriazole (HOBt), triisopropylsilane (TIS), 
dibenzocyclooctyne-PEG4-maleimide, dimethyl sulfoxide (DMSO) and oleic acid were 
purchased from Sigma-Aldrich (Munich, Germany). Syringe microreactors for peptide 
synthesis and (benzotriazol-1-yloxy) tripyrrolidino phosphonium hexafluorophosphate 
(PyBOP) were obtained from MultiSynTech (Witten, Germany). Fmoc-N-amido-
dPEG24-acid from Quanta Biodesign (Powell, Ohio, USA). siRNA duplexes were 
obtained from Axolabs GmbH (Kulmbach, Germany): eGFP-targeting siRNA (siGFP) 
(sense: 5’-AuAucAuGGccGAcAAGcAdTsdT-3’; antisense: 5’-
UGCUUGUCGGCcAUGAuAUdTsdT-3’) for silencing of eGFPLuc; EG5-targeting 
siRNA (siEG5) (sense: 5’-ucGAGAAucuAAAcuAAcudTsdT-3’; antisense: 5’-
AGUuAGUUuAGAUUCUCGAdTsdT-3’) for silencing EG5 motor protein; control 
siRNA (siCtrl) (sense: 5’-AuGuAuuGGccuGuAuuAGdTsdT-3’; antisense: 5’-
CuAAuAcAGGCcAAuAcAUdTsdT-3’); Cy5-labeled siRNA (Cy5-siAHA1) (sense: 5’-
(Cy5)(NHC6)GGAuGAAGuGGAGAuuAGudTsdT-3’; antisense: 5’-
ACuAAUCUCcACUUcAUCCdTsdT-3’); Apoptotic peptides modified siRNA, disulfide-
siEG5 (sense: 5’-(C6SSC6)ucGAGAAucuAAAcuAAcudTsdT-3’; antisense: 5’-
AGUuAGUUuAGAUUCUCGAdTsdT-3’) and disulfide-siCtrl (sense: 5’-
(C6SSC6)AuGuAuuGGccuGuAuuAGdTsdT-3’; antisense: 5’-
CuAAuAcAGGCcAAuAcAUdTsdT-3’); small letters: 2’-methoxy-RNA; s: 
phosphorothioate. Cell culture media, antibiotics and fetal calf serum (FCS) were 
purchased from Invitrogen (Karlsruhe, Germany), HEPES from Biomol GmbH 
(Hamburg, Germany), glucose from Merck (Darmstadt, Germany), agarose (NEEO 
Materials and Methods 
17 
Ultraquality) and ammonia solution 25% from Carl Roth GmbH (Karlsruhe, Germany), 
and GelRed™ from VWR (Darmstadt, Germany). Cell culture lysis buffer and D-
luciferin sodium salt were obtained from Promega (Mannheim, Germany).  
2.2  Methods 
2.2.1  Loading of 2-chlorotrityl chloride resin with Fmoc-protected amino acids 
2-chlorotrityl chloride resin (500 mg, chloride loading 1.55 mmol/g) was swelled in dry 
DCM for 10 min for two times. Subsequently, 0.4 eq mmol Fmoc-L-Cys(Trt)-OH (or 
Fmoc-L-Tyr(tBu)-OH) and 0.9 eq mmol DIPEA were added to the resin and incubated 
at RT for 1 h. After removing the reaction solvents, the resin was incubated with a 
mixture of DCM/MeOH/DIPEA (80/15/5 v/v/v) for 10 min for two times at RT. After 
removal of the reaction mixture, the resin was washed 5 times with DCM and about 30 
mg of the resin was separated for the loading determination. Therefore, an exact 
amount of resin was treated with 1 mL deprotection solution (20% piperidine in DMF) 
for 1 h. Afterwards, the solution was diluted, and absorption was measured at 301 nm. 
The loading was then calculated according to the equation: resin load [mmol/g] = 
(A*1000)/(m [mg]*7800*df) with df as dilution factor. The rest resin was washed 3 times 
with DMF, and then was treated 5 times for 10 minutes with 20 % piperidine in DMF. 
Reaction progress was monitored by Kaiser test. Finally, the resin was washed 3 times 
with DMF, 3 times with DCM, 3 times with n-hexane and dried under vacuum. 
2.2.2  Synthesis of oligomers 
Oligoaminoamides were synthesized analogously as previously reported [28, 65-68] 
by standard Fmoc-based solid phase supported peptide synthesis in syringe reactors. 
2-Chlorotrityl chloride resin was used as solid support. The synthesis of oligomers 
contained three main process: loading, coupling and cleaving off the resin. The 
protocol of TFA cleavage condition was used as previously described, with pre-cooling 
to avoid hydroxylation of the oleic acid double bonds.[67] For the PEG-AP-1 targeting 
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domain, the 3-mercaptopropionic acid-PEG-AP1 sequence was synthesized manually 
by Fmoc solid-phase peptide synthesis using a syringe microreactor. After standard 
deprotection and cleavage condition (TFA/TIS/H2O 95:2.5:2.5), the peptide conjugate 
was specifically coupled via its N-terminal 3-mercaptopropionic acid with maleimide-
PEG4-DBCO at neutral pH in solution. For the apoptotic peptide syntheses, the 
sequences were synthesized by Fmoc solid-phase peptide synthesis using a syringe 
microreactor. An N-terminal cysteine was incorporated onto these apoptotic peptides 
for subsequent coupling with the free thiol of siRNA sense strand.  
2.2.3  Synthesis of different siRNA-Apoptotic peptide conjugates  
The sense strand of the applied siRNA contained a 5’-end modification with C6-ss-C6 
spacer. The modified siRNA was incubated with tris(2-chlorethyl) phosphate (TCEP, 
10 equiv.) for 30 min at 25 °C, resulting in a free thiol on the 5’-end. Purification was 
performed by ethanol precipitation and dissolved in water to a concentration of 1 mM. 
The apoptotic peptides were incubated with 5,5’-dithiobis (2-nitrobenzoic acid) (DTNB, 
10 equiv.) for 1h at RT to activate the thiol. The activation product was purified by 
HPLC (VWR Hitachi Chromaster consisting of 5430 Diode array detector and 5160 
gradient pump, Darmstadt, Deutschland). The products were separated with a XTerra 
C8 column (5 μm, 4.6 x 150 mm, Waters, Eschborn, Germany) and eluted with an 
ACN/0.1M triethylammonium acetate gradient (95:5 to 35:65 in 45 min, pH 8). Product 
containing fractions were lyophilized. The resulting activated apoptotic peptides (1.5 
equiv.) was incubated with free thiol of siRNA. The resulting siRNA-apoptotic peptide 
conjugates were purified by HPLC using the same conditions as described above. 
Fractions were collected and lyophilized and dissolved in 20mM HEPES buffered 5% 
glucose pH 7.4 (HBG) at a concentration of 500 ng/mL. The siRNA conjugates were 
analyzed in a 3.5% agarose gel (100 mV for 100 min) and MALDI-TOF-MS analysis. 
The dimer siRNA and pure siRNA were regarded as controls to determine the purity of 
siRNA conjugate. 
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2.2.4  Synthesis of modified Hyaluronic acid-DBCO 
HA (20 kDa sodium salt, 5 mg, 0.012 mmol monomers), NHS (N-hydroxysuccinimide, 
5eq. 0.06 mmol, 6.9 mg), EDC (3-(ethyliminomethyleneamino)-N,N-dimethylpropan-1-
amine; 5eq. 0.06 mmol, 11.5 mg) were dissolved in 100 mL activation buffer (0.1M, 
TES, 2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]ethanesulfonic acid). The 
pH was adjusted to 7. Afterwards, DBCO-amine (2eq. 0.024 mmol, 6.6 mg) in DMF 
was added into above solutions. After overnight, the product was purified by dialysis 
with a 3500 Da cut-off membrane against deionized water. The yield of DBCO-HA was 
75 % by calculation of weight after lyophilization. The substitution degree for HA 
carboxylic groups was 8% according to the 1H-NMR spectrum, which was also 
confirmed by the increase in absorbance at 309 nm using an extinction coefficient of 
12,000 M-1 · cm-1. 
2.2.5  Kaiser Test 
Free amines of deprotected amino acids on the resin were determined qualitatively by 
the Kaiser test [67]. A small sample of DCM washed resin was transferred into an 
Eppendorf reaction tube. One drop of each 80 % phenol in EtOH (w/v), 5 % ninhydrin 
in EtOH (w/v) and 20 μM potassium cyanide (KCN) in pyridine (mixture of 1 mL 
aqueous 0.001 M KCN solution and 49 mL pyridine) were added. The tube was 
incubated at 99 °C for 4 min under shaking. The presence of free amines was indicated 
by a deep blue color.  
2.2.6  General Cleavage conditions 
All oligomers were cleaved off the resin by incubation with TFA–TIS–H2O (95 : 2.5 : 
2.5) (10 mL g−1 resin) for 90 min. The cleavage solution was concentrated by flushing 
nitrogen and oligomers were precipitated in 50 mL of pre-cooled MTBE – n-hexane (1 : 
1). All oligomers were purified by size exclusion chromatography using a Äkta purifier 
system (GE Healthcare Bio-Sciences AB, Uppsala, Sweden), a Sephadex G-10 
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column and 10 mM hydrochloric acid solution–acetonitrile (7 : 3) as solvent. All 
oligomers were lyophilized.  
2.2.7  Cleavage of oligomers containing oleic acid 
The cleavage of the structures off the resin was performed according to an optimized 
protocol by incubation with TFA–TIS–H2O 95 : 2.5 : 2.5 (10 mL/g resin cooled to 4 °C 
prior to addition) for 30 min followed by immediate precipitation in 40 mL of pre-cooled 
MTBE – n-hexane (1 : 1). The oleic acid containing oligomers were then purified by 
size exclusion chromatography using a Äkta purifier system (GE Healthcare Bio-
Sciences AB, Uppsala, Sweden), a Sephadex G-10 column and 10 mM hydrochloric 
acid solution–acetonitrile (7 : 3) as solvent. The oligomers were lyophilized. 
2.2.8  siRNA formulation 
500 ng of siRNA and the calculated amount of oligomers at the indicated 
nitrogen/phosphate (N/P) ratios were separately diluted in 10 µL of HBG. Only 
protonatable nitrogens were considered into N/P calculation. The oligomers solution 
was added in the nucleic acid solution and mixed by pipetting up and down (3 times) 
to obtain a homogeneous state. The polyplexes were incubated for 45 min at RT. For 
modification of siRNA polyplexes with DBCO agents, the ratio of volume of DBCO 
solutions and polyplexes was 1/4. Equivalents refer to the molar ratios of shielding or 
targeting agents to oligomers in the final solution. The incubation time between azide 
and DBCO click chemistry was 4 h. 
2.2.9  High-performance liquid chromatography (HPLC) 
The siRNA-Apoptotic peptides conjugates were purified by HPLC (VWR Hitachi 
Chromaster consisting of 5430 Diode array detector and 5160 gradient pump, 
Darmstadt, Deutschland). The products were separated with a XTerra C8 column (5 
μm, 4.6 x 150 mm, Waters, Eschborn, Germany) and eluted with an ACN/0.1M 
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triethylammonium acetate gradient (95:5 to 35:65 in 45 min, pH 8). Product containing 
fractions were lyophilized.  
2.2.10  1H-NMR spectroscopy 
1H NMR spectra was performed using a Jeol JNMR-GX 400 (400 MHz) or JNMR-GX 
500 (500 MHz) without TMS as internal standard. Deuterium oxide (D2O) was used as 
solvent. All chemical shifts were calibrated to the residual proton signal of the solvent 
and are reported in ppm. Data are presented as s = singlet, d = doublet, t = triplet, m 
= multiplet. The spectra were analyzed with MestReNova (MestReLab Research).  
2.2.11  MALDI mass spectrometry 
One μL matrix droplet consisting of a saturated solution of Super-DHB (sum of 2,5-
dihydroxybenzoic acid and 2-hydroxy-5-methoxybenzoic acid) in acetonitrile / water (1 : 
1) containing 0.1 % (v/v) TFA was spotted on an MTP AnchorChip (Bruker Daltonics,
Bremen, Germany). After the Super-DHB matrix had crystallized, one μL of the sample 
solution (10 mg/mL in water) was added to the matrix spot. Samples were analyzed 
using an Autoflex II mass spectrometer (Bruker Daltonics, Bremen, Germany). All 
spectra were recorded in positive mode. 
2.2.12  siRNA binding assay 
A 2.5% agarose gel containing GelRed® was prepared. Formulations were prepared 
with 500 ng of siRNA and diluted to a final volume of 20 µL. Samples were mixed with 
loading buffer (6 mL of glycerol, 1.2 mL of 0.5 M EDTA, 2.8 mL of H2O, 0.02 g of 
bromophenol blue). Electrophoresis was performed at 100 V for 40 min. 
2.2.13  siRNA polyplexes stability in 90% serum 
Polyplexes were formed using 2.5 μg siRNA mixed with the oligomer at N/P 12 
resulting in a total volume of 10 μL. Afterwards, the incubation 90 μl fetal bovine serum 
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(FBS) was added to the samples. All samples had a final concentration of 90 % FBS. 
The samples were incubated at 37 °C for 2 h. 20 μL of the samples and 4 μL loading 
buffer were carefully mixed and a binding assay (see 2.2.12) was performed.  
2.2.14  Particle size and zeta potential 
Polyplexes were formed using 4 µg siRNA and diluted with HBG to a total volume of 
20 µL. After 45 min incubation time, polyplexes were diluted with HEPES solution to 
800 µL volume. The polyplex solution was measured in a folded capillary cell (DTS 
1070) using a Zetasizer Nano ZS (Malvern, Worcestershire, UK) with a flexible 
attenuator at an angle of 173 °. The refractive index of the solvent was 1.330 and the 
viscosity was 0.8872 mPa·s. Samples where measured three times with six sub runs 
each. Afterwards, zeta potential was measured with a flexible attenuator at a 90 ° angle. 
Samples were measured three times (10000 total counts, usually 12-15 sub runs). The 
temperature was set at 25 °C. 
2.2.15  Cell culture 
Human cervix carcinoma cells HeLa, KB (subclone of HeLa) and human liver 
carcinoma cells Huh 7 were cultured in Dulbecco’s modified Eagle’s medium (DMEM), 
supplemented with 1 g/L glucose, 10% FBS, 4 mM stable glutamine, 100U/mL 
penicillin and 100 µg/mL streptomycin. Human breast adenocarcinoma cells MDA-MB-
231 stably transfected with the eGFPLuc gene (MDA-MB-231/eGFPLuc) and KB cells 
stably transfected with the eGFPLuc gene (KB/eGFPLuc) were cultured in RPMI 1640 
medium (Invitrogen, Karlsruhe, Germany), supplemented with 10% FBS, 4 mM stable 
glutamine, 100U/mL penicillin and 100 µg/mL streptomycin. Huh 7 cells stably 
transfected with the eGFPLuc gene (Huh 7/eGFPLuc) were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM)/Nutrient Mixture F-12 Ham, supplemented with 10% 
FBS, 4 mM stable glutamine, 100U/mL penicillin and 100 µg/mL streptomycin. Human 
lung carcinoma cells A549 was cultured in Dulbecco’s modified Eagle’s medium 
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(DMEM), supplemented with 4.5 g/L glucose, 10% FBS, 4 mM stable glutamine, 
100U/mL penicillin and 100 µg/mL streptomycin. The cells were maintained in 
ventilated flasks in the incubators at 37 °C with 5% CO2 in a humidified atmosphere. 
Cell lines were grown to 80-90% confluency and harvested. 
2.2.16  Cell internalization 
Cells were seeded in 24-well plates at a density (90000 cells/well for Huh 7) for 24h 
before the experiment. Polyplexes containing 1.35 µg of siRNA, including 20% Cy5-
labeled siRNA, were added into each well incubated 45 min at 37 °C in 5% CO2. 
Afterwards, cells were treated with PBS to remove non-bound polyplexes. Then cells 
were incubated with 500 I.U. heparin to remove the polyplexes associated to the cells 
surface. Finally, the cells were collected and resuspended in PBS buffer with 10% FBS. 
The samples were mixed with DAPI at a final concentration of 1 ng/µL before flow 
cytometry measurement. Dead cells were differentiated by DAPI fluorescence and 
removed by gating in order to analyze the cellular uptake of polyplexes into living cells. 
The amount of Cy5-labeled living cells was counted through excitation at 635 nm and 
detection of emission at 665 nm. The results were evaluated by the FlowJo 7.6.5 
software. All experiments were performed in triplicates. 
2.2.17  Endocytosis pathway 
For the endocytosis pathway, KB and Huh 7 cell lines were seeded into 24-well-plates 
at a density of 16000 cells/well. To determine the endocytosis pathway, the cells were 
pre-incubated with different inhibitors diluted in Millipore water at different 
concentrations (nystatin 15 μg/mL, sucrose 154 mg/mL, amiloride 133 μg/mL, sodium 
azide 1 mg/mL, HA 10 mg/mL) for 1 h at 37°C. The medium was changed and 
incubated at 37°C for 2h after adding polyplexes containing 1.35 µg of siRNA 
(containing 20% of Cy5-labeled siRNA). The samples were prepared for flow 
cytometric measurements with LSR Fortessa (BD biosciences, Singapore) as 
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described above. All experiments were performed in triplicates and evaluated by the 
FlowJo 7.6.5 software. 
2.2.18  Transmission electron microscopy (TEM)   
Carbon coated copper grids (Ted Pella, Redding, CA, USA, 300 mesh, 3.0 mm O. D.) 
were hydrophilized with a plasma cleaner under argon atmosphere. Afterwards, the 
grids were placed activated face down on 10 µL of the siRNA polyplex solution at N/P 
12 (diluted in water). Incubation time was 3 min. The liquid was removed using a filter 
paper. Subsequently, the copper grid was washed with 5 μL staining solution (1% 
uranyl format in purified water, Sigma-Aldrich, Munich, Germany), which was 
immediately removed. Staining was achieved with 5 µL of the same solution that was 
left on the grid for 5 s. Afterwards, all liquid was removed with a filter paper. Grids were 
stored at room temperature and they were analyzed using JEM 1011 transmission 
electron microscope (JEOL, Tokyo, Japan) at 80 kV acceleration voltage. 
2.2.19  Lysotracker assay  
For subcellular distribution, Huh 7 cell lines were seeded into 8-well chamber at a 
density (15000 cells/well) for 24h prior to the experiment. Polyplexes were formed as 
described using 20% Cy5-labeled siRNA at N/P 12 and diluted to a final siRNA 
concentration of 370 nM in HBG. After 2 h of incubation at 37°C, the medium was 
changed before 0.1 μL of LysoTrackerGreen solution (Fisher Scientific) was added into 
each well. The cells were washed twice with 100 μL PBS and incubated for 1h in 37°C 
incubators. After adding the Hoechst 33342, the cells were directly measured by 
confocal laser scanning microscopy. 
2.2.20  Gene silencing with siRNA 
Gene silencing experiments were performed with IL4 receptor-positive KB/eGFPLuc 
cells and Huh 7/eGFPLuc cells. Applied siRNAs were siGFP for silencing the eGFPLuc 
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fusion protein and the control siCtrl. Cells were seeded in 100 µL of medium using 96-
well plates at a density (8000 cells/well for Huh 7/eGFPLuc cells and KB/eGFPLuc 
cells) for 24h prior to the experiment. After the medium was replaced with 80 µL of 
fresh medium, cells were transfected with 20 µL of polyplexes containing 500 ng of 
siRNA at certain N/P ratio at 37 °C for 4 h. Afterwards, the medium was replaced with 
fresh one and cells were incubated 48h. Before measuring the luciferase activity, 100 
µL of cell lysis regent (Promega, Mannheim, Germany) was added to cells per well. 
The luciferase assay kit (Promega, Mannheim, Germany) and a Centro LB 96 plate 
reader luminometer (Berthold, Bad Wildbad, Germany) were used. The relative light 
units (RLU) were related to HBG buffer-treated control cells. 
2.2.21  Cell viability 
To measure cytotoxicity mediated by EG5 knockdown and/or apoptotic peptide 
conjugates, the apoptotic peptide modified siRNAs siEG5-apoptotic peptide (siEG5-
KLK, siEG5-BAK, siEG5-BAD) and their control siCtrl-apoptotic peptide conjugates 
(siCtrl-KLK, siCtrl-BAK, siCtrl-BAD) were used. Cells were seeded on 96-well plate in 
100 µL of medium 24h before the experiment. Medium was replaced by 80 µL of fresh 
medium. Formulation were formed using 20 µL of polyplexes containing 500 ng either 
siRNA or siRNA-apoptotic peptide conjugates at N/P ratio of 12. After incubation at 4h, 
the medium was replaced with 100 µL of fresh medium and cells were cultured for 48 
h. MTT assay (Life Technology, Darmstadt, Germany) was performed to evaluate the 
cell viability. The experiments were performed in triplicates using SpectraFluor Plus 
microplate reader (Tecan, Austria).  
2.2.22  Fluorescence microscopy of aster formation  
Huh 7 cells and KB cells (20 000 cell/well) were seeded in 300 µL of medium using 8-
well Lab-Tek chamber slides for 24 h. After seeding medium was replaced with 250 µL 
of fresh medium, 50 µL of polyplexes containing 1.5 µg of either siRNA or siRNA-
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apoptotic peptide conjugate was added. Medium was replaced by fresh medium 4 h 
after transfection. After 48 h medium was removed, PBS was added to wash the cells. 
The cells were fixed with 4 % PFA and then cell nuclei were stained by DAPI. The data 
was obtained from Axiovert 200 fluorescence microscope (Carl Zeiss, Oberkochen, 
Germany).  
2.2.23  JC-1 assay 
Huh 7 cells (140 000 cells per well) were seeded into 12-well plates for 24 h. The cells 
were incubated with 1) the 1208 + siCtrl + AP-1; 2) 1208 + siCtrl-KLK + AP-1; 3) 1208 
+ siEG5 + AP-1; 4) 1208 + siEG5-KLK + AP-1, loaded with siRNA at a dose of 2.7 µg 
for 4 hours.  The medium was replaced with fresh medium and cells were cultured for 
48 hours. Afterwards, the cells were collected and suspended in 1 mL of warm PBS 
buffer. For positive control, 1 µL of 50 mM CCCP was added and cells were incubated 
for 5 min. Afterwards, 10 µL of 200 µM JC-1 was added each sample and incubated 
for 20 min. Cells were collected and analyzed by a flow cytometry using 488 nm 
excitation. 
2.2.24  Annexin V-FITC / PI apoptosis assay 
Huh 7 cells (140 000 cells per well) were seeded into 12-well plates for 24 h. The cells 
were incubated with 1) the 1208 + siCtrl + AP-1; 2) 1208 + siCtrl-KLK + AP-1; 3) 1208 
+ siEG5 + AP-1; 4) 1208 + siEG5-KLK + AP-1, loaded with siRNA at a dose of 2.7 µg 
for 4 h. The medium was replaced with fresh medium and cells were cultured for 24 h 
and 48 h. Afterwards, the cells were collected and suspended in 0.5 mL of 1 × binding 
buffer, followed by washes twice with ice-cold PBS. Annexin V-FITC (2 µL, 0.15 mg/mL, 
BioVision, USA) was added into the cell suspension with an incubation for 15 min and 
the cells were immediately analyzed by a flow cytometry after adding 2 µL of propidium 
iodide PI (1 mg/mL, BioVision, USA). 
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2.2.25  Animal tumor model 
Female 8-week-old nude mice, Rj: NMRI-nu (nu/nu) (Janvier, Le Genest-Saint-Isle, 
France), were housed in isolated ventilated cages and acclimated for at least 7 days 
prior to experiments. Animals were injected with 5 × 106 Huh 7 hepatocellular 
carcinoma cells subcutaneously for biodistribution study and EG5 silencing assay in 
vivo. The body weight was recorded, and the tumor volume was measured by caliper 
and calculated as [0.5 × (longest diameter) × (shortest diameter)2]. All animal 
experiments were performed according to guidelines of the German law for the 
protection of animal life and were approved by the local animal ethics committee.  
2.2.26  Biodistribution 
For near infrared (NIR) in vivo imaging, unlabeled control siRNA (siCtrl) was spiked 
with 50% of Cy7-labeled siRNA (Cy7-siAHA1). When tumors reached the size of 500 
mm3, the mice (n = 3/per group) were anesthetized with 3% isoflurane in oxygen. 
siRNA polyplexes (N/P 12) in 250 µL of HBG were injected intravenously (i.v.), and 
fluorescence was measured with a CCD camera at different time points. For evaluation 
of images, efficiency of fluorescence signals was analyzed after color bar scales were 
equalized using IVIS Lumina system with Living Image software 3.2 (Caliper Life 
Sciences, Hopkinton, MA, USA).  
2.2.27  Gene silencing of EG5 in vivo 
When tumors reached 500 mm3, mice (n = 5/per group) were injected i.v. with siRNA 
polyplexes containing 50 µg of siEG5 or siCtrl (N/P 12) 48 h and 24 h before euthanasia. 
As a part of terminal procedure, blood samples were obtained by cardiac puncture for 
blood biochemistry examinations. After tumors were harvested and homogenized, total 
RNA was extracted using Trifast (Peqlab, Erlangen, Germany) according to the 
manufacturer’s protocol, and then the reverse transcription and qRT-PCR were 
performed. Total RNA was isolated followed by reverse transcription using qScriptTM 
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cDNA Synthesis Kit (Quantabio, Beverly, USA) according to the manufacturers’ 
protocols. Quantitative RT-PCR was performed in triplicates on a LightCycler 480 
system (Roche, Mannheim, Germany) using UPL Probes (Roche, Mannheim, 
Germany) and Probes Master (Roche, Mannheim, Germany) with GAPDH as 
housekeeping gene. The following probes and primer sequences were used: human 
GAPDH (ready-to-use in UPL, UPL Probe #45), human EG5 (UPL Probe #53) (forward: 
CATCCAGGTGGTGGTGAGAT, reverse: TATTGAATGGGCGCTAGCTT). Results 
were analyzed by the ΔCT method. CT values of GAPDH were subtracted from CT 
values of EG5. ΔCT values of cationic and anionic siRNA polyplexes groups were 
calculated as percentage relative to untreated HBG control groups. 
2.2.28  Blood biochemistry examinations 
To isolate plasma, blood samples were collected in EDTA-coated tubes (Multivette 600, 
Sarstedt, Nümbrecht, Germany) and centrifuged at 3000 rpm for 7 minutes. The 
supernatant was analyzed for clinical biochemistry parameters: alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN) 
and creatinine in the Clinic of Small Animal Medicine, Faculty of Veterinary Medicine, 
Ludwig-Maximilians-Universität München. 
2.2.29  Staining, imaging and 3D reconstruction 
Mice (n = 3/per group) with tumor xenograft over 500 mm3 were injected intravenously 
with cationic or anionic polyplexes containing 50 µg of siCtrl spiked with 50% of Cy3-
labeled siRNA (Cy3-siAHA1) (N/P 12), and anesthetized with Ketamine/Xylaxin at 0.1 
mL/10g bodyweight at 5 min and 45 min after injection. Upon sacrification, mice were 
perfused transcardially using PBS at 10mL/min for 1min, followed by 1% 
paraformaldehyde PFA in PBS at the above same speed for 3min. Subsequently, mice 
were blocked with 1% BSA (97061-420; VWR, PA, USA) in PBS at 10mL/min for 1min 
and stained by 50mL DyLight 488 labeled lycopersicon esculentum tomato lectin (20 
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µg/mL in PBS, DL-1174-1; Vector Laboratories, Burlingame, CA, USA) at 10mL/min. 
Finally, mice were washed using 1% BSA in PBS for 1 min. Tumor xenograft and 
organs (kidneys) were harvested for 50 µm thick sections using a Vibratome (VT1000S; 
Leica, Wetzlar, Germany). Free-floating sections were then collected and mounted 
with antifade mounting medium (H-1400, Vector Laboratories, Burlingame, CA, USA) 
and scanned in a Z-stack manner with 1 µm interval using a confocal microscope 
system (LSM780, Zeiss, Oberkochen, Germany) within 12h due to the easily 
degradable character of tomato lectin. Corresponding 3D reconstruction was 
performed using Imaris 9.0.1(Bitplane, Belfast, UK). 
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3.  Results and Discussion 
3.1 IL4-receptor-targeted antitumoral apoptotic peptide - siRNA conjugate 
lipoplexes 
Section 3.1 has been adapted from: Jie Luo, Miriam Höhn, Sören Reinhard, Dominik M. Loy, 
Philipp Michael Klein and Ernst Wagner, Adv. Funct. Mater. 2019, 29, 1900697. 
siRNA has the potential to downregulate disease-related gene expression in a 
selective and sequence-dependent manner, and thereby provides a promising 
therapeutic approach for severe diseases including genetic diseases or cancer.[69] 
The first siRNA drug, Patisiran, a liposomal formulation of transthyretin (TTR) siRNA 
for treatment of hereditary transthyretin-mediated (ATTR) amyloidosis by gene 
silencing in the liver, has obtained market approval by the US FDA in August 2018.[70] 
Although the biological process of gene silencing is well understood, the main 
challenge of siRNA therapeutics remains the efficient delivery to target sites different 
from liver tissue.[71-73] Steps such as specific recognition of the target cells, stability 
and protection in the cellular environment, and entrance into the cytosol remain 
challenging bottlenecks in the delivery process. Naked siRNA molecules have limited 
stability in biological environments, subjected to fast elimination by the kidneys, and 
their crossing of cell membranes is restricted by the hydrophilicity, negative charge and 
large molecular weight. Thus chemical modification, conjugation or formulation of 
siRNA with carriers, such as liposomal or polymers-based complexes, can improve the 
intracellular delivery.[74-76] 
Sequence-defined oligoaminoamides present a class of nucleic acid carriers with 
multifunctionality and high chemical precision.[17, 77, 78] In our previous work, we 
developed a series of sequence-defined oligoaminoamide carriers with targeting and 
shielding domains for nucleic acid transfections.[28, 33, 79-81] Libraries of lipo-
oligomers were precisely assembled via solid phase-supported synthesis (SPSS) 
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using artificial oligoamino acids and fatty acids.[32, 65, 82, 83] These different 
structures of oligomers with functional moieties mediated enhanced cellular uptake, 
protection of siRNA against degradation, endosomal escape into the cytosol, and thus 
improved gene silencing efficiency. Introduction of shielding and ligand domains was 
found to be essential for specific siRNA delivery into cancer cells.[28, 84, 85] 
Polyethylene glycol (PEG) is known to improve stability of polyplexes and to shield 
their surface, thus reducing binding and aggregation with negative-charged serum 
proteins within the blood circulation.[86-88] Targeting ligands for binding to 
overexpressed cell surface receptors have been also taken into consideration for 
preferential transfection of the intended tissue.[65, 89] 
Based on our understanding of the relationship between structure and activity of 
previous oligoaminoamide libraries and nanoparticle shields, the present study aims at 
a more effective design of a dual-antitumoral siRNA conjugate formulated with a new 
precise multifunctional carrier. 
Previous studies applied siRNA targeting Eglin 5 (EG5), a member of the kinesin-5 
family, which is involved in the assembly of the mitotic spindle apparatus and required 
for centrosome separation.[90] EG5 silencing results in mitotic arrest and tumor cell 
death.[38, 91, 92] In our previous studies potent antitumoral activity required 
combination with other drug agents (methotrexate or pretubulysin).[38, 65] Pro-
apoptotic peptides present another class of potent anti-cancer agents, provided that 
they can be effectively delivered into cells, such as by covalent attachment to polymeric 
carriers.[93] Our current study explores the novel strategy to conjugate an apoptotic 
peptide with siRNA for efficient intracellular co-delivery. After screening siRNA 
conjugates with various apoptotic peptides (KLK, BAK, BAD), EG5 siRNA conjugated 
with KLK provided enhanced tumor cell killing by the combined mechanism of EG5 
silencing and destabilization of mitochondrial membranes.  
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Furthermore, the current study capitalizes on targeting the siRNA-apoptotic peptide 
containing nanoparticles to the interleukin-4 receptor (IL-4R), which is overexpressed 
on a variety of solid cancers.[94-96] AP1, a peptide designed as a ligand from 
atherosclerotic plaque-specific peptide-1, was utilized for binding to the IL-4R; this 
peptide has been previously used for tumor targeted liposome and nanoparticle 
delivery. 
3.1.1 Design and synthesis of azide-bearing T-shaped oligoaminoamides 
Based on the cationizable building block succinoyl-tetraethylene-pentamine (Stp) and 
related analogs,[28, 97] which enable electrostatic interaction with nucleic acids 
(polyplex formation) and endosomal escape of delivered cargo into the cytosol due to 
further endosomal protonation, we have synthesized by solid phase-supported 
synthesis (SPSS) a library of more than 1200 cationizable structures as carriers for 
drug,[98] protein,[99] and nucleic acid delivery.[80, 100] T-shapes present a 
topological subclass of such carriers especially suitable for the delivery of siRNA.[32, 
82, 101] siRNA is far smaller than plasmid DNA and therefore requires additional 
polyplex stabilization beyond electrostatic interaction.[30, 102] The T-shape structured 
oligomer 454 (Tab. 2), which was one starting point for this work, contains a cationic 
backbone of four repeats of Stp, as well as N- and C-terminal units of three tyrosines 
and a cysteine, as well as a central branch containing two oleic acids (OleA) for 
hydrophobic siRNA polyplex stabilization.[103, 104] An analog, oligomer 992 (Tab. 2), 
containing the bioreducible building block ssbb[66] incorporated into the 
oligoaminoamide backbone, was previously found to be more effective and 
biocompatible than the ssbb-free stable analog. N-terminal incorporation of an azido 
lysine into T-shape oligomers resulted in the design of oligomers like 1106 (Tab. 2) 
which enabled subsequent shielding and targeting of formed polyplexes by copper-
free click chemistry.[65, 105]  
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Designing new multifunctional oligoaminoamides (Fig. 4) for the IL-R4 targeted 
delivery of apoptotic peptide-siRNA conjugates, we considered the following five points. 
1) an azido function was to be incorporated into all oligomers for subsequent 
functionalization with AP1 targeting peptides; 2) as the cargo (siRNA-SS-apoptotic 
peptide) presents a bioreducible conjugate, the carrier had to be free of terminal 
cysteines as contained in 454; 3) optionally the bioreducible building block ssbb was 
incorporated into the oligomer backbone, in order to see whether a reducible 
lipopolyplex would perform better; 4) incorporation of histidines[79] and especially 
alternating histidine – Stp units might improve the endosomal escape capability;[79, 
98] and 5) extension of the cationic backbone by duplication of the Stp (or Stp-His) 
domains for enhanced polyplex stability.[81] Based on these considerations, we 
synthesized four oligomers (1208, 1209, 1210 and 1211) derived from oligomers 454 
and four bio-reducible oligomers (1217, 1218, 1219 and 1220) derived from the ssbb 
building block containing oligomers 992 (Fig. 4, Tab. S1, Fig. S1 and Fig. S2). 
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Fig. 4.  Overview of chemical compounds.  Schematic illustration of new sequence-defined 
oligomers, non-reducible (1208, 1209, 1210 and 1211) and bioreducible type (1217, 1218, 
1219 and 1220). Units of the oligomers: Y: tyrosine, K: lysine, H: histidine, Stp: succinoyl-
tetraethylene-pentamine, OleA: Oleic acid, G: glycine, ssbb: succinoyl-cystamine, ss building 
block. The ID are the internal database identification number. 
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Tab. 2 Sequences of plain lipo-oligomers. CholA: cholanic acid. Sequences (left to right) from 
N- to C-terminus. 
 
Tab. 3 Sequences of different apoptotic peptides, which were provided with N-terminal 
cysteines for conjugation with siRNA by disulfide bond formation, and AP-1 targeting and PEG 
shielding domains. Sequences (left to right) from N- to C-terminus. 
 
3.1.2 Design and synthesis of the AP-1 targeting domain 
For shielding and targeting siRNA core nanoparticles formed with the azido-lipo-
oligomers, DBCO–PEG-AP-1 conjugates were synthesized. In our previous work, 
DBCO-PEG-folate conjugates were synthesized completely by SPSS.[65] As DBCO 
was found unstable under standard (95% TFA) peptide deprotection and cleavage 
conditions,[65] a cleavage protocol using 5% TFA was developed. In the current work, 
a different strategy had to be applied. The IL-4 receptor binding peptide AP-1[94] 
(sequence listed in Tab. 3) was first synthesized by standard SPSS, with a precise 
monodisperse PEG24 (24 ethylene oxide units) and an N-terminal 3-mercaptopropionic 
acid also incorporated into the sequence. After cleavage of this PEG-AP-1 sequence 
from solid phase, the terminal thiol group was specifically reacted in solution with 
maleimide-DBCO at neutral pH. 
3.1.3 Design and synthesis of dual antitumoral siRNA-apoptotic peptide 
conjugates 
ID                             Oligomer sequences
 454                 C-Y3-Stp2-K(K(OleA)2)-Stp2-Y3-C
 992              Y3-Stp2-K(G-ssbb-K(CholA)2)-Stp2-Y3 
1106           K(N3)-Y3-Stp2-K(G-K(CholA)2)-Stp2-Y3
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The targeted siRNA polyplex delivery system is designed to include multifunctional 
substructures for siRNA intracellular delivery, but the overall siRNA antitumoral effect 
remains a critical decisive aspect. Short peptides containing pro-apoptotic subgroups 
that antagonize anti-apoptotic biological factors have been developed as means of 
restoring normal apoptotic signaling.[93] Some reported concept used lytic or apoptotic 
peptide covalently attached to polymeric carriers. Sarangthem et al. showed that 
elastin-like polypeptide (ELP) as basic delivery carrier could enhance the cytotoxic 
effect of peptide KLAK. Albarran et al. published that the incorporation of pH-
responsive, membrane-destabilizing poly (propylacrylic acid) (PPAA) markedly 
enhanced the killing effect of BAK BH3 peptides, which induces apoptosis via 
antagonization of suppressor targets such as Bcl-2. In our study, three apoptotic 
peptides (KLK, BAK, BAD), which are the antibacterial and mitochondrial membrane 
disruptive artificial peptide KLK, or peptides derived from the BH3 domain of BAK and 
BAD proteins (Tab. 3), for the first time were directly coupled to the siRNA’s backbone 
to ensure cytosolic co-delivery and thereby achieving a dual antitumoral effect. 
Cysteine was chemically integrated at the N-terminus of these peptides sequences, 
and the peptides were covalently conjugated to the 5’-end of the siRNA’s sense strand, 
to avoid any negative steric effect of the modification on the silencing efficiency. 
Importantly, the conjugate linkage by disulfide bond allows cytosolic separation of the 
two different antitumoral agents after delivery. When conjugates reach the cytosol of 
tumor cells, the strongly increased concentration of glutathione (GSH, ~ 1-11 mM) is 
supposed to cleave the disulfide linkage, and the two active substructures could 
thereby separately achieve their apoptotic functions in different pathways. As shown 
in Fig. 5A, the conjugates were prepared by activation of the apoptotic peptide’s C-
terminal cysteine and subsequent reaction with the siRNA’s thiol group. After 
purification of conjugates by high-performance liquid chromatography (HPLC), the 
purity of conjugates was analyzed by agarose gel electrophoresis; the apoptotic 
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peptide-siRNA conjugates were also analyzed by MALDI-TOF-MS (Fig. 5 B-D, Fig. 6 
and Fig. 7) 
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Fig. 5. A) Overall scheme of synthesized siRNA-apoptotic peptide by disulfide bond. B-D) 
Characterization of siRNA-apoptotic peptide, displayed for the siRNA-BAK conjugate; 
characterization of the other two siRNA-KLK and siRNA-BAD conjugates is shown in the 
Supplementary Information. B) Top: DTNB modified TNB-BAK peptide. Bottom: siRNA-BAK 
conjugate. C) MS data of BAK and siRNA-BAK conjugate. For the siRNA-BAK conjugate, the 
MS data show the molecular weight of two peaks from unconjugated antisense and conjugated 
sense strand. D) Gel electrophoresis to demonstrate the purity of siRNA-based conjugate. 
Free siRNA and disulfide dimer siRNA as control. E) Tris (2-carboxyethyl) phosphine (TCEP) 
was used to cleave the siRNA-BAK conjugate and the fragments were purified by HPLC and 
then characterized by MS, respectively. 
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Fig. 6 (A) HPLC data of siRNA-KLK conjugate. B) MS data of KLK (left) and siRNA-KLK 
conjugate (right). For the siRNA-KLK conjugate, the MS data show the molecular weight of 
two peaks from unconjugated antisense and conjugated sense strand. C) Gel 
electrophoresis to demonstrate the purity of siRNA-based conjugate. Free siRNA and 
disulfide dimer siRNA as control.  
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Fig. 7 (A) HPLC data of siRNA-BAD conjugate. B) MS data of BAD and siRNA-BAD 
conjugate. For the siRNA-BAD conjugate, the MS data show the molecular weight of two 
peaks from unconjugated antisense and conjugated sense strand. C) Gel electrophoresis to 
demonstrate the purity of siRNA-based conjugate. Free siRNA and disulfide dimer siRNA as 
control.  
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3.1.4 Screening of lipo-oligomers for siRNA delivery 
In aqueous solution, lipo-oligomers and siRNA spontaneously assemble into lipo-
polyplexes. The siRNA binding ability of lipo-oligomers was determined by measuring 
the electrophoretic mobility of siRNA in a 2.5% agarose gel (Fig. 8A). Different N/P 
ratios represent the ratio of protonatable amines (N) of the oligomers to phosphates 
(P) of the siRNA. To simulate in vivo stability, polyplexes were incubated with 90% fetal 
bovine serum for 2h and 24 h followed by the agarose gel electrophoresis assay. For 
the non-reducible oligomers (1208, 1209, 1210 and 1211), at 2 h incubation time, some 
siRNA was released from the polyplex at N/P of 6. At the N/P ratio of 12 and higher, 
the oligomers showed complete gel retardation of siRNA. At 24 h incubation time with 
serum, the qualitative analysis of released siRNA amount was 1210>1211>1209≥1208 
at N/P ratio of 12. The oligomers 1208 and 1209 with smallest hydrophilic backbones 
(4 Stp without or with histidines) showed best serum stability, with complete retention 
of siRNA at N/P ratios of 12 and higher. An N/P ratio of 12 was used for all formulations 
in the subsequent experiments.  
Polyplexes with the reducible oligomers 1217, 1218, 1219 released some siRNA at 
N/P ratio of 12 already after 2 h incubation with serum, whereas 1220 mediated higher 
stability. After 24 h incubation time, all reducible oligomer polyplexes showed 
significant siRNA release even at the highest N/P ratio of 20.  
The size and shape of siRNA polyplex was evaluated by dynamic light scattering (DLS) 
and transmission electron microscopy (TEM). Polyplexes had a hydrodynamic 
diameter of 150-300 nm by DLS (Tab. 4). Oligomers containing histidines and 
oligomers containing 8 Stp groups showed a trend of increased size compared to the 
histidine-free analogs and oligomers containing only 4 Stp groups, respectively.  
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Fig. 8. A) Gel electrophoresis of eight oligomers with siCtrl at different N/P ratios incubated 2h 
and 24h in 90% serum. B) Luciferase activity of siRNA formulations at different N/P ratios in 
KB/eGFPLuc cells. 
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Tab. 4 Particle size (z-average) and zeta potential of siCtrl formulations determined with a DLS 
zetasizer. The siRNA polyplex were prepared at N/P 12. 
 
 
To evaluate the transfection efficiency of untargeted oligomer polyplexes, gene 
silencing experiments (Fig. 8B) were performed in KB cells stably expressing an 
eGFPLuc fusion protein gene (enhanced green fluorescent protein/luciferase). 
Silencing of the eGFPLuc fusion protein by siRNA against was quantified by a standard 
luciferase assay. Oligomers 1208 and 1209 (containing 4 Stp units without or with 
alternating histidines, respectively) showed better transfection efficiency than the other 
oligomers. Interestingly, both oligomers with the longer hydrophilic backbones 
containing 8 Stp units (1210 and 1211) displayed far lower gene silencing activity. This 
was not predictable from previous results of DNA and siRNA delivery[12, 13, 98] and 
might reflect small differences such as in stabilizing domains (e.g. lipids) as well as in 
the nucleic acid cargo.[13, 30, 102] 
The reducible oligomers containing the ssbb building block showed lack of gene 
silencing efficiency. The reason is most probably based in the selected KB tumor cell 
system; while the ssbb building block was found to be most favorable in siRNA delivery 
to Neuro2A cells or DU145 cells,[79] it was observed to hamper siRNA delivery in KB 
/HeLa cells, most likely due to immature disulfide bond cleavage before or during 
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cellular internalization into these cells which contain a highly reductive potential.[106] 
Considering the above mentioned results, oligomers 1208 and 1209 were the most 
suitable candidates for the next steps, developing an AP-1 targeted siRNA delivery 
system and subsequent application for siRNA-apoptotic peptide conjugate delivery. 
3.1.5 Evaluation of AP-1 as targeting ligand for receptor-mediated siRNA delivery 
The azido function on the surface of 1208 and 1209 siRNA polyplex serves as anchors 
for modification of shielding and targeting domains. The amount of added DBCO 
surface modified-agents is indicated as molar equivalents (equiv.) related to the 
cationic oligomers (mol/mol). Obviously, as considerable extent of oligomers will be 
located within the interior of the core lipopolyplexes, only a fraction of azides will be 
available for nanoparticle surface modification. 
The unmodified 1208 and 1209 core lipopolyplexes had a hydrodynamic diameter of 
190-220 nm (Fig. 9). Modification with up to 1 equiv. of PEG-AP-1 did not show any 
considerable change in size of formulations, whereas modification with 0.75 and 0.1 
equiv. of PEG showed a decrease in size. The zeta potential of the two 1208 and 1209 
siRNA lipopolyplexes showed similar trends in PEG-AP-1 targeted and PEG shielded 
groups. For the 1208 oligomer, the PEG-AP-1 modification resulted in slightly 
decreased zeta potentials from 28.3 to 22.8 mV (Fig. 9C). In contrast, modification with 
ligand-free PEG represented a sharp decrease in zeta potential. Highest amount of 
PEG at ratio of 1 reduced zeta potential to 10 mV, indicating efficient shielding effect 
for the polyplex. The 1208 formulation with PEG-AP-1 targeting domain visualized by 
TEM (Fig. 9D) has a spherical shape and size around 100 nm, which is similar to 
unshielded 1208 polyplexes. Agarose gel electrophoresis (Fig. 9E) demonstrated a 
complete siRNA binding at N/P 12 for all formulations using different ratios of targeting 
and shielding modification.  
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Fig. 9. Particle size (z-average) (A), PDI (B) and zeta potential (C) of 1208 and 1209 
formulations with siCtrl, as determined by DLS zetasizer. Lipopolyplexes were prepared at N/P 
12 and modified with indicated different molar equiv. of shielding and targeting domains PEG 
or PEG-AP-1. D) TEM pictures of 1208 polyplex before (unshielded) and after 
functionalization with PEG-AP-1. Scale bars: upper graph 2 µm, lower graph 60 nm.  TEM 
experiment performed by Dominik Loy (Department of Pharmacy, LMU Munich). E) Gel 
electrophoresis of 1208 and 1209 formulations with PEG-AP-1 targeting domain or PEG 
shielding domain. 
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To verify AP-1 mediated receptor targeting, the IL-4R overexpressing human 
carcinoma cell lines KB (cervix), MDA-MB-231 (breast) and Huh 7 (liver) were selected 
and treated with PEG-AP-1 targeted or PEG shielded Cy5-labeled siRNA polyplexes 
as well as non-targeted, non-shielded control Cy5-labeled siRNA polyplex at N/P 12. 
Cells were incubated with all formulations for 45 min at 37 °C, to enable the cells to 
actively internalize polyplexes for a limited short period. Subsequently cells were 
washed by PBS and heparin before quantifying the Cy5 intensity by flow cytometry. 
The negatively charged heparin can largely dissociate extracellularly associated 
polyplexes from cell surface membranes. Fig. 10A displays cellular uptake of 
polyplexes by Huh 7 cells, which reaches highest cellular uptake at nanoparticle 
surface modification with 0.5 equiv. PEG-AP-1 targeted agent. Data indicate that AP-
1 can effectively target nanoparticles to Huh 7 cells. In contrast, modification of 
nanoparticles with more than 0.1 equiv. PEG agent decreased uptake of polyplex in a 
PEG-dependent fashion, indicating an efficient polyplex shielding by PEG. In CLSM 
images (Fig. 10B and Fig. 11), generated by an analogous protocol without the heparin 
washing step), the PEG-AP-1 targeting group showed higher degree of polyplex 
internalization into cells compared to the control and PEG shielded groups. To 
demonstrate that the binding of polyplexes to the Huh 7 cells is ligand-dependent, we 
performed an AP-1 peptide competition assay. As shown in Fig. 10A and Fig. 12, the 
cellular uptake of AP-1 targeted polyplexes was almost completely blocked when cells 
were pre-treated with high concentration of AP-1.  
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Fig. 10.  A) Uptake (upper graph) of targeted formulations into Huh 7 cells determined by 
flow cytometry after 45 min incubation at 37°C and heparin wash. 1208 siRNA polyplexes 
were prepared containing 20% Cy5-labeled siRNA and modified with different ratios of PEG-
AP-1 targeting or PEG-shielding agents. The ligand competition study (lower graph) was 
performed in the presence of excess free PEG-AP-1. Huh 7 cells were pre-incubated with 
100 µM of PEG-AP-1 for 45 min before incubation with 1208 siRNA polyplexes for 4h. PEG-
AP-1 targeted siRNA polyplexes were formed at N/P 12 using Cy5-labeled siRNA. The 
number of Cy5-positive cells was analyzed by flow cytometry. Polyplex positive control: 
without ligand competition. B) Cellular association of 1208 siRNA formulations in Huh 7 cells 
acquired by confocal laser scanning microscopy (CLSM). Cells were incubated with the 
formulations for 45 min at 37 °C and washed with PBS buffer. Actin cytoskeleton was stained 
with rhodamine phalloidin, nuclei were stained with DAPI and siRNA was Cy5-labeled. White 
scale bars indicate 25 µm.  Experiment performed by Miriam Höhn (Department of 
Pharmacy, LMU Munich). C) Gene silencing of targeted formulations in Huh 7/eGFPLuc cells 
(left) and KB/eGFPLuc cells (right). Polyplex formulations with 500 ng eGFP-targeted siRNA 
(siGFP) or control siRNA (siCtrl) and 1208 or 1209 were tested at N/P 12 with 0.5 molar 
equiv. of PEG-AP-1 targeting or PEG shielding domains. Cells were incubated with the 
formulations for 45 min at 37°C before cell culture medium was replaced. The luciferase 
activity of the eGFPLuc fusion protein was measured at 48 h. The results are presented as 
percentage of the luciferase gene expression obtained with untreated control cells. 
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Fig. 11 Cellular association of siRNA formulations in KB cells acquired by confocal laser 
scanning microscopy (CLSM). Cells were incubated with the formulations for 45 min at 37 °C 
and washed with PBS buffer. Actin cytoskeleton was stained with rhodamine phalloidin, 
nuclei were stained with DAPI and siRNA was Cy5-labeled. White scale bars indicate 25 µm. 
Experiment performed by Miriam Höhn (Department of Pharmacy, LMU Munich). 
Fig. 12 Ligand competition studies were performed with polyplexes in the absence or 
presence of excess free PEG-AP-1. In the competition experiments, MDA-MB-231 (A) and 
KB (B) cells were pre-incubated with 100 µM of PEG-AP-1 for 45 min before incubation with 
1208 siRNA PEG-AP-1 polyplexes for 4h. siRNA polyplexes were formed at N/P 12 using 
Cy5-labeled siRNA. The number of Cy5-positive cells was analyzed by flow cytometry.  
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Fig. 13  Gene silencing of targeted formulations in MDA-MB-231/eGFPLuc cells. Polyplex 
formulations with eGFP-targeted siRNA (siGFP) or control siRNA (siCtrl) and 1208 or 1209 
were tested at N/P 12. Cells were incubated with the formulations for 45 min at 37°C before 
cell culture medium was replaced. The luciferase activity of the eGFPLuc fusion protein was 
measured at 48 h. The results are presented as percentage of the luciferase gene 
expression obtained with untreated control cells. 
 
To evaluate the targeted transfection efficiency of formulations, gene silencing 
experiments were performed in Huh 7/eGFPLuc (Figure 10C, left), KB/eGFPLuc cells 
(Figure 10C, right), and MDA-MB-231/eGFPLuc (Fig. 13). The silencing of the 
eGFPLuc fusion gene product was evaluated by a luminometric luciferase assay. For 
non-modified 1208 and 1209 siRNA lipo-polyplexes, the knockdown of luciferase 
activity was almost 60% in Huh 7/eGFPLuc and 40% in KB/eGFPLuc, respectively. 
PEG-AP-1 targeting increased the gene silencing efficiency and PEG24 shielded 
domains decreased the silencing efficiency in both cell lines (Fig. 10C). The targeted 
1208 polyplexes provided the highest efficiency and were notably more effective than 
analogous 1209 polyplexes. The luciferase expression levels of cells treated with siCtrl 
polyplexes was not significantly altered, indicating that formulations had no intrinsic 
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unspecific cytotoxicity. Also in MDA-MB-231/eGFPLuc cells, PEG-AP-1 targeted 1208 
polyplexes resulted in the highest silencing efficiency (Fig. 13). In sum, in all three cell 
lines the targeted 1208 polyplexes (containing 4 Stp units without histidines in the 
oligomer backbone, analogously as in 454 and 1106) were most effective and more 
potent than targeted 1209 polyplexes (containing 4 Stp-histidine units per oligomer).  
3.1.6 Cell killing by siRNA-apoptotic peptide conjugates without or with IL4R-
targeted delivery 
We sought to investigate whether we could enhance the antitumoral cytotoxicity of 
siRNA lipopolyplexes by using siRNA conjugated with apoptotic peptides. An initial 
comparison of cell-killing by polyplexes with standard siRNA or the siRNA-apoptotic 
peptide conjugates was performed using the previously established lipo-oligomer 1106 
(Tab. 2) without shielding and targeting. 1106 had comparable transfection efficiency 
as 1208 in Huh 7/eGFPLuc cells and KB/eGFPLuc cells (Fig. 14). Standard siEG5 or 
siEG5 conjugated with one of the three apoptotic peptides (siEG5-KLK, siEG5-BAK, 
siEG5-BAD) or the analogous control siCtrl apoptotic peptide conjugates (siCtrl-KLK, 
siCtrl-BAK, siCtrl-BAD) were transfected into HeLa cells (Figure 6A, left) or A549 cells 
(Figure 6A, right). Cell killing effects were very consistent in both cancer cell types. As 
expected, siEG5 conjugates always mediated superior cell killing over the analogous 
siCtrl conjugates, clearly demonstrating RNA interference contributing to the 
antitumoral effect. Notably, siCtrl-peptide conjugates contributed an up to 40% 
reduction in cell viability, demonstrating a RNA interference-independent cell killing. 
Comparing the apoptotic peptide conjugate, cytotoxicities were in the order of siEG5-
KLK ~ siEG5-BAD > siEG5-BAK > siEG5 in HeLa cells, and siEG5-KLK > siEG5-BAD 
> siEG5-BAK ~ siEG5 in A549 cells (Fig. 15A). Biophysical analysis (binding, DLS and 
cellular uptake) did not show any significant difference between standard siRNA and 
siRNA-KLK conjugates (Tab. 5, Fig. 16 and Fig. 17).  
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Next we examined the cytotoxic effect of the three siEG5-apoptotic peptide conjugates 
or unmodified siEG5 1208 lipoplex formulation on Huh 7 cells (Fig. 15B) without or 
with PEG-AP-1 targeting or PEG-shielding. For the untargeted formulations, KLK-
siEG5 and BAD-siEG5 again enhanced cytotoxicity compared with siEG5 polyplexes, 
whereas the BAK-siEG5 did not present enhanced killing. Consistent with the other 
delivery results of the current report, in general PEG shielding of lipopolyplexes 
reduced and modification with the PEG-AP-1 targeted domain recovered or even 
enhanced tumor cell killing. In particular, PEG-AP-1 targeted 1208 polyplexes of KLK-
siEG5 conjugates showed significantly superior cytotoxicity in Huh7 cells. In sum, 
reviewing all data, out of the three investigated apoptotic peptide conjugates, only 
siEG5-KLK conjugates mediated a robust superior cell killing over siEG5 polyplexes, 
resulting in 2.15-fold, 2.04-fold and 1.77-fold reduced cell viability in HeLa cells, A549 
or Huh7 cells, respectively. To further explore the value of siRNA-KLK conjugates 
versus siRNA, dose-response relationships were performed in Huh 7 cells (Fig. 15C 
and Fig. 18). Fig. 15C shows cell-killing potency of untargeted (left) and AP-1 targeted 
(right) siEG5-KLK versus siEG5 polyplexes, formed either at the standard siRNA 
concentration of 370 nM and 1208 at N/P 12 (14.36 µM), or at different lower 
concentrations of siEG5-KLK conjugates or siEG5. The dose of 1208 was kept 
constant (at the fixed amount of 14.36 µM), in order to avoid delivery problems (such 
as hampered endosomal release) by carrier dilution. The dilution study demonstrated 
superior cell killing by siEG5-KLK even at <20 nM. Dilution studies performed with 
untargeted 1208 polyplexes at N/P 12 (Fig. 18), also demonstrated superior 
cytotoxicity of siEG5-KLK conjugates compared to siEG5. We inferred that the 
augmented tumor cell killing effect was mediated by a dual mechanism from both EG5 
gene silencing and KLK apoptotic peptide action. 
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Fig. 14 Comparison of oligomers 1106 and 1208. Gene silencing of untargeted formulations 
in Huh 7/eGFPLuc cells (upper) and KB/eGFPLuc cells (lower). Polyplex formulations with 
eGFP siRNA (siGFP) or control siRNA (siCtrl) and 1106 or 1208 were tested at N/P 12. The 
luciferase activity of the eGFPLuc fusion protein was measured at 48 h. The results are 
presented as percentage of the luciferase gene expression obtained with untreated control 
cells. 1106 as positive control for testing the gene silencing efficiency of 1208. 
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Fig. 15. Transfection with siEG5-apoptotic peptide or control siCtrl-apoptotic peptide 
conjugates as lipopolyplex formulations in three different cell lines.  A) Viabilities of HeLa cells 
(left) and A549 cells (right) after 48 h transfection with siRNA-apoptotic peptides conjugates 
formulated with 1106 at indicated N/P ratios without targeting and shielding domain.  B) Cell 
viability of Huh 7 cells after 48 h transfection with siRNA-apoptotic peptides conjugate 
formulations with 1208 at N/P = 12 with 0.5 molar equiv. of PEG-AP-1 targeting or PEG 
shielding domains. *** p < 0.001. C) Dose-response relationship of siRNA versus siRNA-KLK 
conjugates in Huh 7 cells. Untargeted (left) and AP-1 targeted 1208 polyplexes (right) formed 
with a fixed amount of 1208 (14.36 µM) and different concentrations of siEG5 or siEG5-KLK 
conjugates. Standard siRNA concentration was 370 nM (500 ng/well). 
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Tab. 5 Particle size (z-average) and zeta potential of polyplex formulations with siCtrl or 
siCtrl-KLK conjugate and 1208 determined with a DLS zetasizer. The polyplexes were 
prepared at N/P 12. 
P o l y p l e x Z - a v e r a g e n m M e a n  P D I M e a n  Z e t a  P o t e n t i a l m V
         s i C t r l
     s i C t r l - K L K
1 9 0 , 3  ±  2 , 5
1 8 5 , 6  ±  2 , 1
0 , 1 8  ±  0 , 0 1
0 . 2 1  ±  0 . 0 2
2 8 . 1  ±  0 . 5
2 9 , 5  ±  0 . 4
 
 
 
Fig. 16 Gel electrophoresis of 1208 formulations with siCtrl or siCtrl-KLK conjugate at 
different N/P ratios of 6 and 12. 
 
Fig. 17 Uptake of untargeted formulations into Huh 7 cells determined by flow cytometry after 
45 min incubation at 37°C and heparin wash. 1208 siRNA polyplexes were prepared 
containing 20% Cy5-labeled siRNA (Cy5-siCtrl and Cy5-siCtrl-KLK). ns: no significant 
difference. 
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Fig. 18 Dose-response relationship of siRNA-KLK conjugates versus siRNA in Huh 7 cells. 
Untargeted 1208 polyplexes at N/P 12 with different concentrations of siEG5 or siEG5-KLK 
conjugates were tested. Standard siRNA concentration (highest concentration) was 370 nM 
(500ng/well). 
3.1.7 Mechanism of augmented cytotoxicity of AP-1 targeted siRNA-KLK 
conjugates 
All subsequent experiments were performed with 0.5 equiv. PEG-AP-1 targeted 1208 
lipopolyplexes (N/P 12) identified above as the most potent delivery system. As 
mentioned above, EG5 is involved in the assembly of the mitotic spindle apparatus and 
responsible for centrosome separation in cell division. Thus, siRNA against EG5 would 
block the formation of bipolar mitotic spindles, causing cell-cycle arrest and 
subsequent apoptosis of tumor cells. Functional EG5 gene silencing was confirmed 
via aster formation of nuclear DNA (Fig. 19A and Fig. 20), where downregulation of 
EG5 induced a mitotic arrest in all siEG5 groups (siEG5-KLK and siEG5). Aster 
formation could not be observed after application of control siRNA groups (siCtrl-KLK 
and siCtrl). We further examined EG5-specific gene silencing at mRNA level in Huh 7 
cells by quantitative real-time polymerase chain reaction (qRT-PCR) (Fig. 19B).  All 
the siEG5 groups triggered efficient downregulation of EG5 mRNA expression levels. 
In the siCtrl groups, the mRNA expression levels were similar to untreated cells.  
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Fig. 19 Mechanism of AP-1 targeted 1208 mediated delivery of siEG5-KLK conjugates.  A) 
Mitotic aster formation induced by siEG5 in Huh 7 cells after 48 hours. Scale bars: 20 µm, and 
10 µm (magnification in right).  B) EG5 mRNA expression levels of different formulations after 
48 hours. C) Mitochondrial membrane disruption induced by siRNA-KLK conjugates
determined by using a JC-1 dye assay; flow cytometry data presenting the shift of green 
fluorescence by various polyplex treatments for 48 h (left), expressed as % mitochondrial 
membrane depolarization compared to the CCCP (carbonyl cyanide 3-chlorophenylhydrazone) 
positive control (right).  D) CLSM images of treated cells (scale bars: 50 µm) displaying high 
intensity of green JC-1 fluorescence (mitochondrial membrane depolarization) from the KLK 
conjugated groups (siEG5-KLK and siCtrl-KLK polyplex treatment for 48 h) and 50 µM of the 
mitochondrial membrane potential disrupter CCCP as positive control. From left to right: Red 
fluorescence of J-aggregates; blue stain of nuclei by Hoechst 33342; green fluorescence of 
monomeric form of JC-1; overlay of all images.  All experiments were performed with 1208 
polyplexes formed at N/P 12 and modified with 0.5 equiv. PEG-AP-1 targeting agent. 
Experiment performed by Miriam Höhn (Department of Pharmacy, LMU Munich). 
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Fig. 20 AP-1 targeted 1208 mediated delivery of siEG5-KLK conjugates. Mitotic aster 
formation induced by siEG5 in KB cells after 48 hours. Scale bars: 20 µm.  
Therefore, these results clearly supported that AP-1 targeted polyplexes enable 
efficient silencing of EG5 expression at mRNA level, followed by mitotic blockade and 
finally cell death in AP-1 receptor-positive cells. Meanwhile, comparing siRNA-KLK 
with peptide free siRNA, we found that the KLK apoptotic peptide did not influence the 
gene silencing of EG5, indicating that siEG5 and KLK independently contributed their 
function in the process of cell death.  
We next investigated the hypothesized function of KLK as inducer of intrinsic 
mitochondrial apoptosis pathway by using a JC-1 assay (Fig. 19C and 19D). The 
mitochondrial membrane potential ∆ψΜ is an important parameter of mitochondrial 
function and has been used as an indicator of cell death. JC-1 can enter the 
mitochondrion and change its fluorescent properties to red wavelength based on the 
aggregation of the probe. In healthy cells with high potential ∆ψΜ, JC-1 forms 
complexes known as J-aggregates with intense red fluorescence. However, in 
apoptotic cells with low potential ∆ψΜ, JC-1 remains in the monomeric form, which 
exhibits green fluorescence. The higher the ratios of green to red fluorescence, the 
lower is the polarization of the mitochondrial membrane. As shown in Fig. 19C, both 
KLK groups (siEG5-KLK and siCtrl-KLK) showed an enhanced shift of green 
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fluorescence, compared to the groups without KLK and negative JC-1 control groups, 
which indicated the higher ratio of cells were in the state of mitochondrial membrane 
depolarization. Comparing the flow cytometry histogram data of the siEG5-KLK and 
siCtrl-KLK groups, we conclude that the siEG5 had a very little influence on the KLK 
function of disruption of mitochondrial membrane. Confocal laser scanning microscopy 
(CLSM, Fig. 19D) confirmed the KLK induced mitochondrial membrane depolarization. 
The green staining is observed siCtrl-KLK and siEG5-KLK as well as the mitochondrial 
membrane potential disrupter CCCP, but not in healthy cells.  
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Fig. 21. Apoptosis of Huh 7 cells at 48 h (A) after transfection with different formulations 
determined by the annexin V-FITC/PI assay. The viable, early apoptosis, and late apoptosis 
cell populations (%) were shown in the lower left, lower right, and upper right quadrants, 
respectively. B) Confocal laser scanning microscopy of cells treated for 24 h. Green 
fluorescence, annexin V-FITC; blue fluorescence, nuclei stained by Hoechst 33342; red 
fluorescence, PI staining of nuclei. Scale bars, upper graph (white) 25 µm, lower graph (gray) 
50µm.  Experiment performed by Miriam Höhn (Department of Pharmacy, LMU Munich). 
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Fig. 22 Apoptosis of Huh 7 cells at 24 h after transfection with different formulations 
determined by the annexin V-FITC/PI assay. The viable, early apoptosis, and late apoptosis 
cell populations (%) were shown in the lower left, lower right, and upper right quadrants, 
respectively. 
We further characterized apoptosis of tumor cells induced from these two components 
(apoptotic peptide conjugated with siRNA) using an annexin V-FITC/propidium iodide 
(PI) assay, as depicted in Fig. 21. Annexin V staining of cells was used to indicate cell 
membrane changes (phosphatidylserine flips from the cytosol to the outer surface of 
the membrane lipid bilayer) that occur in the early stage of apoptosis. Annexin V 
specifically binds to phosphatidylserine in the presence of calcium. By using 
fluorescent-labeled annexin V, the apoptotic cells can be identified by flow cytometry 
or fluorescence microscopy. PI is a membrane impermeant DNA intercalating dye that 
is excluded from viable cells but can stain DNA of dying cells such as the late stage of 
apoptosis. Apoptosis of Huh 7 tumor cells treated with the different formulations for 24 
or 48 h (Fig. 21) was most pronounced for siEG5-KLK, followed by siEG5 > siCtrl-KLK 
>> siCtrl formulations. It has to be noted that the flow cytometric assay provides 
qualitative and not quantitative information, because viability of siEG5-KLK treated 
cells is low (only 20% at 48 h), and dead cells are largely not covered by the cytometric 
assay. Analysis at an earlier time point of 24 h confirms the results (Fig. 22), with 
siEG5-KLK treatment triggering the highest number of apoptotic stage (about 65% of 
cells). The early and late stage of apoptosis cells were also measured by confocal laser 
scanning microscopy (Fig. 21B) confirming that siEG5-KLK exhibits the best apoptosis 
inducing capacity. 
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3.2 Hyaluronate siRNA nanoparticles with positive charge display rapid 
attachment to tumor endothelium and penetration into tumors 
Section 3.2 has been partly adapted from: Jie Luo, Johannes Schmaus, Mochen Cui, Elisa 
Hörterer, Ulrich Wilk, Miriam Höhn, Maike Däther, Simone Berger, Teoman Benli-Hoppe, Lun 
Peng and Ernst Wagner, Hyaluronate siRNA nanoparticles with positive charge display rapid 
attachment to tumor endothelium and penetration into tumors, Journal of Controlled Release, 
2020. DOI:  
Small interfering RNA (siRNA) has emerged as a promising therapeutic approach for 
genetic diseases or cancer due to its potent gene-silencing activity.[69, 107-109] 
Within the last two years the first two siRNA drugs were approved, Patisiran 
(ONPATTRO) for treatment of hereditary transthyretin-mediated amyloidosis[110] and 
Givosiran (GIVLAARI) for treatment of hereditary acute hepatic porphyria,[111] and 
further siRNA drugs are in advanced clinical development.[112] Although arduous and 
impressive efforts have been made, a remaining challenge for siRNA therapeutics is 
the efficient delivery to target sites different from liver tissue and for non-inheritable 
common diseases including cancer. 
Cationic carrier-based siRNA delivery systems are highly dependent on a suitable 
control of relationship among physiochemical properties, stability of siRNA binding and 
toxicity.[29, 113, 114]  Among other examples, [14, 23, 115] cationic PEI polyplexes 
facilitate delivery of siRNA and microRNA into tumors, resulting in therapeutic RNAi 
efficacy.[116] However, complexes with high positive surface charge often are 
subjected to interaction and aggregation with blood components, inflammatory and 
innate immune responses after intravenous administration, thus yielding toxicities in 
vivo.[26, 117-120] To solve this issue, numerous hydrophilic natural or synthetic 
polymers such as polyethylene glycol (PEG) have been incorporated into polyplexes 
for surface shielding.[73] One encouraging strategy has been the introduction of a 
polyanionic coating with hyaluronic acid (HA) in order to shield the positive charge of 
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the nanoparticle.[121-124] In addition to surface shielding, HA can be also used for 
active targeting of CD44. CD44 is a cell surface adhesion molecule, which is expressed 
in most cell types, such as leukocytes, epithelial cells, endothelial cells and tumor cells; 
it was also found to be overexpressed in solid tumor vasculature. [125, 126] 
We previously prepared a series of sequence-defined oligoaminoamide (OAA) carriers 
[28] for intracellular transfer of siRNA or other nucleic acids with shielding (PEG, 
poly(N-(2-hydroxypropyl)methacrylamide) pHMPA, polysarcosine) and targeting 
(folate, epidermal growth factor EGF receptor or c-Met binding peptides, interleukin-4 
IL-4 or interleukin-6 IL-6 receptor binding peptides) domains.[33, 52, 80, 100, 127-130] 
These OAAs mediated ligand-enhanced cellular uptake, endosomal escape into the 
cytosol, protection of siRNA against degradation, and thus improved gene transfer or 
gene silencing efficiency. Results included successful systemic tumor targeting in vivo 
in mouse models resulting in therapeutic effects.[80, 128, 130] Based on our 
understanding of the structure and activity relationships of previous OAA libraries and 
post-modification strategies of polyplexes, the present study refined OAAs for stable 
siRNA lipopolyplex formation, suitable for subsequent surface modification with an 
anionic polymer for in vivo administration. For this purpose, hyaluronic acid (HA) was 
selected as the polyanion with good biocompatibility, biodegradability, cell targeting 
potential, and an excellent record of previous application for nanoparticle surface 
modification.[121-124] Commonly, electrostatic polyplex coating with HA has been 
performed. To avoid the risk of competitive displacement under in vivo conditions, our 
work aimed at covalent attachment of HA to siRNA nanoparticles via copper-free, 
strain-promoted alkyne-azide cycloaddition (SPAAC). Based on this intention, OAAs 
modified with an N-terminal azide and HA modified with DBCO groups were used as 
clickable modules, respectively. By variation of the ratio of DBCO-HA to OAA azide of 
the siRNA nanoparticle, colloidal stable cationic and anionic HA-based siRNA 
polyplexes were established. Evaluation of these nanoparticles should explore any 
relations of surface charge with in vivo tumor accumulation, tumor penetration and 
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subsequent gene silencing efficacy in vivo. We investigated the effect of the different 
coatings on the cellular uptake, endocytic pathways, endosomal escape in vitro, 
followed by study of tumor accumulation, tumor penetration in 3D sight, and gene 
silencing of siRNA carriers in vivo. 
3.2.1 Design of novel T-shaped lipo-oligoaminoamides 
A library of more than 1400 cationizable OAA structures had been developed by solid 
phase-supported synthesis (SPSS), based on the building block succinoyl-
tetraethylene-pentamine (Stp) and related analogs,[28, 97] for use as drug,[98] 
protein,[99] and nucleic acid delivery carriers[80, 100]. T-shaped lipo-OAAs belong to 
a topological subclass of such carriers that is well suitable for siRNA delivery. Oligomer 
1208 (see Fig. 23, middle left; non-reducible, no histidines, R = oleic acid) as an 
previously reported efficient representative[52] contains a cationic backbone of four 
repeats of Stp, terminated at both ends by three tyrosines and an N-terminal azido 
group. It is branched in T-shape configuration by a central lysine which carries a lipidic 
branch containing two oleic acids (OleA). The integration of tyrosine tripeptides and 
additional disulfide-forming terminal cysteines into the OAA design enhanced stability 
of polyplexes and subsequent transfection efficacy;[103, 131] the azido function 
enables subsequent covalent click-coupling.[65] From this starting point, in the current 
work we designed a new library (Fig. 23) consisting of three main classes of lipo-OAA 
backbones; a cysteine-containing disulfide stabilizing type, a non-reducible type, and 
a bio-reducible type containing a cystamine linkage between the lipid domain and 
cationizable Stp backbone; all classes were tested with different incorporated 
saturated and unsaturated fatty acids, and optional also endosomal buffering 
histidines[13, 132, 133] that were integrated into the Stp backbone in alternative 
fashion. Sequences of lipo-OAAs, library identification (ID) numbers, mass spectra and 
proton NMR spectra confirming these structures are presented in Tab. S2, S3 and Fig. 
S3, S4. 
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Fig. 23. Overview of chemical compounds. Schematic illustration of new sequence-defined 
oligomers, disulfide stabilizing, non-reducible and bioreducible types. Units of the oligomers: 
Y: tyrosine, K: lysine, H: histidine, Stp: succinoyl-tetraethylene-pentamine, G: glycine, 
saturated fatty acids (PalA: palmitic acid, SteA: stearic acid, Ara: arachidic acid, BehA: 
behenic acid, LigA: lignoceric acid), unsaturated fatty acids (OleA: oleic acid, LenA: linolenic 
acid), ssbb: succinoyl-cystamine, ss building block.  
3.2.2 Lipo-oligoaminoamides screening for siRNA delivery 
Screening the novel lipo-OAA library identified oligomer 1214 (Fig. 24A) (containing 
cysteines and histidines in the backbone as well as oleic acids in the lipidic domain) as 
the most suitable siRNA carrier for subsequent surface modification. siRNA polyplexes 
were formed by mixing at a defined azido-oligomer /siRNA N/P ratio and incubated for 
45 min. Based on previous titrations, the N/P ratio, representing the ratio of 
protonatable amines (N) of the oligomers to phosphates (P) of the siRNA (Tab. S2), 
was set to 12. The sizes, PDIs, and zeta potentials of siRNA polyplexes was 
determined by dynamic light scattering (DLS) (Fig. 24B and Fig. 25). Most polyplexes 
had a hydrodynamic diameter of 150-300 nm by DLS; the superior 1214 polyplexes 
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had a stable ~200 nm nanoparticle size, which was also confirmed by a low PDI of 
0.20. The average zeta potentials of siRNA polyplexes were around 20-30 mV; 1214 
had a relatively high zeta potential of +28.5 mV. 
Stability of siRNA / lipo-oligomer complexes was analyzed after incubation in 90% fetal 
bovine serum (FBS) followed by the electrophoresis in a 2.5% agarose gel (Fig. 26). 
For the first two classes of cysteine-containing disulfide stabilizing and non-reducible 
types, the oligomers without or with histidine modified backbone containing stearic acid 
(steA) or OleA fatty acids showed complete gel retardation of siRNA and no release of 
free siRNA. For the bioreducible type, all types of polyplexes showed significant siRNA 
release in serum. Incorporation of histidines had no significant influence on 
stabilization of non-reducible type of polyplexes. For disulfide-stabilizing oligomers 
containing PalA side chains, the alternative histidine-Stp backbone improved stability 
of siRNA polyplexes compared to the non-histidine backbone. Among the disulfide 
stabilization and non-reducible types, SteA and OleA both showed stronger binding 
with siRNA compared to other saturated and unsaturated fatty acid. In summary, the 
disulfide stabilizing oligomers containing cysteine, histidine and SteA or OleA 
hydrophobic fatty acid domains mediated suitable stabilization of siRNA polyplexes. 
Gene silencing experiments (Fig. 24C and Fig. 27) were performed using Huh 7 
hepatocellular carcinoma cells stably expressing an eGFPLuc (enhanced green 
fluorescent protein/luciferase fusion protein) marker gene. Specific silencing of the 
eGFPLuc fusion gene by siGFP was measured by a luminometric luciferase assay. 
Unspecific reduction of reporter activity was determined using the analogous siCtrl 
formulations. For all three types of oligomers (disulfide-stabilizing, non-reducible, and 
bioreducible types), oligomer 1214 mediated highest gene silencing efficiency, as 
indicated by the lowest eGFP-luciferase marker activity. In general, the stabilizing 
cysteine-containing class (including oligomer 1214) showed highest functional siRNA 
transfer, followed by non-reducible oligomers with moderate gene silencing, and the 
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bioreducible lipo-OAAs (containing the ssbb building block) lacking gene silencing 
efficiency in the screened reporter cells. In regard to the carbon numbers of fatty acids 
(from C16 to C24), C18 mediated higher silencing efficiency, and the unsaturated fatty 
acid OleA higher efficiency then the saturated fatty acid stearic acid, consistent with a 
previous lipo-OAA screen.[32] In sum, the screening for stabilizing and transfection-
active polyplexes revealed 1) terminal cysteines and 2) alternative Stp and histidine on 
the backbones, as well as 3) oleic acids as unsaturated fatty acids in the lipidic domain 
as most favorable elements. 
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Fig. 24. A) Chemical structure of oligomer 1214. Y: tyrosine, K: lysine, H: histidine, Stp: 
succinoyl-tetraethylene-pentamine, G: glycine, OleA: oleic acid. B) Particle size (z-average) 
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and zeta potential of siCtrl formulations determined with a DLS zetasizer. The 1214 siRNA 
polyplex were prepared at N/P 12. C) Gene silencing activity of siRNA formulations at N/P ratio 
12 tested by luciferase assays in Huh 7/eGFPLuc reporter cells. Specific gene silencing (using 
siGFP) is compared with unspecific reporter silencing (by siCtrl formulations). D) Click 
modification of siRNA polyplexes with HA-DBCO. Particle size (z-average) (E), PDI (E) and 
zeta potential (F) of 1214 formulations with siCtrl, as determined by DLS zetasizer. 
Lipopolyplexes were prepared at N/P 12 and modified with indicated different molar equiv. of 
HA-DBCO. G) Gel electrophoresis of 1214 formulations with different equiv. of HA-DBCO. The 
molar equivalents (equiv. HA) relate to the molar ratio of HA-linked DBCO to the azide of the 
cationic oligomers (DBCO/azide, mol/mol). 
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Fig. 25. Detailed presentation of zetasizer data as presented in main Fig.1B.  Particle 
size (z-average diameter in nm), PDI, and zeta potential of siCtrl formulations as determined 
with a DLS zetasizer. The siRNA polyplexes were prepared at N/P 12. 
 
Fig. 26. Gel electrophoresis of oligomers (disulfide stabilizing, non-reducible and 
bioreducible types) with siCtrl at N/P ratio 12 incubated for 4h in 90% serum.  
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Fig. 27. Detailed presentation of data as presented in main Fig.1 C. Luciferase activity of 
siRNA formulations (500ng siRNA/well) at N/P ratio 12 in Huh 7/eGFPLuc cells after 48 h 
incubation. 
 
 
                                                                      Results and Discussion 
74 
 
 
 
 
Fig. 28 Structure, NMR and UV-VIS of DBCO modified hyaluronic acid (HA). 
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Fig. 29 Gel electrophoresis of 1214 formulations with different equiv. of HA-DBCO. The 
molar equivalents (equiv. HA) relate to the molar ratio of HA-linked DBCO to the azide of the 
cationic oligomers (DBCO/azide, mol/mol). Polyplexes containing 500ng siRNA were 
incubated in 90% serum and analyzed at different time points.  
3.2.3 Hyaluronic acid (HA) for covalent modification of siRNA polyplexes 
For covalent decoration of lipo-OAA / siRNA polyplexes with polyanionic HA (Fig. 24D), 
we had designed lipo-oligomers such as 1214 with an N-terminal azido-lysine, and HA 
was modified with DBCO units as linkage modules. The modification degree of HA’s 
carboxylic groups with DBCO-amine was 8%, as confirmed by UV-VIS and NMR data 
(Fig. 28). This represents approximately 4 DBCO molecules per 20 kDa HA polymer 
chain. 
3.2.4 Formation and stability of cationic and anionic HA-modified siRNA 
polyplexes 
After screening of lipo-OAAs, oligomer 1214 was selected for all subsequent 
investigations. The azido function of 1214 exposed on the surface of siRNA polyplexes 
serves as anchor for polyplex modification with hyaluronic acid (HA). Each 20 kDa HA 
molecule was modified with approximately 4 DBCO linkers (see above) to enable 
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covalent copper-free, strain-promoted alkyne-azide cycloaddition (SPAAC) to the 
siRNA polyplexes. The amount of HA-DBCO is presented as molar equivalents (equiv.) 
of DBCO related to the cationic 1214 oligomer azides (mol/mol). Obviously, as 
considerable extent of oligomers will be located within the interior of the core 
lipopolyplexes, only a fraction of azides is available at the siRNA nanoparticle surface 
for click modification. 
Unmodified 1214 polyplexes had a hydrodynamic diameter of 200 nm (Fig. 24E). 
Modification with up to 0.2 equiv. of HA-DBCO or between 0.4 to 2.0 equiv. HA-DBCO 
did not show any considerable change in nanoparticle size, whereas modification with 
0.3 equiv. of HA-DBCO showed a sharp increase in size (around 810 nm), indicating 
the presence of aggregates. This was confirmed by the high PDI of 0.58 (Fig. 24E) 
and can explained by an almost neutral zeta potential (Fig. 24F). With the increase of 
HA-DBCO modification from 0.04 to 2.0 HA-DBCO, the zeta potential of the 1214 
siRNA lipopolyplexes decreased shifting from positive charge to negative charge (Fig. 
24F). The stability of positively and negatively charged polyplexes was also confirmed 
by agarose gel electrophoresis. Both the positively and negatively charged polyplexes 
displayed colloidial stability. In 20 mM HEPES buffered 5% glucose (HBG, pH 7.4) 
buffer (Fig. 24G), a complete siRNA binding at N/P ratio of 12 for all cationic and 
anionic formulations was observed. Also, in 90% serum, all formulations were stable 
up to 8h (Fig. 29). 
3.2.5 Gene silencing activity and cellular uptake of cationic and anionic HA / 
siRNA polyplexes 
Unless indicated differently, cationic and anionic polyplexes modified with 0.1 equiv. 
HA-DBCO or 0.8 equiv. HA-DBCO, respectively, were selected for subsequent 
experiments. Though the two nanoparticle formulations were similar in sizes (200.3± 
3.9 nm and 205.8 nm± 4,7 in diameter), the difference in zeta potential between low 
0.1HA (+22.7 mV) and high 0.8HA (-21.8 mV) is very large. These two formulations 
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(0.1HA and 0.8HA) also showed the highest cellular uptake in their cationic and anionic 
groups, respectively. Reporter gene silencing experiments with the two HA 
formulations were performed again in Huh 7/eGFPLuc (Fig. 30A). For unmodified 1214 
siRNA lipo-polyplexes, the knockdown of reporter activity was around 60%. Compared 
to this unmodified control, cationic HA modification polyplexes increased the gene 
silencing efficiency by further 5%. The anionic HA polyplexes mediated a higher 
silencing activity of 72% knockdown. eGFP-luciferase marker expression levels of cells 
treated with siCtrl polyplexes did not significantly change compared to untreated cells, 
indicating that the formulations did not have any intrinsic RNAi-independent cytotoxicity. 
Cellular uptake of cationic and anionic HA polyplexes was evaluated by flow cytometry. 
Cells were incubated with Cy5 siRNA formulations for 2 h at 37 °C, and washed with 
PBS and heparin for dissociation of extracellularly associated polyplexes from cell 
surface membranes before analysis. Fig. 30B displays the cellular uptake of siRNA 
polyplexes into Huh 7 cells. Both cationic and anionic polyplexes modified with 0.1 
equiv. HA-DBCO or 0.8 equiv. HA-DBCO, respectively, showed high uptake, which 
was superior over non-coated cationic 1214 siRNA polyplexes. The same formulations 
showed also the highest cellular uptake in KB cells (Fig. 31). 
Further on, endocytotic pathways of cationic and anionic HA siRNA nanoparticles into 
Huh 7 cells were characterized by monitoring the change of Cy5-siRNA internalization 
after pretreatment with different inhibitors for specific pathways,[121, 134] such as 
nystatin (15 μg/mL) for inhibiting caveolin-mediated endocytosis,[135] sucrose (154 
mg/mL) for inhibiting clathrin-mediated endocytosis,[136] amiloride (133 μg/mL) for 
inhibiting macropinocytosis,[137] sodium azide (1 mg/mL) for inhibiting energy-
dependent endocytosis[138] and excessive amount of free HA (10 mg/mL, 20 KDa) for 
competition of HA-mediated endocytosis (Fig. 30C-30D, Fig. 32 and Fig. 33). The 
cytotoxicity of inhibitors at indicated concentrations used in following experiments was 
evaluated and not significantly different from the HBG treated control cell group (Fig. 
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32). The pretreatment of sucrose inhibited the cellular uptake of cationic HA 1214 
polyplexes, suggesting clathrin-medicated endocytosis as main uptake mechanism, 
whereas both amiloride and sucrose inhibited anionic HA 1214 polyplex internalization, 
indicating both clathrin- and macropinocytosis-mediated uptake pathway (Fig. 30C). 
Negatively charged HA has been previously characterized to enter cells by 
macropinocytosis.[139] Entry of anionic 0.8HA polyplexes by macropinocytosis is 
consistent with the fact that the polyplex surface is completely covered with HA. 
Cationic medium-sized (~50-200 nm) nanoparticles such as PEI polyplexes were 
previously found to enter via clathrin- and/or caveolae-mediated endocytosis and not 
macropinocytosis.[140] In HA competition studies (Fig. 30D), excess amount of HA 
decreased cellular uptake of cationic and anionic HA polyplexes into Huh 7 cells by 
>76% or 46%, respectively. 
According to confocal laser scanning microscopy (CLSM) images (Fig. 30E and Fig. 
34), the anionic polyplexes with 0.8 equiv. HA-DBCO showed a higher degree of 
polyplex internalization in two cell lines (Huh7 and KB cells) compared to the non-
coated control and cationic 0.1 equiv. HA-DBCO polyplexes. For all following 
experiments, 1214 polyplexes with either 0.1 HA-DBCO or 0.8 HA-DBCO were 
selected as representative cationic or anionic HA siRNA nanoparticles, respectively. 
The subcellular distribution of cationic and anionic HA polyplexes in Huh 7 cells was 
examined using CLSM (Fig. 30F). After cells were incubated with the different 
polyplexes for 2h, siRNA was mainly colocalizing with Lysotracker, a late endosome 
and lysosome marker, indicating that both types of HA polyplexes were effectively 
taken up by Huh 7 cells into the endosomal compartment. 3D colocalization of cationic 
and anionic polyplexes with CD44 as cellular receptor of HA was demonstrated (Fig. 
35). 
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Fig. 30. Intracellular siRNA delivery mediated by cationic and anionic 1214 polyplexes. A) 
Luciferase activity of cationic and anionic formulations at N/P ratio 12 in Huh 7/eGFPLuc 
reporter cells. The luciferase activity of the eGFPLuc fusion protein was measured at 48 h. The 
results are presented as percentage of the luciferase gene expression obtained with untreated 
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control cells. (B) Uptake of 1214 formulations into Huh 7 cells was determined by flow 
cytometry after 2h incubation at 37°C. 1214 siRNA polyplexes were prepared containing 20% 
Cy5-labeled siRNA and modified with indicated different equiv. of HA-DBCO. C) Endocytosis 
pathways of cationic (left) and anionic (right) 1214 formulations characterized by different 
pretreatments with endocytosis inhibitors in Huh 7 cells determined using the flow cytometry. 
D) To test whether the HA-polyplexes uptake was mediated by receptor, the ligand competition
study was performed in presence of excess of HA (10 mg/mL, 20 kDa) in Huh 7 cells for 1 hour 
before adding various cationic (upper) and anionic (lower) 1214 HA-polyplexes for additional 
2 hours. siRNA polyplexes were formed at N/P 12 using Cy5-labeled siRNA. The number of 
Cy5-positive cells was analyzed by flow cytometry. Polyplex positive control: without HA 
modification competition. E) Cellular association of 1214 siRNA formulations in Huh 7 cells 
acquired by confocal laser scanning microscopy (CLSM). Cells were incubated with the 
formulations for 2h at 37 °C and washed with PBS buffer and heparin. Actin cytoskeleton was 
stained with rhodamine phalloidin, nuclei were stained with DAPI and siRNA was Cy5-labeled. 
Scale bars: 25 µm. F) Subcellular distribution of cationic and anionic 1214 HA formulations 
complexed with Cy5-siRNA in Huh 7 cells. The late endosomes and lysosomes were stained 
with LysoTracker Green. Scale bars: 50 μm.  The statistical significance was determined by 
one way ANOVA (A, B, C); unpaired t test (D). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 
0.0001, n.s., not significant. Confocal microscopy was performed by Miriam Höhn 
(Department of Pharmacy, LMU Munich). 
Fig. 31 Uptake of 1214 formulations into KB cells (A) was determined by flow cytometry after 
2h incubation at 37°C. 1214 siRNA polyplexes (1.25 μg siRNA/well) were prepared containing 
20% Cy5-labeled siRNA and modified with different equiv. of HA-DBCO.  
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Fig. 32 Viability of Huh7 cells pre-treated with different inhibitors for 1h and subsequent 
incubation for 2h (upper) and 24h (lower) with unmodified (1214) and targeted cationic (0.1HA) 
or anionic (0.8HA) 1214 siRNA polyplexes. 
Huh7 cells were seeded on 96-well plates at a density (8000 cells/well) in 100 µL of medium 
24 h before the experiment. Medium was replaced by 80 µL of fresh medium. The cells were 
pre-incubated with 20µL of inhibitor solution (final concentration: nystatin 15 μg/mL, sucrose 
154 mg/mL, amiloride 133 μg/mL, sodium azide 1 mg/mL) for 1 h at 37°C. Afterwards, the 
medium changed and incubated at 37°C for 2h after adding different cationic and anionic 
formulations containing 0.5 µg of siRNA (N/P ratio of 12). The medium was then replaced with 
100 µL of fresh medium and cells were cultured for 2h and 24h time points. MTT assays (Life 
Technology, Darmstadt, Germany) were performed to evaluate the cell viability. The 
experiments were performed in triplicates using SpectraFluor Plus microplate reader (Tecan, 
Austria). The relative percentage were related to HBG buffer-treated control cells. 
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Fig. 33 Cellular uptake of cationic (upper) and anionic (lower) targeted 1214 siRNA polyplexes 
into KB cells determined by flow cytometry. Polyplexes (1.25μg siRNA/well) were formed at 
N/P 12 using 20% Cy5-labeled siRNA. Cells were pre-treated with different inhibitors for 1h. 
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Fig. 34 Cellular association of siRNA formulations in KB cells determined by confocal laser 
scanning microscopy (CLSM). Actin cytoskeleton was stained with rhodamine phalloidin, 
nuclei were stained with DAPI and Cy5-labeled siRNA was used. White scale bars indicate 
25 µm. Experiment performed by Miriam Höhn (Department of Pharmacy, LMU Munich).   
Fig. 35 Colocalization of cationic (upper) and anionic (lower) nanoparticles target CD44 
receptor using Imaris analysis. Scale bar: 10 μm. For enlarged figure, scale bar: 5 μm. 
Together with Mochen Cui (Faculty of Medicine, LMU Munich). 
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3.2.6 Delivery of cationic and anionic HA-modified siRNA polyplexes in vivo 
After the screening and evaluation of polyplexes for intracellular delivery, these 
formulations should undergo evaluation in tumor models in vivo by biodistribution and 
gene silencing assays. 1214 polyplexes and 1214 polyplexes with 0.1 equiv. or 0.8 
equiv. of HA-DBCO modification were analyzed for systemic biodistribution in mice 
bearing subcutaneous Huh7 tumors (Fig. 36A). Mice were injected with polyplexes 
formulating Cy7-conjugated siRNA via tail vein, and the biodistribution of the dye was 
monitored at various time points with a NIR bioimaging system. Compared to the 
unmodified 1214 siRNA polyplexes, it was interesting to note that the 1214 polyplexes 
with 0.1 equiv. of HA-DBCO modification rapidly appeared with a strong fluorescence 
signal in the tumor remaining high for up to 1 h, whereas anionic 1214 siRNA 
polyplexes with 0.8 equiv. of HA-DBCO modification did not accumulate in the Huh 7 
tumor as evidenced by the lack of pronounced fluorescence. In previous experiments 
with this tumor model, we had observed that analogous PEG shielded polyplexes did 
not accumulate in Huh 7 tumors (Fig. 37). The well-understood ‘passive’ enhanced 
permeability and retention (EPR) mechanism for PEGylated nanoparticles would 
require long-term circulation times. Consistent with our previous reports,[130] our class 
of siRNA polyplexes circulates only short-term (Fig. 38). Obviously, transient 
accumulation in tumors must proceed by a different “active” mechanism. Huh 7 tumor 
cells are known to express CD44. Therefore we also applied these formulations in 
another tumor mouse model bearing poorly differentiated CD44 deficient Neuro2a 
neuroblastoma cells known to be non-responsive for HA binding [141] (Fig. 39). 
Nevertheless, we observed also in this model that the cationic 0.1 equiv. HA-DBCO 
containing nanoparticles (0.1HA) display a higher tumor accumulation, compared to 
the cationic unmodified and the anionic 0.8 equiv. HA-DBCO containing (0.8HA) 
formulations. Apparently, 0.1HA polyplexes demonstrated favorable accumulation in 
both (CD44 positive Huh 7 and CD44 negative Neuro2A) tumor cell models. CD44 is 
known to be overexpressed in solid tumor vasculature.[125, 126] Therefore, we 
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hypothesize that in both cases a CD44/HA interaction with tumor vasculature might 
play an active role in the observed tumor accumulation. This hypothesis remains to be 
experimentally proven, for example by replacing HA for other anionic polymers, or by 
in vivo (HA/CD44) competition experiments. 
HA polyplexes were then analyzed for gene silencing in Huh 7 tumors (Fig. 36B). 
Polyplexes were prepared with siEG5 against the kinesin-related motor protein EG5 or 
siCtrl (50 μg of siRNA). Five mice per group were subcutaneously injected with Huh 7 
tumor cells and the weight of the animals was monitored. When tumors reached a size 
of 500mm3, the formulations were administered via tail vein twice at daily interval. At 
24 h after the second injection of formulations, the tumors were harvested, RNA was 
extracted and the EG5 mRNA levels were quantified by quantitative real-time 
polymerase chain reaction (qRT-PCR). The 1214 siEG5 group with 0.1 equiv. of HA-
DBCO modification induced a strong and significant downregulation of EG5 mRNA 
expression by ~78% in tumor treated animals as normalized to untreated HBG group. 
The unmodified 1214 siEG5 group mediated a moderate gene silencing (~30%) of EG5 
mRNA. Interestingly, the formulation of 1214 siEG5 with 0.8 equiv. of HA-DBCO, which 
was most effective in cell culture, revealed negligible gene silencing (~10% on EG5 
mRNA level). None of the control groups with siCtrl formulation showed significant 
reduction of EG5 mRNA as compared to animals treated with HBG control buffer. In 
summary, the 1214 formulation with 0.1 equiv. of HA-DBCO coating targeted Huh 7 
tumors and achieved a strong 78% knockdown of EG5 in vivo. 
Systemic circulation of siRNA polyplexes might also cause potential side effect and 
inflammatory response when they reach non-targeted tissues. Therefore, blood 
biochemistry examinations were carried out in order to realize the biocompatibility of 
the polyplexes (Fig. 36C-36F). Blood samples were collected 24 h after two injections 
of siRNA formulations in healthy mice and four relevant clinical parameters were 
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determined. There is no increase of liver enzymes (ALT and AST) or renal parameters 
(BUN and CREA) were found compared to the untreated HBG group. 
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Fig. 36. In vivo performance of siRNA polyplexes. (A) Biodistribution of siRNA formulations 
(50 µg siRNA, 50% Cy7-labeled, with 1214 at N/P 12) after i. v. administration in Huh 7 
tumor-bearing NMRI nude mice. Biodistribution was determined by NIR fluorescence 
bioimaging comparing unmodified 1214 siRNA polyplexes with polyplexes modified with 
different equiv. of HA-DBCO. The tumor sites containing accumulated siRNA nanoparticles 
are highlighted by white circles. Experiment performed by Johannes Schmaus (veterinary MD 
student, LMU Munich). (B) Tumor-targeted gene silencing efficiency of cationic and anionic 
1214 siRNA formulation with 0.1 and 0.8 equiv. of HA-DBCO with 50 μg of siEG5 or siCtrl 
(mean ± SEM; n=5). (C-F) Clinical biochemistry parameters creatinine (CREA), blood urea 
nitrogen (BUN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) after 
the treatment (5 animals per group) were performed in the Clinic of Small Animal Medicine, 
Faculty of Veterinary Medicine, LMU Munich. Statistical analysis was performed by unpaired t 
test (B); one way ANOVA (C-F). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, n.s., not 
Fig. 37 Biodistribution of siRNA formulations (50 µg siRNA, 50% Cy7 labeled, with 1198 at 
N/P 12) after i. v. administration in Huh7 tumor-bearing mice. The fluorescence scale between 
1.80e-5 and 1.70e-4. The tumor sites are highlighted by blue circles in lateral view. For 
structure of 1198 (His-free analog of 1214) see Table S2. Experiment performed by Sarah 
Kern (veterinary MD student, LMU Munich).
significant.
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Fig. 38 Biodistribution of siRNA formulations (50 µg siRNA, 50% Cy7 labeled, with 1214 at 
N/P 12) after i. v. administration in Huh7 tumor-bearing mice. Biodistribution was determined 
by NIR fluorescence bioimaging comparing unmodified 1214 siRNA polyplexes with polyplexes 
modified with different equiv. of HA-DBCO. The fluorescence scale between 1.40e-5 and 2.5e-4.
The tumor sites are highlighted by blue circles. Experiment performed by Johannes Schmaus 
(veterinary MD student, LMU Munich).
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Fig. 39 Biodistribution of siRNA formulations (50 µg siRNA, 50% Cy7 labeled, with 1214 at 
N/P 12) after i. v. administration in Neuro2a neuroblastoma-bearing mice. Biodistribution was 
determined by NIR fluorescence bioimaging comparing unmodified 1214 siRNA polyplexes 
with polyplexes modified with 0.1 or 0.8 equiv. of HA-DBCO. The fluorescence scale of upper 
and middle figures between 2.20e-5 and 7.00e-5. The fluorescence scale of lower figures 
between 5.50e-5 and 1.50e-4. The tumor sites are highlighted by blue circles. Experiment 
performed by Elisa Hörterer and Ulrich Wilk (veterinary MD students, LMU Munich).
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Fig. 40 Colocalization and microenvironmental distribution of cationic and anionic siRNA 
polyplexes in Huh 7 tumors. (A) Observation of three formulations (unmodified 1214, 0.1HA 
cationic and 0.8HA anionic polyplexes) after 5 min i.v. injection adhesion to endothelial cells 
of tumor blood vessels by confocal laser scanning microscopy. Scale bar = 20 μm. Enlarged 
sites from blood vessels to tumor tissue in the selected region. Scale bar = 2 μm. siRNA 
polyplexes were labeled with cy3, endothelial cells of blood vessels were stained with DyLight 
488 labeled lycopersicon esculentum (tomato) lectin. Yellow was meant to colocalization of 
nanopolyplexes (Red) in endothelial cells (Green). (B) Distribution of 0.1HA cationic siRNA 
polyplex in tumor tissues after 45 min i.v. injection. Scale bar = 20 μm. Enlarged sites, scale 
bar = 2 μm. (C) Quantitative data of cationic and anionic siRNA polyplexes colocalizing or 
having passed across tumor endothelium after 5 min i.v. injection. (D) Comparison of distance 
of 1214 0.1HA nanoparticles from endothelium after 5 min and 45 min i.v. injection. Statistical 
analysis was performed by unpaired t test (C, D). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 
0.0001, n.s., not significant. Confocal microscopy was operated by Mochen Cui (Faculty of 
Medicine, LMU Munich)
3.2.7 Tumor penetration of HA coated siRNA polyplexes in vivo 
We further investigated the micro-environmental distribution of HA coated siRNA 
polyplexes in Huh 7 tumor mice by 3D analysis of 50 µm thick tumor/organ sections 
using CLSM microscopy (Fig. 40). This method is far more sensitive and space-
resolved than NIR fluorescence bioimaging and also more quantitative in micro-
environmental distribution of nanoparticles. We used Imaris software in 3-dimensional 
sight to demonstrate the accurate distribution of nanoparticles inside/outside the 
endothelium of tumor (Fig. 41-43) and in different organs (Fig. 44-45). As indicated in 
Fig. 40A, at the very early time point of 5 min post injection, the red fluorescence was 
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mainly retained within the endothelial cells of blood vessels. In the magnification figure 
of each formulation, the yellow dots indicate the colocalization of Cy3-nanoparticles 
within lectin-labeled endothelial cells, and the red dots show the nanoparticle released 
from endothelial cells. The 1214 polyplexes with 0.1 equiv. of HA-DBCO modification 
indicated much higher colocalization with endothelial cells, compared to the unmodified 
1214 polyplexes and anionic 1214 polyplexes with 0.8 equiv. of HA-DBCO (Fig. 40A, 
Fig. 41 and Fig. 42). Afterwards, at 45 min post-injection (Fig. 40B and Fig. 43), the 
fluorescence signals of 0.1 equiv. of HA-DBCO modified 1214 polyplexes diffused from 
blood vessels to further distribute in the extravascular regions. 
Fig. 41 Testing for colocalization for two formulations (0.1HA cationic and 0.8HA anionic 
polyplexes) after 5 min i.v. injection adhesion to endothelial cells of tumor blood vessels by 
confocal laser scanning microscopy. Scale bar = 20 μm. siRNA polyplexes were labeled with 
Cy3, endothelial cells of blood vessels were stained with DyLight 488 labeled lycopersicon 
esculentum (tomato) lectin. Yellow was meant to colocalization of nanopolyplexes (Red) in 
endothelial cells (Green). Confocal microscopy was operated by Mochen Cui (Faculty of 
Medicine, LMU Munich)
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Fig. 42 Colocalization of 0.1HA cationic after 5 min i.v. injection adhesion to endothelial cells 
of tumor blood vessels as evaluated by confocal laser scanning microscopy. Scale bar = 20 
μm. siRNA polyplexes were labeled with Cy3, endothelial cells of blood vessels were stained 
with DyLight 488 labeled lycopersicon esculentum (tomato) lectin. Yellow was meant to 
colocalization of nanopolyplexes (Red) in endothelial cells (Green). Confocal microscopy 
was operated by Mochen Cui (Faculty of Medicine, LMU Munich)
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Fig. 43 Imaris reconstruction of 0.1HA cationic siRNA polyplexes in different site of Huh 7 
tumors. Observation of polyplex after 45 min i.v. injection from endothelial cells by confocal 
laser scanning microscopy. Scale bar = 15 μm. siRNA polyplexes were labeled with Cy3, 
endothelial cells of blood vessels were stained with DyLight 488 labeled lycopersicon 
esculentum (tomato) lectin. Yellow refers to colocalization of nanopolyplexes (red) with 
endothelial cells (green). Confocal microscopy was operated by Mochen Cui (Faculty of 
Medicine, LMU Munich)
Fig. 44 Distribution of 0.1HA cationic polyplexes in kidneys after 5min i.v. injection. Scale 
bar = 30 μm. siRNA polyplexes were labeled with Cy3, endothelial cells of blood vessels 
were stained with DyLight 488 labeled lycopersicon esculentum (tomato) lectin. Experiment 
performed by Mochen Cui (Faculty of Medicine, LMU Munich)
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Fig. 45 Distribution of 0.1HA cationic polyplexes in liver after 5min i.v. injection by confocal 
laser scanning microscopy. Scale bar = 30 μm. siRNA polyplexes were labeled with Cy3, 
endothelial cells were stained with DyLight 488 labeled lycopersicon esculentum (tomato) 
lectin. Experiment performed by Mochen Cui (Faculty of Medicine, LMU Munich)
The quantitative data of cationic and anionic siRNA polyplexes associated with 
endothelial cells are shown in Fig. 40C. Both cationic siRNA polyplex types (non-
coated and 0.1HA coated) show far higher association with endothelial cells after 5 
min i.v. than the negatively charged polyplexes (0.1HA > 1214 >> 0.8HA). In tumor 
sections, accumulation of 1214 unmodified HA nanoparticles was significant lower 
(~60%) than 0.1HA and far lower (~2%) for 0.8HA. Evaluation of the distribution of 
1214 0.1 HA polyplexes in tumor tissue with time (Fig. 40D) demonstrated that this 
formulation can penetrate from endothelial cells into the tumor core up to 40 μm within 
the short period of only 45 min.  
The other organs (kidneys, liver and brain) of tumor-bearing mice were also analyzed 
by confocal laser scanning microscopy (Fig. 44-45). We observed 0.1HA 1214 
polyplexes also distributed in kidneys and liver. 
3.2.8 Tumor-targeting mechanisms of HA siRNA polyplexes in perspective of 
state-of-the-art mechanistic models. 
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Our results obtained with cationic 200 nm nanosized 1214 0.1HA nanoparticles that 
are short-term circulating, attach to tumor endothelium within 5 min and subsequently 
penetrate into tumors in short time need to be placed in perspective with the common 
mechanistic models for tumor targeting.  
After investigations over several decades, the mechanisms of delivery of nanoparticle 
drugs into solid tumors (‘tumor targeting’) are still not fully understood. However, a 
series of reliable mechanistic models (Fig. 46) have been developed and are under 
continuous review and refinement. [142-156]  Nanoparticles sized up to 400 nm in 
diameter and well surface–shielded to enable a stable long-term systemic circulation  
may passively accumulate in solid experimental tumors, as can be explained by the 
mechanism of enhanced permeability and retention (EPR) effect of tumor tissues 
containing leaky blood vessels.[142-144]  This EPR principle was first observed by 
Maeda and colleagues in 1986. [142]  The passive tumor accumulation takes time 
(several hours to days), the enhanced permeability is attributed to the fenestration in 
leaky tumor blood vessels, and the retention of macromolecules or nanoparticles 
arises from the poor lymphatic drainage in tumors. Jain and colleagues independently 
confirmed this principle; they injected differently sized liposomes into blood and 
investigated molecular size dependence of microvascular permeability in tumors.[143] 
In the pharmacological and clinical reality, tumor targeting of nanoparticles is often 
suboptimum and far lower than an EPR effect might promise.[144, 145] Such low 
accumulation values can be partly attributed to suboptimum nanoparticle properties, 
such as lack of extended blood circulation times due to insufficient stability and surface 
shielding. Obviously, the demonstrated positive tumor targeting observed with our 
0.1HA siRNA nanoparticles cannot be explained by an EPR-dominated mechanism. 
Apart from nanoparticle issues, the EPR-effect can be strong in some solid tumor types, 
but between tumors a high heterogeneity in degree of accumulation was observed. 
[146] 
                                                                      Results and Discussion 
98 
 
 
Fig. 46 Possible mechanisms of nanoparticle accumulation in tumors. For details see section 
3.2.8.  Mechanistic models include passive enhanced permeability and retention (EPR) and 
active adhesion to tumoral vasculature. Transfer across tumor endothelial cell (EC) barrier can 
be by transfer between ECs (permeation or paracellular transport) or transcytosis. Examples 
of nanoparticles (NPs) from left to right: long circulated PEGylated NPs accumulating by the 
EPR effect, 0.1HA 1214 polyplexes, cationic PEGylated NPs, cationic liposomes, or NPs using 
transcytosis, respectively. 
As known from literature,[157, 158] nanoparticles with neutral and negative charges 
display a reduced absorption of serum proteins, resulting in longer circulation times in 
vivo. The extension of circulation time of nanoparticles would favor tumor accumulation 
by the mentioned EPR effect, but may not be the only and sufficient factor for achieving 
systemic delivery into tumors. In our study, the negatively charged, well coated 0.8HA 
siRNA nanoparticles neither accumulated nor mediated gene silencing in tumors.  
Another mechanistic solid tumor targeting model comprises effective adhesion to 
angiogenic tumor endothelial cells. Early work by Donald McDonald and 
coworkers[147] demonstrated that cationic liposomes or cationic DNA lipoplexes 
display high binding to tumor endothelial cells and internalization into tumors. Dellian 
et al. demonstrated[148] that modified cationized bovine serum albumin and IgG 
                                                                      Results and Discussion 
99 
 
extravasate faster from tumor endothelial cells into tumors compared to similar proteins 
with neutral or negative charges. More recent work by Kam Leong and Jun Wang 
demonstrated that a cationic surface charge on PEGylated stable nanoparticles was 
required for enhanced tumor penetration and therapeutic efficacy of anti-cancer 
nanomedicines.[149] Consistently, also in our study only the cationic 0.1HA-containing 
nanoparticles displayed very fast and effective attachment to tumor endothelium. 
However, in our study cationic charge was necessary but not sufficient for the observed 
fast tumor attachment of nanoparticles; coating with 0.1HA, a known ligand for cell 
surface CD44, was another requirement for nanoparticle attachment. CD44 is known 
to be overexpressed in several tumor types and also tumor vasculature. [125, 126] As 
0.1HA polyplexes demonstrated favorable accumulation in both CD44 positive Huh 7 
and CD44 negative Neuro2A tumor cells in vivo models, we hypothesize that in both 
cases a HA interaction with CD44 on tumor vasculature might play an active role in the 
observed tumor accumulation. 
The further process of 0.1HA nanoparticle penetration from tumor vasculature into the 
tumor was also a fast process as detectable by 3D confocal microscopy already at 45 
min after nanoparticle administration. The involved mechanism, transcellular transfer 
across endothelial cells, or paracellular transfer between endothelial cells of leaky 
vasculature, and a possible active participation of HA/CD44, remains to be clarified.  
Early pioneering work by Schnitzer in 1992 [150] reported that albumin is actively 
transported through the vascular endothelium by transcytosis. Schnitzer and co-
workers also found[151] that the active transendothelial portal to infiltrate tumors can 
be explained by caveolae pumping system. Recently, Chan and co-workers[152] 
reported that nanoparticles penetrate into tumors mainly through an active transcytosis 
process (up to 97%) across endothelial cells, rather than via the endothelial gaps or 
fenestrae. Recent evidence on penetration into tumor lesions via an active transcytosis 
process was provided by Tao and colleagues [153]. 
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4. Summary
In the first part, a systematic approach was applied to rationally design a more
effective and multifunctional carrier with dual-antitumoral siRNA conjugate based on 
the thorough understanding of the relationship between structure and activity of 
previously designed oligoaminoamides. We designed new siRNA carriers based on 
sequence-defined cationizable oligoaminoamides containing an N-terminal azido 
domain and a hydrophobic bis (oleic acid) domain attached with T-shaped topology in 
either a reducible or non-reducible form. Following a screening discovering the 
histidine-free lipo-oligomer 1208 formulation as most favorable for siRNA delivery, 
DBCO-functionalized PEG-AP-1 targeting and PEG shielding agents were designed 
for copper-free click chemistry surface functionalization by 1208 siRNA polyplexes 
via their integrated azido groups. Independently, three siRNA-apoptotic peptide 
conjugates were designed, and siEG5-KLK was identified as the most antitumoral 
entity. Incorporation of siEG5-KLK into the optimized PEG-AP-1 1208 nanoparticles 
which target IL-4 receptor-positive tumor cells induced a strong antitumoral effect, 
based on EG5 gene silencing and KLK mediated mitochondrial destabilization as two 
separate mechanisms. In sum, dual antitumoral siRNA-KLK conjugates and their 
targeted formulations present an encouraging strategy; future in vivo tumor targeting 
experiments will be critical for understanding their in vivo biosafety and potency. 
The ‘passive tumor targeting’ mechanism (EPR effect) requires a prolonged 
circulation of nanoparticles in blood for accumulation in tumors. This process cannot 
be utilized by the siRNA nanoparticles of the current study which are short-term 
circulating. Direct comparison of tumor penetration of three very similar siRNA 
nanoparticle formulations, containing the same optimized cationic 
lipooligoaminoamide core, but differing in the surface by charge and covalently 
coupled hyaluronic acid (HA) content (two cationic formulations: 0HA, 0.1HA, and one 
anionic: 0.8HA), demonstrated upon intravenous administration a very fast 
Summary 
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accumulation of one formulation (0.1HA). This fast, apparently more active tumor 
targeting process differs from the well-established EPR mechanism. As evidenced by 
3D nanoparticle distribution within the tumor, 0.1HA-coated cationic siRNA 
nanoparticles attach to the tumor endothelium within 5 minutes and deeply penetrate 
into the tumor within 45 minutes. The finding that only one (0.1HA) of the two cationic 
systems and not the better shielded negatively charged (0.8HA) system is superior, 
goes beyond common knowledge. Common assumption would predict that better 
shielded NPs would result in improved blood circulation and subsequent improved 
tumor accumulation. The intravenous treatment with 0.1HA cationic nanoparticles 
also resulted in potent gene silencing in the distant tumor. Notably, neither the non-
coated cationic siRNA nanoparticles nor the analogous HA-coated anionic siRNA 
nanoparticles mediated such a strong tumor accumulation and gene silencing. The 
cationic formulation without HA displayed some reduced attachment to tumor 
vasculature and subsequent moderate gene silencing. Against our initial expectations 
based on in vitro results, the anionic siRNA nanoparticles with the high degree of HA 
coating and highest gene silencing activity in cell culture were neither accumulating 
nor gene silencing in the tumor in vivo. This was surprising because a complete 
coating with the natural carbohydrate biopolymer was predicted to provide a better 
surface shielding in the blood stream.  
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5   Supporting Information 
Tab. S1 Definition of protonable amines in the newly synthesized lipo-oligomers in N/P 
calculations. The new sequence-defined oligomers, non-reducible (1208, 1209, 1210 and 1211) 
and bioreducible type (1217, 1218, 1219 and 1220) differ in number of protonable N. For 
historic reasons and compatibility with our previous publications, only protonable nitrogens of 
the Stp backbone units were included in these calculations, but not protonable histidine 
nitrogens. Units of the oligomers: Y: tyrosine, K: lysine, H: histidine, Stp: succinoyl-
tetraethylene-pentamine, OleA: Oleic acid, G: glycine, ssbb: succinoyl-cystamine, ss building 
block. For siRNAs, the number of phoshates (P) of siRNA was always used as fixed value (i.e. 
42). Note that the few charges (if any) of conjugated apoptotic peptides were not included in 
the calculations. 
 
Oligomer 
MW 
free 
base 
MW 
(with 
HCl) 
amines 
in total 
protonable 
amines (N) structures: 
1208 
3022 3496.5 13 13 
K(N3)-Y3-Stp2-K(K(OleA)2)-
Stp2-Y3 
1209 
3844 4537.5 19 13 
K(N3)-Y3-(H-Stp)2-H-
K(K(OleA)2)-H-(Stp-H)2-Y3 
1210 
4107 5019.5 25 25 
K(N3)-Y3-Stp4-K(K(OleA)2)-
Stp4-Y3 
1211 
5478 6755.5 35 25 
K(N3)-Y3-(H-Stp)4-H-
K(K(OleA)2)-H-(Stp-H)4-Y3 
1217 3313 3787.5 13 13 
K(N3)-Y3-Stp2-K(G-ssbb-
K(OleA)2)-Stp2-Y3 
1218 4135 4828.5 19 13 
K(N3)-Y3-(H-Stp)2-H-K(G-
ssbb-K(OleA)2)-H-(Stp-H)2-Y3 
1219 4399 5311.5 25 25 
K(N3)-Y3-Stp4-K(G-ssbb-
K(OleA)2)-Stp4-Y3 
1220 5769 7046.5 35 25 
K(N3)-Y3-(H-Stp)4-H-K(G-
ssbb-K(OleA)2)-H-(Stp-H)4-Y3 
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Fig. S1 MS data of the eight oligomers. 
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1208: Sequence (C→N) Y3-Stp2-[(OleA)2-K]K-Stp2-Y3-K(N3) 
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1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 oleic acid), 0.85-2.25 
(m, 72 H, βγδH lysine, βγδεH azidolysine ,-CH2- oleic acid), 2.25-2.60 (m, 20 H, -CO-CH2-
CH2-CO- Stp, -CO-CH2- oleic acid), 2.65-3.1 (m, 16 H, εH lysine and tyrosine), 3.1-3.65 (m, 
64 H, -CH2- Stp), 3.70-4.55 (m, 9 H, αH amino acids), 5.05 – 5.25 (s, 4 H, -CH=CH- oleic 
acid), 6.60 -7.15 (m, 24 H, -CH- tyrosine). 
 
Fig. S2 NMR data of the eight oligomers. 
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1209: Sequence (C→N) Y3-(H-Stp)2-H-[(OleA)2-K]K-(H-Stp)2-H-Y3-K(N3) 
O
NH
HN
O
O
N
H
NH
H
N
N
H
H
N
N
H
H
N
O
O
O
HO
N
H
H
N
HN
O
O
O
HO HO
HO
N
HN
N
H
N
H
H
N
O
O
O
NH
HO
HO
HO
N
HN
N
H
O
H
N
N
H
H
N
N
H
H
N
O
O
N
HN
N
H
N
HN
N
H
O
OO NH2
O
N
N
+
N
-
eu
2
eu
2
a
bb b
b
a b a
b
a b
b
b
b
c
c
d
d dd
d
d
d
d d d
d
d d
e
e
e
e
e
e e
e
f
f
f
f
f
f
f f
f
f f
g
g
g
g
h
h
h
h
h
h
i
i
h
 
 
 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 oleic acid), 0.85-2.25 
(m, 72 H, βγδH lysine, βγδεH azidolysine ,-CH2- oleic acid), 2.25-2.60 (m, 20 H, -CO-CH2-
CH2-CO- Stp, -CO-CH2- oleic acid), 2.65-3.1 (m, 28 H, εH lysine, tyrosine and histidine), 3.1-
3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 15 H, αH amino acids), 5.05 – 5.25 (s, 4 H, -
CH=CH- oleic acid), 6.60 -7.15 (m, 30 H, -CH- tyrosine, aromatic H histidine), 8.45-8.60 (m, 6 
H, aromatic H histidine). 
 
Fig. S2 (continued). 
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1210: Sequence (C→N) Y3-Stp4-[(OleA)2-K]K-Stp4-Y3-K(N3) 
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1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 oleic acid), 0.85-2.25 
(m, 72 H, βγδH lysine, βγδεH azidolysine ,-CH2- oleic acid), 2.25-2.60 (m, 36 H, -CO-CH2-
CH2-CO- Stp, -CO-CH2- oleic acid), 2.65-3.1 (m, 16 H, εH lysine and tyrosine), 3.1-3.65 (m, 
128 H, -CH2- Stp), 3.70-4.55 (m, 9 H, αH amino acids), 5.05 – 5.25 (s, 4 H, -CH=CH- oleic 
acid), 6.60 -7.15 (m, 24 H, -CH- tyrosine). 
 
Fig. S2 (continued). 
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1211: Sequence (C→N) Y3-(H-Stp)4-H-[(OleA)2-K]K-(H-Stp)4-H-Y3-K(N3) 
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1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 oleic acid), 0.85-2.25 
(m, 72 H, βγδH lysine, βγδεH azidolysine ,-CH2- oleic acid), 2.25-2.60 (m, 36 H, -CO-CH2-
CH2-CO- Stp, -CO-CH2- oleic acid), 2.65-3.1 (m, 36 H, εH lysine, tyrosine and histidine), 3.1-
3.65 (m, 128 H, -CH2- Stp), 3.70-4.55 (m, 19 H, αH amino acids), 5.05 – 5.25 (s, 4 H, -
CH=CH- oleic acid), 6.60 -7.15 (m, 34 H, -CH- tyrosine, aromatic H histidine), 8.45-8.60 (m, 
10 H, aromatic H histidine). 
 
 
Fig. S2 (continued). 
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1217: Sequence (C→N) Y3-Stp2-[(OleA)2-K-ssbb-G]K-Stp2-Y3-K(N3) 
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1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 oleic acid), 0.85-2.25 
(m, 72 H, βγδH lysine, βγδεH azidolysine ,-CH2- oleic acid), 2.25-2.60 (m, 24 H, -CO-CH2-
CH2-CO- Stp and ssbb, -CO-CH2- oleic acid), 2.65-3.1 (m, 24 H, εH lysine and tyrosine, -
CH2- ssbb), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 11 H, αH amino acids), 5.05 – 5.25 
(s, 4 H, -CH=CH- oleic acid), 6.60 -7.15 (m, 24 H, -CH- tyrosine). 
 
Fig. S2 (continued). 
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1218: Sequence (C→N) Y3-(H-Stp)2-H-[(OleA)2-K-ssbb-G]K-H-(H-Stp)2-Y3-K(N3) 
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1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 oleic acid), 0.85-2.25 
(m, 72 H, βγδH lysine, βγδεH azidolysine ,-CH2- oleic acid), 2.25-2.60 (m, 24 H, -CO-CH2-
CH2-CO- Stp and ssbb, -CO-CH2- oleic acid), 2.65-3.1 (m, 36 H, εH lysine, tyrosine and 
histidine, -CH2- ssbb), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 17 H, αH amino acids), 
5.05 – 5.25 (s, 4 H, -CH=CH- oleic acid), 6.60 -7.15 (m, 30 H, -CH- tyrosine, aromatic H 
histidine), 8.45-8.60 (m, 6 H, aromatic H histidine). 
 
Fig. S2 (continued). 
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1219: Sequence (C→N) Y3-Stp4-[(OleA)2-K-ssbb-G]K-Stp4-Y3-K(N3) 
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1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 oleic acid), 0.85-2.25 
(m, 72 H, βγδH lysine, βγδεH azidolysine ,-CH2- oleic acid), 2.25-2.60 (m, 40 H, -CO-CH2-
CH2-CO- Stp and ssbb, -CO-CH2- oleic acid), 2.65-3.1 (m, 24 H, εH lysine and tyrosine, -
CH2- ssbb), 3.1-3.65 (m, 128 H, -CH2- Stp), 3.70-4.55 (m, 11 H, αH amino acids), 5.05 – 5.25 
(s, 4 H, -CH=CH- oleic acid), 6.60 -7.15 (m, 24 H, -CH- tyrosine). 
 
Fig. S2 (continued). 
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1220: Sequence (C→N) Y3-(H-Stp)4-H-[(OleA)2-K-ssbb-G]K-H-(H-Stp)4-Y3-K(N3) 
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1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 oleic acid), 0.85-2.25 
(m, 72 H, βγδH lysine, βγδεH azidolysine ,-CH2- oleic acid), 2.25-2.60 (m, 40 H, -CO-CH2-
CH2-CO- Stp and ssbb, -CO-CH2- oleic acid), 2.65-3.1 (m, 44 H, εH lysine, tyrosine and 
histidine, -CH2- ssbb), 3.1-3.65 (m, 128 H, -CH2- Stp), 3.70-4.55 (m, 21 H, αH amino acids), 
5.05 – 5.25 (s, 4 H, -CH=CH- oleic acid), 6.60 -7.15 (m, 34 H, -CH- tyrosine, aromatic H 
histidine), 8.45-8.60 (m, 10 H, aromatic H histidine). 
 
Fig. S2 (continued). 
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Tab. S2 Synthesized sequence-defined oligomers. Definition of protonable amines in N/P 
calculations. For historic reasons and compatibility with our previous publications, only 
protonable nitrogens of the Stp backbone units were included in these calculations, but not 
the also protonable histidine nitrogens. Units of the oligomers: Y: tyrosine, K: lysine, H: 
histidine, Stp: succinoyl-tetraethylene-pentamine, G: glycine, C: cysteine, ssbb: succinoyl-
cystamine, ss building block, PalA: palmitic acid, SteA: stearic acid, Ara: arachidic acid, 
BehA: behenic acid, LigA: lignoceric acid, OleA: oleic acid, LenA: linolenic acid. For siRNAs, 
the number of phosphates (P) of siRNA was always used as fixed value (i.e. 42).  
Disulfide-stabilizing type of oligomers 
Oligomer 
(library 
ID 
number) 
MW 
free 
base 
MW 
with 
HCl 
amines 
in total 
protonable 
amines(N) sequence (from N- to C- terminus) 
1336 3176.11 3651 13 13 K(N3)-C-Y3-Stp2-K(K(PalA)2)-Stp2-Y3-C 
1337 3232.22 3707 13 13 K(N3)-C-Y3-Stp2-K(K(SteA)2)-Stp2-Y3-C 
1198 3228.18 3703 13 13 K(N3)-C-Y3-Stp2-K(K(OleA)2)-Stp2-Y3-C 
1383 3288.32 3763 13 13 K(N3)-C-Y3-Stp2-K(K(AraA)2)-Stp2-Y3-C 
1384 3344.43 3819 13 13 K(N3)-C-Y3-Stp2-K(K(BehA)2)-Stp2-Y3-C 
1385 3400.53 3875 13 13 K(N3)-C-Y3-Stp2-K(K(LigA)2)-Stp2-Y3-C 
1200 3220.12 3695 13 13 K(N3)-C-Y3-Stp2-K(K(LenA)2)-Stp2-Y3-C 
1277 3998.95 4692 19 13 
K(N3)-C-Y3-(H-Stp)2-H-K(K(PalA)2)-H-(Stp-
H)2-Y3-C 
1278 4055.05 4749 19 13 
K(N3)-C-Y3-(H-Stp)2-H-K(K(SteA)2)-H-(Stp-
H)2-Y3-C 
1214 4051.02 4745 19 13 
K(N3)-C-Y3-(H-Stp)2-H-K(K(OleA)2)-H-(Stp-
H)2-Y3-C 
1386 4111.16 4805 19 13 
K(N3)-C-Y3-(H-Stp)2-H-K(K(AraA)2)-H-(Stp-
H)2-Y3-C 
1387 4167.26 4861 19 13 
K(N3)-C-Y3-(H-Stp)2-H-K(K(BehA)2)-H-
(Stp-H)2-Y3-C 
1388 4223.37 4917 19 13 
K(N3)-C-Y3-(H-Stp)2-H-K(K(LigA)2)-H-(Stp-
H)2-Y3-C 
1390 4099.06 4793 19 13 
K(N3)-C-Y3-(H-Stp)2-H-K(K(LenA)2)-H-
(Stp-H)2-Y3-C 
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Non-reducible type of oligomers 
Oligomer 
(library ID 
number)  
MW 
free 
base 
MW 
with 
HCl 
amine
s in 
total 
protonable 
amines(N) sequence (from N- to C- terminus) 
1360 
2969.8
2 3444 13 13 K(N3)-Y3-Stp2-K(K(PalA)2)-Stp2-Y3 
1361 
3025.9
3 3500 13 13 K(N3)-Y3-Stp2-K(K(SteA)2)-Stp2-Y3 
1208 
3021.9
0 3496 13 13 K(N3)-Y3-Stp2-K(K(OleA)2)-Stp2-Y3 
1371 
3082.0
4 3557 13 13 K(N3)-Y3-Stp2-K(K(AraA)2)-Stp2-Y3 
1372 
3138.1
4 3613 13 13 K(N3)-Y3-Stp2-K(K(BehA)2)-Stp2-Y3 
1373 
3194.2
5 3669 13 13 K(N3)-Y3-Stp2-K(K(LigA)2)-Stp2-Y3 
1320 
3792.6
6 4486 19 13 
K(N3)-Y3-(H-Stp)2-H-K(K(PalA)2)- 
H-(H-Stp)2-Y3 
1321 
3848.7
7 4542 19 13 
K(N3)-Y3-(H-Stp)2-H-K(K(SteA)2)- 
H-(H-Stp)2-Y3 
1209 
3844.7
3 4538 19 13 
K(N3)-Y3-(H-Stp)2-H-K(K(OleA)2)- 
H-(H-Stp)2-Y3 
1374 
3904.8
7 4598 19 13 
K(N3)-Y3-(H-Stp)2-H-K(K(AraA)2)- 
H-(H-Stp)2-Y3 
1375 
3960.9
8 4654 19 13 
K(N3)-Y3-(H-Stp)2-H-K(K(BehA)2)- 
H-(H-Stp)2-Y3 
1376 
4017.0
8 4711 19 13 
K(N3)-Y3-(H-Stp)2-H-K(K(LigA)2)- 
H-(H-Stp)2-Y3 
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Bioreducible type of oligomers 
Oligomer 
(library 
ID 
number)  
MW 
free 
base 
MW 
with 
HCl 
amines 
in total 
protonable 
amines(N) sequence (from N- to C- terminus) 
1348 3261.21 3736 13 13 
K(N3)-Y3-Stp2-K(G-ssbb-K(PalA)2)-
Stp2-Y3 
1349 3317.32 3792 13 13 
K(N3)-Y3-Stp2-K(G-ssbb-K(SteA)2)-
Stp2-Y3 
1217 3313.29 3788 13 13 
K(N3)-Y3-Stp2-K(G-ssbb-K(OleA)2)-
Stp2-Y3 
1377 3373.43 3848 13 13 
K(N3)-Y3-Stp2-K(G-ssbb-K(AraA)2)-
Stp2-Y3 
1378 3429.53 3904 13 13 
K(N3)-Y3-Stp2-K(G-ssbb-K(BehA)2)-
Stp2-Y3 
1379 3485.64 3960 13 13 
K(N3)-Y3-Stp2-K(G-ssbb-K(LigA)2)-
Stp2-Y3 
1305 4084.05 4778 19 13 
K(N3)-Y3-(H-Stp)2-H-K(G-ssbb-
K(PalA)2)-H-(H-Stp)2-Y3 
1306 4140.16 4834 19 13 
K(N3)-Y3-(H-Stp)2-H-K(G-ssbb-
K(SteA)2)-H-(H-Stp)2-Y3 
1218 4136.12 4830 19 13 
K(N3)-Y3-(H-Stp)2-H-K(G-ssbb-
K(OleA)2)-H-(H-Stp)2-Y3 
1380 4196.26 4890 19 13 
K(N3)-Y3-(H-Stp)2-H-K(G-ssbb-
K(AraA)2)-H-(H-Stp)2-Y3 
1381 4252.37 4946 19 13 
K(N3)-Y3-(H-Stp)2-H-K(G-ssbb-
K(BehA)2)-H-(H-Stp)2-Y3 
1382 4308.48 5002 19 13 
K(N3)-Y3-(H-Stp)2-H-K(G-ssbb-
K(LigA)2)-H-(H-Stp)2-Y3 
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Tab. S3 Mass spectral data of all oligomers recorded with a Bruker MALDI-TOF instrument 
in positive mode. 
Disulfide stabilizing type of oligomers 
Oligomer 
ID 
Molecular 
Formula 
Calculated 
MASS 
Found 
MASS 
1336 C158H260N36O28S2 3176.1 3175.2 
1337 C162H268N36O28S2 3232.2 3233.5 
1198 C162H264N36O28S2 3228.1 3227.2 
1383 C166H276N36O28S2 3288.3 3287.8 
1384 C170H284N36O28S2 3344.4 3343.2 
1385 C174H292N36O28S2 3400.5 3400.8 
1200 C162H256N36O28S2 3220.1 3220.6 
1277 C194H302N54O34S2 3998.9 3997.8 
1278 C198H310N54O34S2 4055.1 4054.2 
1214 C198H306N54O34S2 4051.0 4050.1 
1386 C202H318N54O34S2 4111.1 4111.1 
1387 C206H326N54O34S2 4167.2 4166.5 
1388 C210H334N54O34S2 4223.3 4222.2 
1390 C202H306N54O34S2 4099.1 4098.4 
 
Non-reducible type of oligomers 
Oligomer ID 
Molecular  
Formula 
Calculated 
MASS 
Found  
MASS 
1360 C152H250N34O26 2969.8 2968.4 
1361 C156H258N34O26 3025.9 3026.5 
1208 C156H254N34O26 3021.8 3021.2 
1371 C160H266N34O26 3082.0 3080.9 
1372 C164H274N34O26 3138.1 3137.2 
1373 C168H282N34O26 3194.2 3193.2 
1320 C188H292N52O32 3792.6 3792.1 
1321 C192H300N52O32 3848.7 3847.1 
1209 C192H296N52O32 3844.7 3842.9 
1374 C196H308N52O32 3904.8 3902.8 
1375 C200H316N52O32 3960.9 3960.2 
1376 C204H324N52O32 4017.1 4016.2 
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Bioreducible type of oligomers 
Oligomer 
ID 
Molecular  
Formula 
Calculated 
MASS 
Found  
MASS 
1348 C162H267N37O29S2 3261.2 3260.2 
1349 C166H275N37O29S2 3317.3 3319.0 
1217 C166H271N37O29S2 3313.2 3312.0 
1377 C170H283N37O29S2 3373.4 3372.2 
1378 C174H291N37O29S2 3429.5 3428.4 
1379 C178H299N37O29S2 3485.6 3484.4 
1305 C198H309N55O35S2 4084.1 4083.2 
1306 C202H317N55O35S2 4140.1 4141.0 
1218 C202H313N55O35S2 4136.1 4135.0 
1380 C206H325N55O35S2 4196.2 4196.8 
1381 C210H333N55O35S2 4252.3 4253.2 
1382 C214H341N55O35S2 4308.4 4307.2 
 
 
Fig. S3 MS data of the selected oligomer 1214. 
  
                                                                       Supporting information                                                                                                                                                                                     
117 
 
1214: Sequence (N→C) K(N3)-C-Y3-(H-Stp)2-H-K(K(OleA)2)-H-(H-Stp)2-Y3-C 
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1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 oleic acid), 0.85-2.25 
(m, 70 H, βγδH lysine, βγδH azidolysine ,-CH2- oleic acid), 2.25-2.60 (m, 20 H, -CO-CH2-
CH2-CO- Stp, -CO-CH2- oleic acid), 2.65-3.1 (m, 34 H, εH lysine, tyrosine, histidine and 
azidolysine, βH cysteine), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 17 H, αH amino 
acids), 5.05 – 5.25 (s, 4 H, -CH=CH- oleic acid), 6.60 -7.15 (m, 30 H, -CH- tyrosine, aromatic 
H histidine), 8.45-8.60 (m, 6 H, aromatic H histidine). 
 
Fig. S4 NMR data of the selected oligomer 1214. 
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NMR data of all listed oligomers 
Disulfide-stabilizing type of oligomers 
1336: Sequence (N→C) K(N3)-C-Y3-Stp2-K(K(PalA)2)-Stp2-Y3-C 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 palmitic acid), 0.85-
2.25 (m, 70 H, βγδH lysine, βγδH azidolysine ,-CH2- palmitic acid), 2.25-2.60 (m, 20 H, -CO-
CH2-CH2-CO- Stp, -CO-CH2- palmitic acid), 2.65-3.1 (m, 22 H, εH lysine, tyrosine and 
azidolysine, βH cysteine), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 11 H, αH amino 
acids), 6.60 -7.15 (m, 24 H, -CH- tyrosine). 
1337: Sequence (N→C) K(N3)-C-Y3-Stp2-K(K(SteA)2)-Stp2-Y3-C 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 stearic acid), 0.85-
2.25 (m, 78 H, βγδH lysine, βγδH azidolysine ,-CH2- stearic acid), 2.25-2.60 (m, 20 H, -CO-
CH2-CH2-CO- Stp, -CO-CH2- stearic acid), 2.65-3.1 (m, 22 H, εH lysine, tyrosine and 
azidolysine, βH cysteine), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 11 H, αH amino 
acids), 6.60 -7.15 (m, 24 H, -CH- tyrosine). 
1199: Sequence (N→C) K(N3)-C-Y3-Stp2-K(K(LinA)2)-Stp2-Y3-C 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 linoleic acid), 0.85-
2.25 (m, 58 H, βγδH lysine, βγδH azidolysine ,-CH2- linoleic acid), 2.25-2.60 (m, 20 H, -CO-
CH2-CH2-CO- Stp, -CO-CH2- linoleic acid), 2.65-3.1 (m, 26 H, εH lysine, tyrosine and 
azidolysine, βH cysteine, -C=C-CH2-C=C- linoleic acid), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-
4.55 (m, 11 H, αH amino acids), 5.05 – 5.25 (s, 8 H, -CH=CH- linoleic acid), 6.60 -7.15 (m, 
24 H, -CH- tyrosine). 
1383: Sequence (N→C) K(N3)-C-Y3-Stp2-K(K(AraA)2)-Stp2-Y3-C 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 arachidic acid), 0.85-
2.25 (m, 86 H, βγδH lysine, βγδH azidolysine ,-CH2- arachidic acid), 2.25-2.60 (m, 20 H, -
CO-CH2-CH2-CO- Stp, -CO-CH2- arachidic acid), 2.65-3.1 (m, 22 H, εH lysine, tyrosine and 
azidolysine, βH cysteine), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 11 H, αH amino 
acids), 6.60 -7.15 (m, 24 H, -CH- tyrosine). 
1384: Sequence (N→C) K(N3)-C-Y3-Stp2-K(K(BehA)2)-Stp2-Y3-C 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 behenic acid), 0.85-
2.25 (m, 94 H, βγδH lysine, βγδH azidolysine ,-CH2- behenic acid), 2.25-2.60 (m, 20 H, -CO-
CH2-CH2-CO- Stp, -CO-CH2- behenic acid), 2.65-3.1 (m, 22 H, εH lysine, tyrosine and 
azidolysine, βH cysteine), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 11 H, αH amino 
acids), 6.60 -7.15 (m, 24 H, -CH- tyrosine). 
1385: Sequence (N→C) K(N3)-C-Y3-Stp2-K(K(LigA)2)-Stp2-Y3-C 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 lignoceric acid), 0.85-
2.25 (m, 102 H, βγδH lysine, βγδH azidolysine ,-CH2- lignoceric acid), 2.25-2.60 (m, 20 H, -
CO-CH2-CH2-CO- Stp, -CO-CH2- lignoceric acid), 2.65-3.1 (m, 22 H, εH lysine, tyrosine and 
azidolysine, βH cysteine), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 11 H, αH amino 
acids), 6.60 -7.15 (m, 24 H, -CH- tyrosine). 
1200: Sequence (N→C) K(N3)-C-Y3-Stp2-K(K(LenA)2)-Stp2-Y3-C 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 linolenic acid), 0.85-
2.25 (m, 46 H, βγδH lysine, βγδH azidolysine ,-CH2- linolenic acid), 2.25-2.60 (m, 20 H, -CO-
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CH2-CH2-CO- Stp, -CO-CH2- linolenic acid), 2.65-3.1 (m, 30 H, εH lysine, tyrosine and 
azidolysine, βH cysteine, -C=C-CH2-C=C- linolenic acid), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-
4.55 (m, 11 H, αH amino acids), 5.05 – 5.25 (s, 12 H, -CH=CH- linolenic acid), 6.60 -7.15 (m, 
24 H, -CH- tyrosine). 
1277: Sequence (N→C) K(N3)-C-Y3-(H-Stp)2-H-K(K(PalA)2)-H-(H-Stp)2-Y3-C 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 palmitic acid), 0.85-
2.25 (m, 70 H, βγδH lysine, βγδH azidolysine ,-CH2- palmitic acid), 2.25-2.60 (m, 20 H, -CO-
CH2-CH2-CO- Stp, -CO-CH2- palmitic acid), 2.65-3.1 (m, 34 H, εH lysine, tyrosine, histidine 
and azidolysine, βH cysteine), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 17 H, αH amino 
acids), 6.60 -7.15 (m, 30 H, -CH- tyrosine, aromatic H histidine), 8.45-8.60 (m, 6 H, aromatic 
H histidine). 
1278: Sequence (N→C) K(N3)-C-Y3-(H-Stp)2-H-K(K(SteA)2)-H-(H-Stp)2-Y3-C 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 stearic acid), 0.85-
2.25 (m, 78 H, βγδH lysine, βγδH azidolysine ,-CH2- stearic acid), 2.25-2.60 (m, 20 H, -CO-
CH2-CH2-CO- Stp, -CO-CH2- stearic acid), 2.65-3.1 (m, 34 H, εH lysine, tyrosine, histidine 
and azidolysine, βH cysteine), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 17 H, αH amino 
acids), 6.60 -7.15 (m, 30 H, -CH- tyrosine, aromatic H histidine), 8.45-8.60 (m, 6 H, aromatic 
H histidine). 
1214: Sequence (N→C) K(N3)-C-Y3-(H-Stp)2-H-K(K(OleA)2)-H-(H-Stp)2-Y3-C 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 oleic acid), 0.85-2.25 
(m, 70 H, βγδH lysine, βγδH azidolysine ,-CH2- oleic acid), 2.25-2.60 (m, 20 H, -CO-CH2-
CH2-CO- Stp, -CO-CH2- oleic acid), 2.65-3.1 (m, 34 H, εH lysine, tyrosine, histidine and 
azidolysine, βH cysteine), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 17 H, αH amino 
acids), 5.05 – 5.25 (s, 4 H, -CH=CH- oleic acid), 6.60 -7.15 (m, 30 H, -CH- tyrosine, aromatic 
H histidine), 8.45-8.60 (m, 6 H, aromatic H histidine). 
1386: Sequence (N→C) K(N3)-C-Y3-(H-Stp)2-H-K(K(AraA)2)-H-(H-Stp)2-Y3-C 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 arachidic acid), 0.85-
2.25 (m, 86 H, βγδH lysine, βγδH azidolysine ,-CH2- arachidic acid), 2.25-2.60 (m, 20 H, -
CO-CH2-CH2-CO- Stp, -CO-CH2- arachidic acid), 2.65-3.1 (m, 34 H, εH lysine, tyrosine, 
histidine and azidolysine, βH cysteine), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 17 H, αH 
amino acids), 6.60 -7.15 (m, 30 H, -CH- tyrosine, aromatic H histidine), 8.45-8.60 (m, 6 H, 
aromatic H histidine). 
1387: Sequence (N→C) K(N3)-C-Y3-(H-Stp)2-H-K(K(BehA)2)-H-(H-Stp)2-Y3-C 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 behenic acid), 0.85-
2.25 (m, 94 H, βγδH lysine, βγδH azidolysine ,-CH2- behenic acid), 2.25-2.60 (m, 20 H, -CO-
CH2-CH2-CO- Stp, -CO-CH2- behenic acid), 2.65-3.1 (m, 34 H, εH lysine, tyrosine, histidine 
and azidolysine, βH cysteine), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 17 H, αH amino 
acids), 6.60 -7.15 (m, 30 H, -CH- tyrosine, aromatic H histidine), 8.45-8.60 (m, 6 H, aromatic 
H histidine). 
1388: Sequence (N→C) K(N3)-C-Y3-(H-Stp)2-H-K(K(LigA)2)-H-(H-Stp)2-Y3-C 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 lignoceric acid), 0.85-
2.25 (m, 102 H, βγδH lysine, βγδH azidolysine ,-CH2- lignoceric acid), 2.25-2.60 (m, 20 H, -
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CO-CH2-CH2-CO- Stp, -CO-CH2- lignoceric acid), 2.65-3.1 (m, 34 H, εH lysine, tyrosine, 
histidine and azidolysine, βH cysteine), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 17 H, αH 
amino acids), 6.60 -7.15 (m, 30 H, -CH- tyrosine, aromatic H histidine), 8.45-8.60 (m, 6 H, 
aromatic H histidine). 
1390: Sequence (N→C) K(N3)-C-Y3-(H-Stp)2-H-K(K(LenA)2)-H-(H-Stp)2-Y3-C 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 linolenic acid), 0.85-
2.25 (m, 46 H, βγδH lysine, βγδH azidolysine ,-CH2- linolenic acid), 2.25-2.60 (m, 20 H, -CO-
CH2-CH2-CO- Stp, -CO-CH2- linolenic acid), 2.65-3.1 (m, 42 H, εH lysine, tyrosine, histidine 
and azidolysine, βH cysteine, -C=C-CH2-C=C- linolenic acid), 3.1-3.65 (m, 64 H, -CH2- Stp), 
3.70-4.55 (m, 17 H, αH amino acids), 5.05 – 5.25 (s, 12 H, -CH=CH- linolenic acid), 6.60 -
7.15 (m, 30 H, -CH- tyrosine, aromatic H histidine), 8.45-8.60 (m, 6 H, aromatic H histidine). 
 
Non-reducible type of oligomers 
1360: Sequence (N→C) K(N3)-Y3-Stp2-K(K(PalA)2)-Stp2-Y3 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 palmitic acid), 0.85-
2.25 (m, 70 H, βγδH lysine, βγδH azidolysine,-CH2- palmitic acid), 2.25-2.60 (m, 20 H, -CO-
CH2-CH2-CO- Stp, -CO-CH2- palmitic acid), 2.65-3.1 (m, 18 H, εH lysine, tyrosine and 
azidolysine), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 9 H, αH amino acids), 6.60 -7.15 
(m, 24 H, -CH- tyrosine). 
1361: Sequence (N→C) K(N3)-Y3-Stp2-K(K(SteA)2)-Stp2-Y3 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 stearic acid), 0.85-
2.25 (m, 78 H, βγδH lysine, βγδH azidolysine,-CH2- stearic acid), 2.25-2.60 (m, 20 H, -CO-
CH2-CH2-CO- Stp, -CO-CH2- stearic acid), 2.65-3.1 (m, 18 H, εH lysine, tyrosine and 
azidolysine), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 9 H, αH amino acids), 6.60 -7.15 
(m, 24 H, -CH- tyrosine). 
1208: Sequence (N→C) K(N3)-Y3-Stp2-K(K(OleA)2)-Stp2-Y3 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 oleic acid), 0.85-2.25 
(m, 70 H, βγδH lysine, βγδH azidolysine ,-CH2- oleic acid), 2.25-2.60 (m, 20 H, -CO-CH2-
CH2-CO- Stp, -CO-CH2- oleic acid), 2.65-3.1 (m, 18 H, εH lysine, tyrosine and azidolysine), 
3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 9 H, αH amino acids), 5.05 – 5.25 (s, 4 H, -
CH=CH- oleic acid), 6.60 -7.15 (m, 24 H, -CH- tyrosine). 
1371: Sequence (N→C) K(N3)-Y3-Stp2-K(K(AraA)2)-Stp2-Y3 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 arachidic acid), 0.85-
2.25 (m, 86 H, βγδH lysine, βγδH azidolysine,-CH2- arachidic acid), 2.25-2.60 (m, 20 H, -CO-
CH2-CH2-CO- Stp, -CO-CH2- arachidic acid), 2.65-3.1 (m, 18 H, εH lysine, tyrosine and 
azidolysine), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 9 H, αH amino acids), 6.60 -7.15 
(m, 24 H, -CH- tyrosine). 
1372: Sequence (N→C) K(N3)-Y3-Stp2-K(K(BehA)2)-Stp2-Y3 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 behenic acid), 0.85-
2.25 (m, 94 H, βγδH lysine, βγδH azidolysine,-CH2- behenic acid), 2.25-2.60 (m, 20 H, -CO-
CH2-CH2-CO- Stp, -CO-CH2- behenic acid), 2.65-3.1 (m, 18 H, εH lysine, tyrosine and 
azidolysine), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 9 H, αH amino acids), 6.60 -7.15 
(m, 24 H, -CH- tyrosine). 
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1373: Sequence (N→C) K(N3)-Y3-Stp2-K(K(LigA)2)-Stp2-Y3 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 lignoceric acid), 0.85-
2.25 (m, 102 H, βγδH lysine, βγδH azidolysine,-CH2- lignoceric acid), 2.25-2.60 (m, 20 H, -
CO-CH2-CH2-CO- Stp, -CO-CH2- lignoceric acid), 2.65-3.1 (m, 18 H, εH lysine, tyrosine and 
azidolysine), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 9 H, αH amino acids), 6.60 -7.15 
(m, 24 H, -CH- tyrosine). 
1320: Sequence (N→C) K(N3)-Y3-(H-Stp)2-H-K(K(PalA)2)-H-(H-Stp)2-Y3 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 palmitic acid), 0.85-
2.25 (m, 70 H, βγδH lysine, βγδH azidolysine ,-CH2- palmitic acid), 2.25-2.60 (m, 20 H, -CO-
CH2-CH2-CO- Stp, -CO-CH2- palmitic acid), 2.65-3.1 (m, 30 H, εH lysine, tyrosine, histidine 
and azidolysine), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 15 H, αH amino acids), 6.60 -
7.15 (m, 30 H, -CH- tyrosine, aromatic H histidine), 8.45-8.60 (m, 6 H, aromatic H histidine). 
1321: Sequence (N→C) K(N3)-Y3-(H-Stp)2-H-K(K(SteA)2)-H-(H-Stp)2-Y3 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 stearic acid), 0.85-
2.25 (m, 78 H, βγδH lysine, βγδH azidolysine ,-CH2- stearic acid), 2.25-2.60 (m, 20 H, -CO-
CH2-CH2-CO- Stp, -CO-CH2- stearic acid), 2.65-3.1 (m, 30 H, εH lysine, tyrosine, histidine 
and azidolysine), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 15 H, αH amino acids), 6.60 -
7.15 (m, 30 H, -CH- tyrosine, aromatic H histidine), 8.45-8.60 (m, 6 H, aromatic H histidine). 
1209: Sequence (N→C) K(N3)-Y3-(H-Stp)2-H-K(K(OleA)2)-H-(H-Stp)2-Y3 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 oleic acid), 0.85-2.25 
(m, 70 H, βγδH lysine, βγδH azidolysine ,-CH2- oleic acid), 2.25-2.60 (m, 20 H, -CO-CH2-
CH2-CO- Stp, -CO-CH2- oleic acid), 2.65-3.1 (m, 30 H, εH lysine, tyrosine, histidine and 
azidolysine), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 15 H, αH amino acids), 5.05 – 5.25 
(s, 4 H, -CH=CH- oleic acid), 6.60 -7.15 (m, 30 H, -CH- tyrosine, aromatic H histidine), 8.45-
8.60 (m, 6 H, aromatic H histidine). 
1374: Sequence (N→C) K(N3)-Y3-(H-Stp)2-H-K(K(AraA)2)-H-(H-Stp)2-Y3 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 arachidic acid), 0.85-
2.25 (m, 86 H, βγδH lysine, βγδH azidolysine ,-CH2- arachidic acid), 2.25-2.60 (m, 20 H, -
CO-CH2-CH2-CO- Stp, -CO-CH2- arachidic acid), 2.65-3.1 (m, 30 H, εH lysine, tyrosine, 
histidine and azidolysine), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 15 H, αH amino 
acids), 6.60 -7.15 (m, 30 H, -CH- tyrosine, aromatic H histidine), 8.45-8.60 (m, 6 H, aromatic 
H histidine). 
1375: Sequence (N→C) K(N3)-Y3-(H-Stp)2-H-K(K(BehA)2)-H-(H-Stp)2-Y3 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 behenic acid), 0.85-
2.25 (m, 94 H, βγδH lysine, βγδH azidolysine ,-CH2- behenic acid), 2.25-2.60 (m, 20 H, -CO-
CH2-CH2-CO- Stp, -CO-CH2- behenic acid), 2.65-3.1 (m, 30 H, εH lysine, tyrosine, histidine 
and azidolysine), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 15 H, αH amino acids), 6.60 -
7.15 (m, 30 H, -CH- tyrosine, aromatic H histidine), 8.45-8.60 (m, 6 H, aromatic H histidine). 
1376: Sequence (N→C) K(N3)-Y3-(H-Stp)2-H-K(K(LigA)2)-H-(H-Stp)2-Y3 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 lignoceric acid), 0.85-
2.25 (m, 102 H, βγδH lysine, βγδH azidolysine ,-CH2- lignoceric acid), 2.25-2.60 (m, 20 H, -
CO-CH2-CH2-CO- Stp, -CO-CH2- lignoceric acid), 2.65-3.1 (m, 30 H, εH lysine, tyrosine, 
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histidine and azidolysine), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 15 H, αH amino 
acids), 6.60 -7.15 (m, 30 H, -CH- tyrosine, aromatic H histidine), 8.45-8.60 (m, 6 H, aromatic 
H histidine). 
 
Bioreducible type of oligomers 
1348: Sequence (N→C) K(N3)-Y3-Stp2-K(G-ssbb-K(PalA)2)-Stp2-Y3 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 palmitic acid), 0.85-
2.25 (m, 70 H, βγδH lysine, βγδH azidolysine ,-CH2- palmitic acid), 2.25-2.60 (m, 24 H, -CO-
CH2-CH2-CO- Stp and ssbb, -CO-CH2- palmitic acid), 2.65-3.1 (m, 26 H, εH lysine, tyrosine 
and azidolysine, -CH2- ssbb), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 11 H, αH amino 
acids), 6.60 -7.15 (m, 24 H, -CH- tyrosine). 
1349: Sequence (N→C) K(N3)-Y3-Stp2-K(G-ssbb-K(SteA)2)-Stp2-Y3 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 stearic acid), 0.85-
2.25 (m, 78 H, βγδH lysine, βγδH azidolysine ,-CH2- stearic acid), 2.25-2.60 (m, 24 H, -CO-
CH2-CH2-CO- Stp and ssbb, -CO-CH2- stearic acid), 2.65-3.1 (m, 26 H, εH lysine, tyrosine 
and azidolysine, -CH2- ssbb), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 11 H, αH amino 
acids), 6.60 -7.15 (m, 24 H, -CH- tyrosine). 
1217: Sequence (N→C) K(N3)-Y3-Stp2-K(G-ssbb-K(OleA)2)-Stp2-Y3 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 oleic acid), 0.85-2.25 
(m, 70 H, βγδH lysine, βγδH azidolysine ,-CH2- oleic acid), 2.25-2.60 (m, 24 H, -CO-CH2-
CH2-CO- Stp and ssbb, -CO-CH2- oleic acid), 2.65-3.1 (m, 26 H, εH lysine, tyrosine and 
azidolysine, -CH2- ssbb), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 11 H, αH amino acids), 
5.05 – 5.25 (s, 4 H, -CH=CH- oleic acid), 6.60 -7.15 (m, 24 H, -CH- tyrosine). 
1377: Sequence (N→C) K(N3)-Y3-Stp2-K(G-ssbb-K(AraA)2)-Stp2-Y3 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 arachidic acid), 0.85-
2.25 (m, 86 H, βγδH lysine, βγδH azidolysine ,-CH2- arachidic acid), 2.25-2.60 (m, 24 H, -
CO-CH2-CH2-CO- Stp and ssbb, -CO-CH2- arachidic acid), 2.65-3.1 (m, 26 H, εH lysine, 
tyrosine and azidolysine, -CH2- ssbb), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 11 H, αH 
amino acids), 6.60 -7.15 (m, 24 H, -CH- tyrosine). 
1378: Sequence (N→C) K(N3)-Y3-Stp2-K(G-ssbb-K(BehA)2)-Stp2-Y3 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 behenic acid), 0.85-
2.25 (m, 94 H, βγδH lysine, βγδH azidolysine ,-CH2- behenic acid), 2.25-2.60 (m, 24 H, -CO-
CH2-CH2-CO- Stp and ssbb, -CO-CH2- behenic acid), 2.65-3.1 (m, 26 H, εH lysine, tyrosine 
and azidolysine, -CH2- ssbb), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 11 H, αH amino 
acids), 6.60 -7.15 (m, 24 H, -CH- tyrosine). 
1379: Sequence (N→C) K(N3)-Y3-Stp2-K(G-ssbb-K(LigA)2)-Stp2-Y3 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 lignoceric acid), 0.85-
2.25 (m, 102 H, βγδH lysine, βγδH azidolysine ,-CH2- lignoceric acid), 2.25-2.60 (m, 24 H, -
CO-CH2-CH2-CO- Stp and ssbb, -CO-CH2- lignoceric acid), 2.65-3.1 (m, 26 H, εH lysine, 
tyrosine and azidolysine, -CH2- ssbb), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 11 H, αH 
amino acids), 6.60 -7.15 (m, 24 H, -CH- tyrosine). 
1305: Sequence (N→C) K(N3)-Y3-(H-Stp)2-H-K(G-ssbb-K(PalA)2)-H-(H-Stp)2-Y3 
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1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 palmitic acid), 0.85-
2.25 (m, 70 H, βγδH lysine, βγδH azidolysine ,-CH2- palmitic acid), 2.25-2.60 (m, 24 H, -CO-
CH2-CH2-CO- Stp and ssbb, -CO-CH2- palmitic acid), 2.65-3.1 (m, 38 H, εH lysine, tyrosine, 
histidine and azidolysine, -CH2- ssbb), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 17 H, αH 
amino acids), 6.60 -7.15 (m, 30 H, -CH- tyrosine, aromatic H histidine), 8.45-8.60 (m, 6 H, 
aromatic H histidine). 
1306: Sequence (N→C) K(N3)-Y3-(H-Stp)2-H-K(G-ssbb-K(SteA)2)-H-(H-Stp)2-Y3 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 stearic acid), 0.85-
2.25 (m, 78 H, βγδH lysine, βγδH azidolysine ,-CH2- stearic acid), 2.25-2.60 (m, 24 H, -CO-
CH2-CH2-CO- Stp and ssbb, -CO-CH2- stearic acid), 2.65-3.1 (m, 38 H, εH lysine, tyrosine, 
histidine and azidolysine, -CH2- ssbb), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 17 H, αH 
amino acids), 6.60 -7.15 (m, 30 H, -CH- tyrosine, aromatic H histidine), 8.45-8.60 (m, 6 H, 
aromatic H histidine). 
1218: Sequence (N→C) K(N3)-Y3-(H-Stp)2-H-K(G-ssbb-K(OleA)2)-H-(H-Stp)2-Y3 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 oleic acid), 0.85-2.25 
(m, 70 H, βγδH lysine, βγδH azidolysine ,-CH2- oleic acid), 2.25-2.60 (m, 24 H, -CO-CH2-
CH2-CO- Stp and ssbb, -CO-CH2- oleic acid), 2.65-3.1 (m, 38 H, εH lysine, tyrosine, histidine 
and azidolysine, -CH2- ssbb), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 17 H, αH amino 
acids), 5.05 – 5.25 (s, 4 H, -CH=CH- oleic acid), 6.60 -7.15 (m, 30 H, -CH- tyrosine, aromatic 
H histidine), 8.45-8.60 (m, 6 H, aromatic H histidine). 
1380: Sequence (N→C) K(N3)-Y3-(H-Stp)2-H-K(G-ssbb-K(AraA)2)-H-(H-Stp)2-Y3 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 arachidic acid), 0.85-
2.25 (m, 86 H, βγδH lysine, βγδH azidolysine ,-CH2- arachidic acid), 2.25-2.60 (m, 24 H, -
CO-CH2-CH2-CO- Stp and ssbb, -CO-CH2- arachidic acid), 2.65-3.1 (m, 38 H, εH lysine, 
tyrosine, histidine and azidolysine, -CH2- ssbb), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 
17 H, αH amino acids), 6.60 -7.15 (m, 30 H, -CH- tyrosine, aromatic H histidine), 8.45-8.60 
(m, 6 H, aromatic H histidine). 
1381: Sequence (N→C) K(N3)-Y3-(H-Stp)2-H-K(G-ssbb-K(BehA)2)-H-(H-Stp)2-Y3 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 behenic acid), 0.85-
2.25 (m, 94 H, βγδH lysine, βγδH azidolysine ,-CH2- behenic acid), 2.25-2.60 (m, 24 H, -CO-
CH2-CH2-CO- Stp and ssbb, -CO-CH2- behenic acid), 2.65-3.1 (m, 38 H, εH lysine, tyrosine, 
histidine and azidolysine, -CH2- ssbb), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 17 H, αH 
amino acids), 6.60 -7.15 (m, 30 H, -CH- tyrosine, aromatic H histidine), 8.45-8.60 (m, 6 H, 
aromatic H histidine). 
1382: Sequence (N→C) K(N3)-Y3-(H-Stp)2-H-K(G-ssbb-K(LigA)2)-H-(H-Stp)2-Y3 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 lignoceric acid), 0.85-
2.25 (m, 102 H, βγδH lysine, βγδH azidolysine ,-CH2- lignoceric acid), 2.25-2.60 (m, 24 H, -
CO-CH2-CH2-CO- Stp and ssbb, -CO-CH2- lignoceric acid), 2.65-3.1 (m, 38 H, εH lysine, 
tyrosine, histidine and azidolysine, -CH2- ssbb), 3.1-3.65 (m, 64 H, -CH2- Stp), 3.70-4.55 (m, 
17 H, αH amino acids), 6.60 -7.15 (m, 30 H, -CH- tyrosine, aromatic H histidine), 8.45-8.60 
(m, 6 H, aromatic H histidine). 
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6.  Abbreviations 
ACN  Acetonitrile  
Boc  tert-Butoxycarbonyl  
BSA Bovine serum albumin 
D2O  Deuterium oxide  
DAPI  4',6-Diamidino-2-phenylindole  
DBCO Dibenzocyclooctyne group 
DCM  Dichloromethane  
Dde  1-(4,4-Dimethyl-2,6-dioxocyclohex-1-ylidene)-3-ethyl  
DIPEA  N,N-Diisopropylethylamine  
DLS  Dynamic laser-light scattering  
DMEM  Dulbecco’s modified Eagle’s medium  
DMF  N,N-Dimethylformamide  
DMSO  Dimethylsulfoxide  
dsRNA  Double-strand RNA 
DTNB  5,5’-Dithio-bis(2-nitrobenzoic acid)  
EDTA  Ethylendiaminetetraacetic acid  
EGFP Enhanced green fluorescent protein 
FBS  Fetal bovine serum  
FCS Fluorescence correlation spectroscopy 
FITC Fluorescein isothiocyanate 
Fmoc  Fluorenylmethoxycarbonyl  
FolA  Folic acid  
FR  Folate receptor  
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GSH Glutathione 
Gtt Glutaroyl triethylene tetramine 
HA Hyaluronic acid 
HBG Hepes-buffered glucose 
HBTU 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate 
HCl  Hydrochloric acid  
HEPES  N-(2-hydroxethyl) piperazine-N‘-(2-ethansulfonic acid)  
HOBt  1-Hydroxybenzotriazole  
INF7  An endosomolytic influenza virus derived peptide  
ivDde 1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl  
LenA Linolenic acid 
LinA Linoleic acid 
MTBE  Methyl tert-butyl ether  
MTT  3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide  
MWCO Molecular Weight Cut Off 
MyrA  Myristic acid  
NaOH  Sodium hydroxide  
NHS N-Hydroxysuccinimide 
NMR  Nuclear magnetic resonance  
OleA Oleic acid 
PBS  Phosphate buffered saline  
PDI  Polydispersity index  
PEG  Polyethylene glycol  
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PyBOP  Benzotriazol-1-yloxy-tripyrrolidinophosphonium 
hexafluorophosphate  
RNA Ribonucleic acid 
RNase A Ribonuclease A 
RP-HPLC  Reversed-phase high performance liquid chromatography  
RPMI  Roswell Park Memorial Institute medium  
RT  Room temperature  
SEC  Size-exclusion chromatography  
siRNA Small interfering RNA 
Sph  Succinoyl-pentaethylene hexamine  
SPS  Solid-phase synthesis  
SteA Stearic acid 
Stp  Succinoyl-tetraethylene pentamine  
TEPA  Tetraethylene pentamine  
TEM  Transmission electron microscopy  
TFA  Trifluoroacetic acid  
THF Tetrahydrofuran 
TIS  Triisopropylsilane  
 
 
 
 
 
 
 
 
                                                                                     References                                                                                                                                                                                                                                                     
127 
 
7.  References 
[1] D. Adams, A. Gonzalez-Duarte, W.D. O’Riordan, C.-C. Yang, M. Ueda, A.V. Kristen, I. 
Tournev, H.H. Schmidt, T. Coelho, J.L. Berk, K.-P. Lin, G. Vita, S. Attarian, V. Planté-Bordeneuve, 
M.M. Mezei, J.M. Campistol, J. Buades, T.H. Brannagan, B.J. Kim, J. Oh, Y. Parman, Y. Sekijima, 
P.N. Hawkins, S.D. Solomon, M. Polydefkis, P.J. Dyck, P.J. Gandhi, S. Goyal, J. Chen, A.L. Strahs, 
S.V. Nochur, M.T. Sweetser, P.P. Garg, A.K. Vaishnaw, J.A. Gollob, O.B. Suhr, Patisiran, an RNAi 
Therapeutic, for Hereditary Transthyretin Amyloidosis, New England Journal of Medicine 
379(1) (2018) 11-21. 
[2] L. Hartmann, E. Krause, M. Antonietti, H.G. Borner, Solid-phase supported polymer 
synthesis of sequence-defined, multifunctional poly(amidoamines), Biomacromolecules. 7(4) 
(2006) 1239-1244. 
[3] L. Hartmann, S. Häfele, R. Peschka-Süss, M. Antonietti, H.G. Börner, Sequence Positioning 
of Disulfide Linkages to Program the Degradation of Monodisperse Poly(amidoamines), 
Macromolecules 40(22) (2007) 7771-7776. 
[4] L. Hartmann, S. Hafele, R. Peschka-Suss, M. Antonietti, H.G. Borner, Tailor-Made 
Poly(amidoamine)s for Controlled Complexation and Condensation of DNA, Chemistry. 14(7) 
(2008) 2025-2033. 
[5] S.A. Hill, C. Gerke, L. Hartmann, Recent Developments in Solid-Phase Strategies towards 
Synthetic, Sequence-Defined Macromolecules, Chemistry, an Asian journal 13(23) (2018) 
3611-3622. 
[6] W. Tai, X. Gao, Functional peptides for siRNA delivery, Advanced drug delivery reviews 110-
111 (2017) 157-168. 
[7] A.D. Tagalakis, D.H.D. Lee, A.S. Bienemann, H. Zhou, M.M. Munye, L. Saraiva, D. McCarthy, 
Z. Du, C.A. Vink, R. Maeshima, E.A. White, K. Gustafsson, S.L. Hart, Multifunctional, self-
assembling anionic peptide-lipid nanocomplexes for targeted siRNA delivery, Biomaterials 
35(29) (2014) 8406-8415. 
[8] P. Majumder, S. Bhunia, J. Bhattacharyya, A. Chaudhuri, Inhibiting tumor growth by 
targeting liposomally encapsulated CDC20siRNA to tumor vasculature: Therapeutic RNA 
interference, Journal of Controlled Release 180 (2014) 100-108. 
[9] Y. Huang, X. Wang, W. Huang, Q. Cheng, S. Zheng, S. Guo, H. Cao, X.-J. Liang, Q. Du, Z. Liang, 
Systemic Administration of siRNA via cRGD-containing Peptide, Scientific Reports 5(1) (2015) 
12458. 
[10] J. Jiang, S.-j. Yang, J.-c. Wang, L.-j. Yang, Z.-z. Xu, T. Yang, X.-y. Liu, Q. Zhang, Sequential 
treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or 
doxorubicin, European Journal of Pharmaceutics and Biopharmaceutics 76(2) (2010) 170-178. 
[11] Q.R. Chen, L. Zhang, P.W. Luther, A.J. Mixson, Optimal transfection with the HK polymer 
depends on its degree of branching and the pH of endocytic vesicles, Nucleic Acids Res. 30(6) 
(2002) 1338-1345. 
[12] Q. Leng, A.J. Mixson, Modified branched peptides with a histidine-rich tail enhance in 
vitro gene transfection, Nucleic Acids Res 33(4) (2005) e40. 
                                                                                     References                                                                                                                                                                                                                                                     
128 
 
[13] Q. Leng, P. Scaria, J. Zhu, N. Ambulos, P. Campbell, A.J. Mixson, Highly branched HK 
peptides are effective carriers of siRNA, J Gene Med 7(7) (2005) 977-986. 
[14] Q. Leng, A.J. Mixson, Small interfering RNA targeting Raf-1 inhibits tumor growth in vitro 
and in vivo, Cancer Gene Ther. 12(8) (2005) 682-690. 
[15] Q. Leng, S.T. Chou, P.V. Scaria, M.C. Woodle, A.J. Mixson, Increased tumor distribution 
and expression of histidine-rich plasmid polyplexes, J Gene Med 16(9-10) (2014) 317-28. 
[16] Q. Leng, A.J. Mixson, The neuropilin-1 receptor mediates enhanced tumor delivery of H2K 
polyplexes, J Gene Med 18(7) (2016) 134-44. 
[17] T. Lehto, R. Abes, N. Oskolkov, J. Suhorutsenko, D.M. Copolovici, I. Mager, J.R. Viola, O.E. 
Simonson, K. Ezzat, P. Guterstam, E. Eriste, C.I. Smith, B. Lebleu, A. Samir El, U. Langel, Delivery 
of nucleic acids with a stearylated (RxR)4 peptide using a non-covalent co-incubation strategy, 
J Control Release 141(1) (2010) 42-51. 
[18] S.E. Andaloussi, T. Lehto, I. Mager, K. Rosenthal-Aizman, Oprea, II, O.E. Simonson, H. Sork, 
K. Ezzat, D.M. Copolovici, K. Kurrikoff, J.R. Viola, E.M. Zaghloul, R. Sillard, H.J. Johansson, F. 
Said Hassane, P. Guterstam, J. Suhorutsenko, P.M. Moreno, N. Oskolkov, J. Halldin, U. 
Tedebark, A. Metspalu, B. Lebleu, J. Lehtio, C.I. Smith, U. Langel, Design of a peptide-based 
vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo, Nucleic 
Acids Res 39(9) (2011) 3972-87. 
[19] K. Ezzat, S.E. Andaloussi, E.M. Zaghloul, T. Lehto, S. Lindberg, P.M. Moreno, J.R. Viola, T. 
Magdy, R. Abdo, P. Guterstam, R. Sillard, S.M. Hammond, M.J. Wood, A.A. Arzumanov, M.J. 
Gait, C.I. Smith, M. Hallbrink, U. Langel, PepFect 14, a novel cell-penetrating peptide for 
oligonucleotide delivery in solution and as solid formulation, Nucleic Acids Res 39(12) (2011) 
5284-98. 
[20] X.L. Wang, R. Xu, X. Wu, D. Gillespie, R. Jensen, Z.R. Lu, Targeted systemic delivery of a 
therapeutic siRNA with a multifunctional carrier controls tumor proliferation in mice, Mol 
Pharm. 6(3) (2009) 738-746. 
[21] X.-L. Wang, R. Xu, Z.-R. Lu, A peptide-targeted delivery system with pH-sensitive 
amphiphilic cell membrane disruption for efficient receptor-mediated siRNA delivery, Journal 
of Controlled Release 134(3) (2009) 207-213. 
[22] A.S. Malamas, M. Gujrati, C.M. Kummitha, R. Xu, Z.R. Lu, Design and evaluation of new 
pH-sensitive amphiphilic cationic lipids for siRNA delivery, J Control Release 171(3) (2013) 296-
307. 
[23] J.G. Parvani, M.D. Gujrati, M.A. Mack, W.P. Schiemann, Z.R. Lu, Silencing beta3 Integrin 
by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast 
Cancer, Cancer Res 75(11) (2015) 2316-2325. 
[24] O. Boussif, F. Lezoualc'h, M.A. Zanta, M.D. Mergny, D. Scherman, B. Demeneix, J.P. Behr, 
A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: 
polyethylenimine, Proc.Natl.Acad.Sci.U.S.A 92(16) (1995) 7297-7301. 
[25] A. Kichler, C. Leborgne, E. Coeytaux, O. Danos, Polyethylenimine-mediated gene delivery: 
a mechanistic study, J Gene Med 3(2) (2001) 135-144. 
[26] A. Hall, U. Lachelt, J. Bartek, E. Wagner, S.M. Moghimi, Polyplex Evolution: Understanding 
Biology, Optimizing Performance, Mol Ther 25(7) (2017) 1476-1490. 
                                                                                     References                                                                                                                                                                                                                                                     
129 
 
[27] D. Schaffert, N. Badgujar, E. Wagner, Novel Fmoc-polyamino acids for solid-phase 
synthesis of defined polyamidoamines, Organic letters 13(7) (2011) 1586-1589. 
[28] D. Schaffert, C. Troiber, E.E. Salcher, T. Frohlich, I. Martin, N. Badgujar, C. Dohmen, D. 
Edinger, R. Klager, G. Maiwald, K. Farkasova, S. Seeber, K. Jahn-Hofmann, P. Hadwiger, E. 
Wagner, Solid-phase synthesis of sequence-defined T-, i-, and U-shape polymers for pDNA and 
siRNA delivery, Angew Chem Int Ed Engl 50(38) (2011) 8986-9. 
[29] E. Wagner, Polymers for siRNA Delivery: Inspired by Viruses to be Targeted, Dynamic, and 
Precise, Acc Chem Res 45(7) (2012) 1005-13. 
[30] C. Scholz, E. Wagner, Therapeutic plasmid DNA versus siRNA delivery: Common and 
different tasks for synthetic carriers, J Control Release 161(2) (2012) 554-65. 
[31] E.E. Salcher, P. Kos, T. Fröhlich, N. Badgujar, M. Scheible, E. Wagner, Sequence-defined 
four-arm oligo (ethanamino) amides for pDNA and siRNA delivery: Impact of building blocks 
on efficacy, Journal of controlled release 164(3) (2012) 380-386. 
[32] T. Frohlich, D. Edinger, R. Klager, C. Troiber, E. Salcher, N. Badgujar, I. Martin, D. Schaffert, 
A. Cengizeroglu, P. Hadwiger, H.P. Vornlocher, E. Wagner, Structure-activity relationships of 
siRNA carriers based on sequence-defined oligo (ethane amino) amides, J Control Release 
160(3) (2012) 532-41. 
[33] C. Dohmen, D. Edinger, T. Frohlich, L. Schreiner, U. Lachelt, C. Troiber, J. Radler, P. 
Hadwiger, H.P. Vornlocher, E. Wagner, Nanosized Multifunctional Polyplexes for Receptor-
Mediated SiRNA Delivery, ACS Nano 6(6) (2012) 5198-208. 
[34] C. Dohmen, T. Frohlich, U. Lachelt, I. Rohl, H.-P. Vornlocher, P. Hadwiger, E. Wagner, 
Defined Folate-PEG-siRNA Conjugates for Receptor-specific Gene Silencing, Mol Ther Nucleic 
Acids 1 (2012) e7. 
[35] K. Mechtler, E. Wagner, Gene transfer mediated by influenza virus peptides: the role of 
peptide sequence, New J Chem 21 (1997) 105-11. 
[36] C. Plank, B. Oberhauser, K. Mechtler, C. Koch, E. Wagner, The influence of endosome-
disruptive peptides on gene transfer using synthetic virus-like gene transfer systems, J 
Biol.Chem. 269(17) (1994) 12918-12924. 
[37] U. Lachelt, V. Wittmann, K. Muller, D. Edinger, P. Kos, M. Hohn, E. Wagner, Synthetic 
polyglutamylation of dual-functional MTX ligands for enhanced combined cytotoxicity of 
poly(I:C) nanoplexes, Mol Pharm 11(8) (2014) 2631-9. 
[38] D.-J. Lee, E. Kessel, D. Edinger, D. He, P.M. Klein, L. Voith von Voithenberg, D.C. Lamb, U. 
Lächelt, T. Lehto, E. Wagner, Dual antitumoral potency of EG5 siRNA nanoplexes armed with 
cytotoxic bifunctional glutamyl-methotrexate targeting ligand, Biomaterials 77 (2016) 98-110. 
[39] P.M. Klein, S. Reinhard, D.-J. Lee, K. Müller, D. Ponader, L. Hartmann, E. Wagner, Precise 
redox-sensitive cleavage sites for improved bioactivity of siRNA lipopolyplexes, Nanoscale 
8(42) (2016) 18098-18104. 
[40] J. Gilleron, W. Querbes, A. Zeigerer, A. Borodovsky, G. Marsico, U. Schubert, K. Manygoats, 
S. Seifert, C. Andree, M. Stöter, Image-based analysis of lipid nanoparticle–mediated siRNA 
delivery, intracellular trafficking and endosomal escape, Nature biotechnology 31(7) (2013) 
638. 
                                                                                     References                                                                                                                                                                                                                                                     
130 
 
[41] A. Wittrup, A. Ai, X. Liu, P. Hamar, R. Trifonova, K. Charisse, M. Manoharan, T. Kirchhausen, 
J. Lieberman, Visualizing lipid-formulated siRNA release from endosomes and target gene 
knockdown, Nature biotechnology 33(8) (2015) 870. 
[42] S. Reinhard, Y. Wang, S. Dengler, E. Wagner, Precise Enzymatic Cleavage Sites for 
Improved Bioactivity of siRNA Lipo-Polyplexes, Bioconjug Chem 29(11) (2018) 3649-3657. 
[43] D.-J. Lee, D. He, E. Kessel, K. Padari, S. Kempter, U. Lächelt, J.O. Rädler, M. Pooga, E. 
Wagner, Tumoral gene silencing by receptor-targeted combinatorial siRNA polyplexes, Journal 
of controlled release 244 (2016) 280-291. 
[44] D.-J. Lee, E. Wagner, Combinatorial siRNA Polyplexes for Receptor Targeting, in: L. Dinesh 
Kumar (Ed.), RNA Interference and Cancer Therapy: Methods and Protocols, Springer New 
York, New York, NY, 2019, pp. 83-98. 
[45] P. Kos, U. Lächelt, A. Herrmann, F.M. Mickler, M. Döblinger, D. He, A.K. Levačić, S. Morys, 
C. Bräuchle, E. Wagner, Histidine-rich stabilized polyplexes for cMet-directed tumor-targeted 
gene transfer, Nanoscale 7(12) (2015) 5350-5362. 
[46] D. He, K. Müller, A. Krhac Levacic, P. Kos, U. Lächelt, E. Wagner, Combinatorial 
optimization of sequence-defined oligo (ethanamino) amides for folate receptor-targeted 
pDNA and siRNA delivery, Bioconjugate chemistry 27(3) (2016) 647-659. 
[47] D.-J. Lee, E. Kessel, T. Lehto, X. Liu, N. Yoshinaga, K. Padari, Y.-C. Chen, S. Kempter, S. 
Uchida, J.O. Rädler, Systemic delivery of folate-PEG siRNA lipopolyplexes with enhanced 
intracellular stability for in vivo gene silencing in leukemia, Bioconjugate chemistry 28(9) (2017) 
2393-2409. 
[48] K. Müller, E. Kessel, P.M. Klein, M. Höhn, E. Wagner, Post-PEGylation of siRNA lipo-
oligoamino amide polyplexes using tetra-glutamylated folic acid as ligand for receptor-
targeted delivery, Molecular pharmaceutics 13(7) (2016) 2332-2345. 
[49] K. Müller, P.M. Klein, P. Heissig, A. Roidl, E. Wagner, EGF receptor targeted lipo-
oligocation polyplexes for antitumoral siRNA and miRNA delivery, Nanotechnology 27(46) 
(2016) 464001. 
[50] B. Steinborn, I. Truebenbach, S. Morys, U. Lächelt, E. Wagner, W. Zhang, Epidermal 
growth factor receptor targeted methotrexate and small interfering RNA co‐delivery, The 
journal of gene medicine 20(7-8) (2018) e3041. 
[51] W. Zhang, K. Müller, E. Kessel, S. Reinhard, D. He, P.M. Klein, M. Höhn, W. Rödl, S. Kempter, 
E. Wagner, Targeted siRNA delivery using a lipo‐ oligoaminoamide nanocore with an 
influenza peptide and transferrin shell, Advanced healthcare materials 5(12) (2016) 1493-1504. 
[52] J. Luo, M. Höhn, S. Reinhard, D.M. Loy, P.M. Klein, E. Wagner, IL4-Receptor-Targeted Dual 
Antitumoral Apoptotic Peptide—siRNA Conjugate Lipoplexes, Advanced Functional Materials 
29(25) (2019) 1900697. 
[53] Y. Wang, J. Luo, I. Truebenbach, S.r. Reinhard, P.M. Klein, M. Höhn, S. Kern, S. Morys, D.M. 
Loy, E. Wagner, Double Click-Functionalized siRNA Polyplexes for Gene Silencing in Epidermal 
Growth Factor Receptor-Positive Tumor Cells, ACS Biomaterials Science & Engineering  
(2020). 
[54] P. Klein, K. Klinker, W. Zhang, S. Kern, E. Kessel, E. Wagner, M. Barz, Efficient shielding of 
polyplexes using heterotelechelic polysarcosines, Polymers 10(6) (2018) 689. 
                                                                                     References                                                                                                                                                                                                                                                     
131 
 
[55] P.M. Klein, S. Kern, D.-J. Lee, J. Schmaus, M. Höhn, J. Gorges, U. Kazmaier, E. Wagner, 
Folate receptor-directed orthogonal click-functionalization of siRNA lipopolyplexes for tumor 
cell killing in vivo, Biomaterials 178 (2018) 630-642. 
[56] I. Truebenbach, W. Zhang, Y. Wang, S. Kern, M. Höhn, S. Reinhard, J. Gorges, U. Kazmaier, 
E. Wagner, Co-delivery of pretubulysin and siEG5 to EGFR overexpressing carcinoma cells, 
International Journal of Pharmaceutics 569 (2019) 118570. 
[57] P.M. Klein, E. Wagner, Click-Shielded and Targeted Lipopolyplexes, Oligonucleotide-Based 
Therapies, Springer2019, pp. 141-164. 
[58] U. Lächelt, V. Wittmann, K. Müller, D. Edinger, P. Kos, M. Höhn, E. Wagner, Synthetic 
polyglutamylation of dual-functional MTX ligands for enhanced combined cytotoxicity of poly 
(I: C) nanoplexes, Molecular pharmaceutics 11(8) (2014) 2631-2639. 
[59] J.M. Baskin, J.A. Prescher, S.T. Laughlin, N.J. Agard, P.V. Chang, I.A. Miller, A. Lo, J.A. 
Codelli, C.R. Bertozzi, Copper-free click chemistry for dynamic <em>in vivo</em> imaging, 
104(43) (2007) 16793-16797. 
[60] P.V. Chang, J.A. Prescher, E.M. Sletten, J.M. Baskin, I.A. Miller, N.J. Agard, A. Lo, C.R. 
Bertozzi, Copper-free click chemistry in living animals, 107(5) (2010) 1821-1826. 
[61] V.V. Rostovtsev, L.G. Green, V.V. Fokin, K.B. Sharpless, A Stepwise Huisgen Cycloaddition 
Process: Copper(I)-Catalyzed Regioselective “Ligation” of Azides and Terminal Alkynes, 41(14) 
(2002) 2596-2599. 
[62] D.M. Loy, P.M. Klein, R. Krzysztoń, U. Lächelt, J.O. Rädler, E. Wagner, A microfluidic 
approach for sequential assembly of siRNA polyplexes with defined structure–activity 
relationship, PeerJ Preprints, 2019. 
[63] L.D. Mayer, T.O. Harasym, P.G. Tardi, N.L. Harasym, C.R. Shew, S.A. Johnstone, E.C. 
Ramsay, M.B. Bally, A.S. Janoff, Ratiometric dosing of anticancer drug combinations: 
Controlling drug ratios after systemic administration regulates therapeutic activity in tumor-
bearing mice, Molecular Cancer Therapeutics 5(7) (2006) 1854-1863. 
[64] I. Truebenbach, S. Kern, D.M. Loy, M. Höhn, J. Gorges, U. Kazmaier, E. Wagner, 
Combination Chemotherapy of L1210 Tumors in Mice with Pretubulysin and Methotrexate 
Lipo-Oligomer Nanoparticles, Molecular Pharmaceutics 16(6) (2019) 2405-2417. 
[65] P.M. Klein, S. Kern, D.J. Lee, J. Schmaus, M. Hohn, J. Gorges, U. Kazmaier, E. Wagner, 
Folate receptor-directed orthogonal click-functionalization of siRNA lipopolyplexes for tumor 
cell killing in vivo, Biomaterials  (2018). 
[66] P.M. Klein, S. Reinhard, D.J. Lee, K. Muller, D. Ponader, L. Hartmann, E. Wagner, Precise 
redox-sensitive cleavage sites for improved bioactivity of siRNA lipopolyplexes, Nanoscale 
8(42) (2016) 18098-18104. 
[67] S. Reinhard, W. Zhang, E. Wagner, Optimized Solid-Phase-Assisted Synthesis of Oleic Acid 
Containing siRNA Nanocarriers, ChemMedChem 12(17) (2017) 1464-1470. 
[68] S. Reinhard, Y. Wang, S. Dengler, E. Wagner, Precise Enzymatic Cleavage Sites for 
Improved Bioactivity of siRNA Lipo-Polyplexes, Bioconjugate Chemistry 29(11) (2018) 3649-
3657. 
                                                                                     References                                                                                                                                                                                                                                                     
132 
 
[69] A. Fire, S. Xu, M.K. Montgomery, S.A. Kostas, S.E. Driver, C.C. Mello, Potent and specific 
genetic interference by double-stranded RNA in Caenorhabditis elegans, Nature 391(6669) 
(1998) 806-811. 
[70] N. Adams, U.S. Schubert, Poly(2-oxazolines) in biological and biomedical application 
contexts, Advanced Drug Delivery Reviews 59(15) (2007) 1504-1520. 
[71] D. Haussecker, Current issues of RNAi therapeutics delivery and development, J Control 
Release 195 (2014) 49-54. 
[72] A. Wittrup, A. Ai, X. Liu, P. Hamar, R. Trifonova, K. Charisse, M. Manoharan, T. Kirchhausen, 
J. Lieberman, Visualizing lipid-formulated siRNA release from endosomes and target gene 
knockdown, Nat Biotechnol 33(8) (2015) 870-6. 
[73] U. Lachelt, E. Wagner, Nucleic Acid Therapeutics Using Polyplexes: A Journey of 50 Years 
(and Beyond), Chem Rev 115(19) (2015) 11043-78. 
[74] P.R. Cullis, M.J. Hope, Lipid Nanoparticle Systems for Enabling Gene Therapies, Mol Ther 
25(7) (2017) 1467-1475. 
[75] S. Reinhard, E. Wagner, How to Tackle the Challenge of siRNA Delivery with Sequence-
Defined Oligoamino Amides, Macromol Biosci 17(1) (2017). 
[76] G. Sahay, W. Querbes, C. Alabi, A. Eltoukhy, S. Sarkar, C. Zurenko, E. Karagiannis, K. Love, 
D. Chen, R. Zoncu, Y. Buganim, A. Schroeder, R. Langer, D.G. Anderson, Efficiency of siRNA 
delivery by lipid nanoparticles is limited by endocytic recycling, Nat Biotechnol 31(7) (2013) 
653-8. 
[77] L. Hartmann, H.G. Börner, Precision Polymers: Monodisperse, Monomer-Sequence-
Defined Segments to Target Future Demands of Polymers in Medicine, Advanced Materials 
21(32-33) (2009) 3425-3431. 
[78] T. Lehto, O.E. Simonson, I. Mager, K. Ezzat, H. Sork, D.M. Copolovici, J.R. Viola, E.M. 
Zaghloul, P. Lundin, P.M. Moreno, M. Mae, N. Oskolkov, J. Suhorutsenko, C.I. Smith, S.E. 
Andaloussi, A peptide-based vector for efficient gene transfer in vitro and in vivo, Mol Ther 
19(8) (2011) 1457-67. 
[79] P. Kos, U. Lächelt, A. Herrmann, F.M. Mickler, M. Döblinger, D. He, A. Krhač Levačić, S. 
Morys, C. Bräuchle, E. Wagner, Histidine-rich stabilized polyplexes for cMet-directed tumor-
targeted gene transfer, Nanoscale 7(12) (2015) 5350-5362. 
[80] S. Wang, S. Reinhard, C. Li, M. Qian, H. Jiang, Y. Du, U. Lachelt, W. Lu, E. Wagner, R. Huang, 
Antitumoral Cascade-Targeting Ligand for IL-6 Receptor-Mediated Gene Delivery to Glioma, 
Mol Ther 25(7) (2017) 1556-1566. 
[81] C. Scholz, P. Kos, L. Leclercq, X. Jin, H. Cottet, E. Wagner, Correlation of Length of Linear 
Oligo(ethanamino) Amides with Gene Transfer and Cytotoxicity, ChemMedChem  (2014). 
[82] K. Muller, P.M. Klein, P. Heissig, A. Roidl, E. Wagner, EGF receptor targeted lipo-
oligocation polyplexes for antitumoral siRNA and miRNA delivery, Nanotechnology 27(46) 
(2016) 464001. 
[83] Y. Lee, H. Koo, Y.B. Lim, H. Mo, J.S. Park, New cationic lipids for gene transfer with high 
efficiency and low toxicity: T-shape cholesterol ester derivatives, Bioorg.Med.Chem.Lett. 
14(10) (2004) 2637-2641. 
                                                                                     References                                                                                                                                                                                                                                                     
133 
 
[84] K. Muller, E. Kessel, P.M. Klein, M. Hohn, E. Wagner, Post-PEGylation of siRNA Lipo-
oligoamino Amide Polyplexes Using Tetra-glutamylated Folic Acid as Ligand for Receptor-
Targeted Delivery, Mol Pharm 13(7) (2016) 2332-45. 
[85] X. Wang, F. He, L. Li, H. Wang, R. Yan, L. Li, Conjugated oligomer-based fluorescent 
nanoparticles as functional nanocarriers for nucleic acids delivery, ACS applied materials & 
interfaces 5(12) (2013) 5700-8. 
[86] F. Pittella, H. Cabral, Y. Maeda, P. Mi, S. Watanabe, H. Takemoto, H.J. Kim, N. Nishiyama, 
K. Miyata, K. Kataoka, Systemic siRNA delivery to a spontaneous pancreatic tumor model in 
transgenic mice by PEGylated calcium phosphate hybrid micelles, J Control Release 178 (2014) 
18-24. 
[87] S. Khargharia, K. Kizzire, M.D. Ericson, N.J. Baumhover, K.G. Rice, PEG length and chemical 
linkage controls polyacridine peptide DNA polyplex pharmacokinetics, biodistribution, 
metabolic stability and in vivo gene expression, J Control Release 170(3) (2013) 325-33. 
[88] Y. Sakurai, H. Hatakeyama, Y. Sato, M. Hyodo, H. Akita, H. Harashima, Gene silencing via 
RNAi and siRNA quantification in tumor tissue using MEND, a liposomal siRNA delivery system, 
Mol Ther 21(6) (2013) 1195-203. 
[89] S. Morys, S. Urnauer, C. Spitzweg, E. Wagner, EGFR Targeting and Shielding of pDNA 
Lipopolyplexes via Bivalent Attachment of a Sequence-Defined PEG Agent, Macromol Biosci 
18(1) (2018). 
[90] T.M. Kapoor, T.U. Mayer, M.L. Coughlin, T.J. Mitchison, Probing spindle assembly 
mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5, J Cell Biol 
150(5) (2000) 975-88. 
[91] A.D. Judge, M. Robbins, I. Tavakoli, J. Levi, L. Hu, A. Fronda, E. Ambegia, K. McClintock, I. 
MacLachlan, Confirming the RNAi-mediated mechanism of action of siRNA-based cancer 
therapeutics in mice, J Clin Invest 119(3) (2009) 661-73. 
[92] D. Edinger, R. Kläger, C. Troiber, C. Dohmen, E. Wagner, Gene Silencing and Antitumoral 
Effects of Eg5 or Ran siRNA Oligoaminoamide Polyplexes, Drug deliv. and Transl. Res.  (2013) 
in press. 
[93] H.M. Ellerby, W. Arap, L.M. Ellerby, R. Kain, R. Andrusiak, G.D. Rio, S. Krajewski, C.R. 
Lombardo, R. Rao, E. Ruoslahti, D.E. Bredesen, R. Pasqualini, Anti-cancer activity of targeted 
pro-apoptotic peptides, Nat.Med. 5(9) (1999) 1032-1038. 
[94] M.A. Rogy, B.G. Beinhauer, W. Reinisch, L. Huang, P. Pokieser, Transfer of interleukin-4 
and interleukin-10 in patients with severe inflammatory bowel disease of the rectum 97, 
Hum.Gene Ther. 11(12) (2000) 1731-1741. 
[95] S.S. Diebold, M. Cotten, E. Wagner, M. Zenke, Gene-modified dendritic cells by receptor-
mediated transfection, Adv.Exp.Med Biol. 451 (1998) 449-455. 
[96] A. Avraméas, D. McIlroy, A. Hosmalin, B. Autran, P. Debré, M. Monsigny, R.C. Roche, P. 
Midoux, Expression of a mannose/fucose membrane lectin on human dendritic cells 33, Eur J 
Immunol 25 (1996). 
[97] D. Schaffert, N. Badgujar, E. Wagner, Novel Fmoc-polyamino acids for solid-phase 
synthesis of defined polyamidoamines, Org Lett 13(7) (2011) 1586-9. 
                                                                                     References                                                                                                                                                                                                                                                     
134 
 
[98] B. Steinborn, I. Truebenbach, S. Morys, U. Lächelt, E. Wagner, W. Zhang, Epidermal 
growth factor receptor targeted methotrexate and small interfering RNA co-delivery, The 
Journal of Gene Medicine 20(7-8) (2018) e3041. 
[99] P. Zhang, D. He, P.M. Klein, X. Liu, R. Röder, M. Döblinger, E. Wagner, Enhanced 
Intracellular Protein Transduction by Sequence Defined Tetra-Oleoyl Oligoaminoamides 
Targeted for Cancer Therapy, Advanced Functional Materials 25(42) (2015) 6627-6636. 
[100] A.K. Levacic, S. Morys, S. Kempter, U. Lächelt, E. Wagner, Minicircle Versus Plasmid DNA 
Delivery by Receptor-Targeted Polyplexes, Human Gene Therapy 28(10) (2017) 862-874. 
[101] D.J. Lee, E. Kessel, T. Lehto, X. Liu, N. Yoshinaga, K. Padari, Y.C. Chen, S. Kempter, S. 
Uchida, J.O. Radler, M. Pooga, M.T. Sheu, K. Kataoka, E. Wagner, Systemic Delivery of Folate-
PEG siRNA Lipopolyplexes with Enhanced Intracellular Stability for In Vivo Gene Silencing in 
Leukemia, Bioconjug Chem 28(9) (2017) 2393-2409. 
[102] A. Kwok, S.L. Hart, Comparative structural and functional studies of nanoparticle 
formulations for DNA and siRNA delivery, Nanomedicine 7(2) (2011) 210-9. 
[103] C. Troiber, D. Edinger, P. Kos, L. Schreiner, R. Klager, A. Herrmann, E. Wagner, Stabilizing 
effect of tyrosine trimers on pDNA and siRNA polyplexes, Biomaterials 34(5) (2013) 1624-33. 
[104] W. Zhang, K. Muller, E. Kessel, S. Reinhard, D. He, P.M. Klein, M. Hohn, W. Rodl, S. 
Kempter, E. Wagner, Targeted siRNA Delivery Using a Lipo-Oligoaminoamide Nanocore with 
an Influenza Peptide and Transferrin Shell, Adv Healthc Mater 5(12) (2016) 1493-504. 
[105] P.V. Chang, J.A. Prescher, E.M. Sletten, J.M. Baskin, I.A. Miller, N.J. Agard, A. Lo, C.R. 
Bertozzi, Copper-free click chemistry in living animals, Proceedings of the National Academy 
of Sciences 107(5) (2010) 1821-1826. 
[106] L. Brulisauer, N. Kathriner, M. Prenrecaj, M.A. Gauthier, J.C. Leroux, Tracking the 
bioreduction of disulfide-containing cationic dendrimers, Angew Chem Int Ed Engl 51(50) 
(2012) 12454-8. 
[107] M.E. Davis, J.E. Zuckerman, C.H.J. Choi, D. Seligson, A. Tolcher, C.A. Alabi, Y. Yen, J.D. 
Heidel, A. Ribas, Evidence of RNAi in humans from systemically administered siRNA via 
targeted nanoparticles, Nature 464(7291) (2010) 1067-1070. 
[108] J. Tabernero, G.I. Shapiro, P.M. LoRusso, A. Cervantes, G.K. Schwartz, G.J. Weiss, L. Paz-
Ares, D.C. Cho, J.R. Infante, M. Alsina, M.M. Gounder, R. Falzone, J. Harrop, A.C. White, I. 
Toudjarska, D. Bumcrot, R.E. Meyers, G. Hinkle, N. Svrzikapa, R.M. Hutabarat, V.A. Clausen, J. 
Cehelsky, S.V. Nochur, C. Gamba-Vitalo, A.K. Vaishnaw, D.W. Sah, J.A. Gollob, H.A. Burris, 3rd, 
First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer 
patients with liver involvement, Cancer discovery 3(4) (2013) 406-17. 
[109] A. Wittrup, J. Lieberman, Knocking down disease: a progress report on siRNA 
therapeutics, Nat Rev Genet 16(9) (2015) 543-52. 
[110] A. Rawshani, A. Rawshani, S. Franzén, N. Sattar, B. Eliasson, A.-M. Svensson, B. Zethelius, 
M. Miftaraj, D.K. McGuire, A. Rosengren, S. Gudbjörnsdottir, Risk Factors, Mortality, and 
Cardiovascular Outcomes in Patients with Type 2 Diabetes, New England Journal of Medicine 
379(7) (2018) 633-644. 
[111] M. Ratner, Patients with porphyria bask in sunlight of FDA approval, Nature 
Biotechnology 37(12) (2019) 1390-1391. 
                                                                                     References                                                                                                                                                                                                                                                     
135 
 
[112] D.P. Judge, A.V. Kristen, M. Grogan, M.S. Maurer, R.H. Falk, M. Hanna, J. Gillmore, P. 
Garg, A.K. Vaishnaw, J. Harrop, C. Powell, V. Karsten, X. Zhang, M.T. Sweetser, J. Vest, P.N. 
Hawkins, Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-
Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR), Cardiovasc Drugs Ther 
34(3) (2020) 357-370. 
[113] I.A. Khalil, Y. Yamada, H. Harashima, Optimization of siRNA delivery to target sites: issues 
and future directions, Expert Opin Drug Deliv 15(11) (2018) 1053-1065. 
[114] Y. Dong, K.T. Love, J.R. Dorkin, S. Sirirungruang, Y. Zhang, D. Chen, R.L. Bogorad, H. Yin, 
Y. Chen, A.J. Vegas, C.A. Alabi, G. Sahay, K.T. Olejnik, W. Wang, A. Schroeder, A.K.R. Lytton-
Jean, D.J. Siegwart, A. Akinc, C. Barnes, S.A. Barros, M. Carioto, K. Fitzgerald, J. Hettinger, V. 
Kumar, T.I. Novobrantseva, J. Qin, W. Querbes, V. Koteliansky, R. Langer, D.G. Anderson, 
Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman 
primates, Proceedings of the National Academy of Sciences 111(11) (2014) 3955-3960. 
[115] Y. Sakurai, T. Hada, A. Kato, Y. Hagino, W. Mizumura, H. Harashima, Effective Therapy 
Using a Liposomal siRNA that Targets the Tumor Vasculature in a Model Murine Breast Cancer 
with Lung Metastasis, Molecular therapy oncolytics 11 (2018) 102-108. 
[116] A.F. Ibrahim, U. Weirauch, M. Thomas, A. Grünweller, R.K. Hartmann, A. Aigner, 
MicroRNA Replacement Therapy for miR-145 and miR-33a Is Efficacious in a Model of Colon 
Carcinoma, Cancer Research 71(15) (2011) 5214-5224. 
[117] C. Plank, K. Mechtler, F.C. Szoka, E. Wagner, Activation of the Complement System by 
Synthetic DNA Complexes: A Potential Barrier for Intravenous Gene Delivery, Human Gene 
Therapy 7(12) (1996) 1437-1446. 
[118] M. Ogris, S. Brunner, S. Schuller, R. Kircheis, E. Wagner, PEGylated DNA/transferrin-PEI 
complexes: reduced interaction with blood components, extended circulation in blood and 
potential for systemic gene delivery, Gene Ther 6(4) (1999) 595-605. 
[119] O.M. Merkel, R. Urbanics, P. Bedocs, Z. Rozsnyay, L. Rosivall, M. Toth, T. Kissel, J. Szebeni, 
In vitro and in vivo complement activation and related anaphylactic effects associated with 
polyethylenimine and polyethylenimine-graft-poly(ethylene glycol) block copolymers, 
Biomaterials 32(21) (2011) 4936-42. 
[120] D. Rosenblum, N. Joshi, W. Tao, J.M. Karp, D. Peer, Progress and challenges towards 
targeted delivery of cancer therapeutics, Nat Commun 9(1) (2018) 1410. 
[121] Q. Sun, Z. Kang, L. Xue, Y. Shang, Z. Su, H. Sun, Q. Ping, R. Mo, C. Zhang, A Collaborative 
Assembly Strategy for Tumor-Targeted siRNA Delivery, Journal of the American Chemical 
Society 137(18) (2015) 6000-6010. 
[122] E.C. Dreaden, S.W. Morton, K.E. Shopsowitz, J.-H. Choi, Z.J. Deng, N.-J. Cho, P.T. 
Hammond, Bimodal Tumor-Targeting from Microenvironment Responsive Hyaluronan Layer-
by-Layer (LbL) Nanoparticles, ACS Nano 8(8) (2014) 8374-8382. 
[123] T. Sato, M. Nakata, Z. Yang, Y. Torizuka, S. Kishimoto, M. Ishihara, In vitro and in vivo 
gene delivery using chitosan/hyaluronic acid nanoparticles: Influences of molecular mass of 
hyaluronic acid and lyophilization on transfection efficiency, The Journal of Gene Medicine 
19(8) (2017) e2968. 
                                                                                     References                                                                                                                                                                                                                                                     
136 
 
[124] A.E. Dillinger, M. Guter, F. Froemel, G.R. Weber, K. Perkumas, W.D. Stamer, A. Ohlmann, 
R. Fuchshofer, M. Breunig, Intracameral Delivery of Layer-by-Layer Coated siRNA 
Nanoparticles for Glaucoma Therapy, Small 14(50) (2018) 1803239. 
[125] L. Chen, C. Fu, Q. Zhang, C. He, F. Zhang, Q. Wei, The role of CD44 in pathological 
angiogenesis, FASEB journal : official publication of the Federation of American Societies for 
Experimental Biology  (2020). 
[126] A.W. Griffioen, M.J.H. Coenen, C.A. Damen, S.M.M. Hellwig, D. H.J. van Weering, W. 
Vooys, G.H. Blijham, G. Groenewegen, CD44 Is Involved in Tumor Angiogenesis; an Activation 
Antigen on Human Endothelial Cells, Blood 90(3) (1997) 1150-1159. 
[127] L. Beckert, L. Kostka, E. Kessel, A. Krhac Levacic, H. Kostkova, T. Etrych, U. Lachelt, E. 
Wagner, Acid-labile pHPMA modification of four-arm oligoaminoamide pDNA polyplexes 
balances shielding and gene transfer activity in vitro and in vivo, Eur J Pharm Biopharm 105 
(2016) 85-96. 
[128] S. Urnauer, S. Morys, A. Krhac Levacic, A.M. Muller, C. Schug, K.A. Schmohl, N. Schwenk, 
C. Zach, J. Carlsen, P. Bartenstein, E. Wagner, C. Spitzweg, Sequence-defined cMET/HGFR-
targeted Polymers as Gene Delivery Vehicles for the Theranostic Sodium Iodide Symporter 
(NIS) Gene, Mol Ther 24(8) (2016) 1395-404. 
[129] P.M. Klein, K. Klinker, W. Zhang, S. Kern, E. Kessel, E. Wagner, M. Barz, Efficient Shielding 
of Polyplexes Using Heterotelechelic Polysarcosines, Polymers 10(6) (2018). 
[130] P.M. Klein, S. Kern, D.J. Lee, J. Schmaus, M. Hohn, J. Gorges, U. Kazmaier, E. Wagner, 
Folate receptor-directed orthogonal click-functionalization of siRNA lipopolyplexes for tumor 
cell killing in vivo, Biomaterials 178 (2018) 630-642. 
[131] P.M. Klein, K. Muller, C. Gutmann, P. Kos, A. Krhac Levacic, D. Edinger, M. Hohn, J.C. 
Leroux, M.A. Gauthier, E. Wagner, Twin disulfides as opportunity for improving stability and 
transfection efficiency of oligoaminoethane polyplexes, J Control Release 205 (2015) 109-19. 
[132] S.T. Chou, Q. Leng, P. Scaria, J.D. Kahn, L.J. Tricoli, M. Woodle, A.J. Mixson, Surface-
modified HK:siRNA nanoplexes with enhanced pharmacokinetics and tumor growth inhibition, 
Biomacromolecules 14(3) (2013) 752-60. 
[133] U. Lachelt, P. Kos, F.M. Mickler, A. Herrmann, E.E. Salcher, W. Rodl, N. Badgujar, C. 
Brauchle, E. Wagner, Fine-tuning of proton sponges by precise diaminoethanes and histidines 
in pDNA polyplexes, Nanomedicine 10(1) (2014) 35-44. 
[134] F. Fazlollahi, S. Angelow, N.R. Yacobi, R. Marchelletta, A.S.L. Yu, S.F. Hamm-Alvarez, Z. 
Borok, K.-J. Kim, E.D. Crandall, Polystyrene nanoparticle trafficking across MDCK-II, 
Nanomedicine : nanotechnology, biology, and medicine 7(5) (2011) 588-594. 
[135] Z.-h. Sui, H. Xu, H. Wang, S. Jiang, H. Chi, L. Sun, Intracellular Trafficking Pathways of 
Edwardsiella tarda: From Clathrin- and Caveolin-Mediated Endocytosis to Endosome and 
Lysosome, Frontiers in Cellular and Infection Microbiology 7(400) (2017). 
[136] D. Dutta, J.G. Donaldson, Search for inhibitors of endocytosis: Intended specificity and 
unintended consequences, Cell Logist 2(4) (2012) 203-208. 
[137] M. Koivusalo, C. Welch, H. Hayashi, C.C. Scott, M. Kim, T. Alexander, N. Touret, K.M. 
Hahn, S. Grinstein, Amiloride inhibits macropinocytosis by lowering submembranous pH and 
preventing Rac1 and Cdc42 signaling, The Journal of Cell Biology 188(4) (2010) 547-563. 
                                                                                     References                                                                                                                                                                                                                                                     
137 
 
[138] J.-S. Kim, T.-J. Yoon, K.-N. Yu, M.-S. Noh, M. Woo, B.-G. Kim, K.-H. Lee, B.-H. Sohn, S.-B. 
Park, J.-K. Lee, M.-H. Cho, Cellular uptake of magnetic nanoparticle is mediated through 
energy-dependent endocytosis in A549 cells, J Vet Sci 7(4) (2006) 321-326. 
[139] H.J. Greyner, T. Wiraszka, L.S. Zhang, W.M. Petroll, M.E. Mummert, Inducible 
macropinocytosis of hyaluronan in B16-F10 melanoma cells, Matrix Biol 29(6) (2010) 503-10. 
[140] K. von Gersdorff, N.N. Sanders, R. Vandenbroucke, S.C. De Smedt, E. Wagner, M. Ogris, 
The Internalization Route Resulting in Successful Gene Expression Depends on both Cell Line 
and Polyethylenimine Polyplex Type, Molecular Therapy 14(5) (2006) 745-753. 
[141] Z. Zheng, R.D. Cummings, P.E. Pummill, P.W. Kincade, Growth as a solid tumor or 
reduced glucose concentrations in culture reversibly induce CD44-mediated hyaluronan 
recognition by Chinese hamster ovary cells, The Journal of clinical investigation 100(5) (1997) 
1217-1229. 
[142] Y. Matsumura, H. Maeda, A new concept for macromolecular therapeutics in cancer 
chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent 
smancs, Cancer Res. 46(12 Pt 1) (1986) 6387-6392. 
[143] F. Yuan, M. Dellian, D. Fukumura, M. Leunig, D.A. Berk, V.P. Torchilin, R.K. Jain, Vascular 
permeability in a human tumor xenograft: molecular size dependence and cutoff size, Cancer 
Res 55(17) (1995) 3752-3756. 
[144] Y. Shi, R. van der Meel, X. Chen, T. Lammers, The EPR effect and beyond: Strategies to 
improve tumor targeting and cancer nanomedicine treatment efficacy, Theranostics 10(17) 
(2020) 7921-7924. 
[145] S. Wilhelm, A.J. Tavares, Q. Dai, S. Ohta, J. Audet, H.F. Dvorak, W.C.W. Chan, Analysis of 
nanoparticle delivery to tumours, Nature Reviews Materials 1(5) (2016) 16014. 
[146] A.E. Hansen, A.L. Petersen, J.R. Henriksen, B. Boerresen, P. Rasmussen, D.R. Elema, 
P.M.a. Rosenschöld, A.T. Kristensen, A. Kjæ r, T.L. Andresen, Positron Emission Tomography 
Based Elucidation of the Enhanced Permeability and Retention Effect in Dogs with Cancer 
Using Copper-64 Liposomes, ACS Nano 9(7) (2015) 6985-6995. 
[147] G. Thurston, J.W. McLean, M. Rizen, P. Baluk, A. Haskell, T.J. Murphy, D. Hanahan, D.M. 
McDonald, Cationic liposomes target angiogenic endothelial cells in tumors and chronic 
inflammation in mice, The Journal of clinical investigation 101(7) (1998) 1401-1413. 
[148] M. Dellian, F. Yuan, V.S. Trubetskoy, V.P. Torchilin, R.K. Jain, Vascular permeability in a 
human tumour xenograft: molecular charge dependence, British Journal of Cancer 82(9) (2000) 
1513-1518. 
[149] H.-X. Wang, Z.-Q. Zuo, J.-Z. Du, Y.-C. Wang, R. Sun, Z.-T. Cao, X.-D. Ye, J.-L. Wang, K.W. 
Leong, J. Wang, Surface charge critically affects tumor penetration and therapeutic efficacy of 
cancer nanomedicines, Nano Today 11(2) (2016) 133-144. 
[150] J.E. Schnitzer, gp60 is an albumin-binding glycoprotein expressed by continuous 
endothelium involved in albumin transcytosis, American Journal of Physiology-Heart and 
Circulatory Physiology 262(1) (1992) H246-H254. 
[151] P. Oh, J.E. Testa, P. Borgstrom, H. Witkiewicz, Y. Li, J.E. Schnitzer, In vivo proteomic 
imaging analysis of caveolae reveals pumping system to penetrate solid tumors, Nature 
Medicine 20(9) (2014) 1062-1068. 
                                                                                     References                                                                                                                                                                                                                                                     
138 
 
[152] S. Sindhwani, A.M. Syed, J. Ngai, B.R. Kingston, L. Maiorino, J. Rothschild, P. MacMillan, 
Y. Zhang, N.U. Rajesh, T. Hoang, J.L.Y. Wu, S. Wilhelm, A. Zilman, S. Gadde, A. Sulaiman, B. 
Ouyang, Z. Lin, L. Wang, M. Egeblad, W.C.W. Chan, The entry of nanoparticles into solid 
tumours, Nature Materials 19(5) (2020) 566-575. 
[153] Y. Liu, Y. Huo, L. Yao, Y. Xu, F. Meng, H. Li, K. Sun, G. Zhou, D.S. Kohane, K. Tao, 
Transcytosis of Nanomedicine for Tumor Penetration, Nano Letters 19(11) (2019) 8010-8020. 
[154] I. de Lázaro, D.J. Mooney, A nanoparticle’s pathway into tumours, Nature Materials 19(5) 
(2020) 486-487. 
[155] S. Pandit, D. Dutta, S. Nie, Active transcytosis and new opportunities for cancer 
nanomedicine, Nature Materials 19(5) (2020) 478-480. 
[156] Challenging paradigms in tumour drug delivery, Nature Materials 19(5) (2020) 477-477. 
[157] K. Xiao, Y. Li, J. Luo, J.S. Lee, W. Xiao, A.M. Gonik, R.G. Agarwal, K.S. Lam, The effect of 
surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles, 
Biomaterials 32(13) (2011) 3435-3446. 
[158] E. Blanco, H. Shen, M. Ferrari, Principles of nanoparticle design for overcoming biological 
barriers to drug delivery, Nature Biotechnology 33(9) (2015) 941-951. 
 
 
 
  
                                                                                     Publications                                                                                                                                                                                                                                                     
139 
 
8.  Publications  
Original articles   
Luo J, Höhn M, Reinhard S, Loy DM, Klein PM, Wagner E (2019) IL4-Receptor-
Targeted Dual Antitumoral Apoptotic Peptide—siRNA Conjugate Lipoplexes. 
Advanced Functional Materials, 29, 1900697.  
Luo J, Schmaus J, Cui M, Hörterer E, Wilk U, Höhn M, Däther M, Berger S, Benli-
Hoppe T, Peng L, Wagner E (2020) Hyaluronate siRNA nanoparticles with positive 
charge display rapid attachment to tumor endothelium and penetration into tumors. 
Journal of Controlled Release, DOI: 
Wang Y., Luo J, Truebenbach I, Reinhard S, Klein PM, Höhn M, Kern S, Morys S, Loy 
DM, Wagner E, Zhang W. (2020) Double Click-Functionalized siRNA Polyplexes for 
Gene Silencing in Epidermal Growth Factor Receptor-Positive Tumor Cells. ACS 
Biomaterials Science and Engineering, 6, 1074-1089.  
Review 
Luo J, Wagner E, Wang YF (2020) Artificial Peptides for Antitumoral siRNA Delivery. 
Journal of Materials Chemistry B, 2020, 8, 2020-2031. 
Poster presentation 
Luo J, Schmaus J, Cui M, Hörterer E, Wagner E. Surface charge of lipopolyplexes 
influences on the tumor penetration. The Controlled Release Society German Local 
Chapter, Munich, Germany, February 20-21, 2020. (Best Poster Presentation)
                                                                                    
 Acknowledgements                                                                                                                                                                                                                                                  
140 
 
9.  Acknowledgements  
Time flies! At the end of my PhD study, I would like to express my gratitude to all people 
supporting me during the past four years.  
First of all, I would like to thank my supervisor Prof. Dr. Ernst Wagner for giving me the 
opportunity to do my PhD in his research group. I greatly appreciate his scientific 
support and professional guidance. I have learned a lot from not only the informative 
discussions with him but also the email communications with him even after midnight.  
I would like to thank Johannes Schmaus, Mochen Cui, and Elisa Hörterer for their 
generous help on the animal experiment. I also thanks Dr. Philipp Klein, Dr. Sören 
Reinhard, and Dr. Ines Trrübenbach for teaching me synthesis, as well as Dr. Ulrich 
Lächelt, Dr. Wei Zhang, Dr. Dianjang Lee, and Dr. Peng Zhang for discussion about 
my project. I would also like to thank Dominik M. Loy for his help with TEM and Nader 
Danaf for the FCS measurements. I want to thank Miriam for her instructions on cell 
culture at the beginning of my PhD, Andi for the safety instructions, as well as Yanfang 
for keeping the cell culture room tidy and clean. I am very grateful to Wolfgang for 
solving the computer and equipment problems, as well as Anna, Ursula, Melinda, 
Marus and Olga for keeping the lab running. I also thanks Teoman for MASS, Simone 
for co-synthesis of oligomers and discussions with projects, Bianca, Ann-Katrin for 
teaching qPCR.  
Many thanks to Uli for preparing the traditional Weißwurst, St. Nicholas chocolate and 
Glühwein, as well as Ines, Jasmin and Dominik for the organization of lab activities, 
especially the impressive and great music played by our Christmas band, Dominik, 
Philipp H. and Ines. I would also like to thank our lunch groups, in my first two years of 
PhD, (Dianjang Lee, Peng Zhang, Wei Zhang, Yanfang Wang) and in my later two 
years of PhD,(Peng Lun, Yi Lin, Meng Lv, Yanfang Wang) for the interesting and 
extensive discussions. Many thanks to all the AK Wagner members for the nice 
                                                                                    
 Acknowledgements                                                                                                                                                                                                                                                  
141 
 
atmosphere and unforgettable time we spent together. Special thanks to China 
Scholarship Council for supporting my study and life in Munich. Many thanks to all my 
friends for helping and caring me all the time. 
Finally, I want to express my gratitude to my parents for their constant support and 
trust in my life. Whenever I’m in trouble, they always make me calm and optimistic. 
